

## PROGNOSIS AND MANAGEMENT OF TRAUMA PATIENTS

PROGNOSIS AND MANAGEMENT OF PATIENTS WHO HAVE INJURIES  
NECESSITATING ORTHOPEDIC SURGERY

By

YAPING CHANG, M.Sc.

A Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the  
Requirements for the Degree of Doctor of Philosophy

McMaster University DOCTOR OF PHILOSOPHY (2018)

Hamilton, Ontario (Health Research Methodology)

TITLE: Prognosis and Management of Patients who had Trauma Necessitating  
Orthopedic Surgeries

AUTHOR: Yaping Chang, M.Sc.

SUPERVISOR: Distinguished Professor Gordon Guyatt

NUMBER OF PAGES: xiv, 139

## **ABSTRACT**

The current thesis aims to address the prognosis and management of patients who have injuries necessitating orthopaedic surgery.

In Chapter 1 I introduce the thesis, and in Chapter 5 I offer conclusions and summarize the contribution of the work. In Chapter 5, I address the scope, rationale, key findings, limitations and implications.

Chapter 2 is a systematic review and meta-analysis investigating the effectiveness of antibiotic prophylaxis in patients with open fracture of the extremities. The results demonstrate moderate quality evidence of an important reduction in the infection rate in patients receiving, versus not receiving, antibiotic prophylaxis. We found no difference in infection rate with longer (3 to 5 days) versus shorter (1 day) duration of antibiotics – this finding warrants only low confidence.

Chapter 3 is a systematic survey of current practice and recommendations regarding antibiotic prophylaxis in open fracture management. Authors of publications over the last decade strongly support early systemic antibiotics prophylaxis for patients with open fractures of extremities. In practice, most used systemic antibiotics with both gram-positive and gram-negative coverage, and continued the administration for 2 to 3 days. Most recommendations suggested gram-positive coverage for less severe injuries, and administration duration of no more than 3 days (half suggested 1 day). For more severe injuries, most

recommendations suggested broad antimicrobial coverage continued for 2 to 3 days.

Chapter 4 is a longitudinal study investigating predictors of persistent post-surgical pain after tibia fracture. We found significant independent associations between resolution of pain and male sex, non-smoking and alcohol consumption. Age, obesity, type of fracture (closed versus open), additional injuries, and post-operative weight-bearing status did not predict resolution of pain. Our findings suggest that clinicians should be particularly alert to the possibility of troublesome post-operative pain in female smokers who do not drink alcohol. Clinicians may consider counselling patients to discontinue smoking, inform them that they are at nearly double the risk of incidence of troublesome post-operative pain (in addition to the long-term adverse health consequences of smoking).

## ACKNOWLEDGEMENTS

I would like to express my utmost gratitude to my supervisors, Distinguished Professor Gordon Guyatt, Drs. Mohit Bhandari, Jason Busse and Lehana Thabane, who enlightened my mind on evidence-based medicine research. Their professional guidance, invaluable comments and unending encouragement set the foundation of my interest on this topic and understanding of the research questions.

I would like to send my genuine appreciation to our exceptional team of teachers, supporters and friends for their collaboration and contributions to my thesis: Sean Alexander Kennedy, Kan Lun Zhu, Wei Qi, Luciane Cruz Lopes, Li Wang, Qi Zhou, Diane Heels-Ansdell, Neera Bhatnagar, Rachel Couban, Cristiane de C´assia Bergamaschi, Maria Carolina de Oliveirae Silva, S. Mohsen Mousavi, Saqib Khurshid, Melody Ren, Sukhmani K. Sodhi, Reza Donald Mirza, Mohamad Alshurafa, Lisa Cronin, Yanping Zhao, Ahmed Negm, Faysal N Naji, Lazar Milovanovic, Yutong Fei, Rakhshan Kamran, Sung Min Cho, Stefan Schandelmaier, Lin Jin, Shiyun Hu, Mei Wang, Arnav Agarwal, Michal Seweryn, Kamran Naseem, Thomas Agoritsas, Arnaud Merglen, Ingmarie Skoglund, Aurelia Desplain, Andy Radoslav, Hejia Song, Mark Loeb, Paul Elias Alexander, Sohail Mulla, Nigar Sekercioglu, Behnam Sadeghirad, Toshiaki A. Furukawa, Souzan Mirza, Regina Kunz, Victor Wang, Yong Fang Zhu, Joan Burri, Huyu Wu, Sun Makosso, Ying Zhang, Yuan Zhang, Ivan D. Florez, Nasim Zamir, Augustin

Toma, Norman Buckley, Ramesh Zacharias, Reed A.C. Siemieniuk, Brad Petrisor, Bill Ristevski, Sheila Sprague, Paula McKay, Nicole Simunovic and the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST) Investigators.

My special thanks go to Michael G. DeGroot Institute for Pain Research and Care, School of Graduate Studies and the CLARITY research group, for student awards; all other classmates and staff at Health Research Methodology Program of McMaster University, my husband Chenglin, my son Jerry and the rest of my extended family for their unending support, care and friendship that made this period of my study as comfortable as possible.

## TABLE OF CONTENTS

|  |      |
|--|------|
| Abstract .....   | iii  |
| Acknowledgements .....   | v    |
| List of figures .....  | viii |
| List of tables .....   | ix   |
| List of appendixes .....   | xi   |
| List of abbreviations .....  | xii  |
| Declaration of academic achievement .....  | xiv  |
| Chapter 1. Introduction .....  | 1    |
| Chapter 2. Effects of Antibiotic Prophylaxis in Patients with Open Fracture of the<br>Extremities: A Systematic Review of Randomized Controlled Trials ..... | 7    |
| Chapter 3. Antibiotic Prophylaxis in the Management of Open Fractures: A<br>Systematic Survey of Current Practice and Recommendations .....                  | 43   |
| Chapter 4. Risk Factors for Persistent Post-surgical Pain after Tibia Fracture:<br>A Longitudinal Study .....  | 99   |
| Chapter 5. Conclusion .....  | 135  |



## LIST OF FIGURES

### Chapter 2

|   |    |
|---|----|
| Figure 1. Eligibility assessment flow diagram according to PRISMA guidelines<br>.....   | 32 |
| Figure 2. Risk of bias in the individual studies included.....  | 33 |
| Figure 3. Forest plot showing fracture site infection with antibiotic prophylaxis<br>versus no antibiotic prophylaxis .....     | 34 |
| Figure 4. Forest plot showing fracture site infection with three to five days versus<br>one day of antibiotic prophylaxis ..... | 35 |

### Chapter 3

|  |    |
|--|----|
| Figure 1 Eligibility assessment flow diagram ..... | 84 |
|--|----|

### Chapter 4

|   |     |
|---|-----|
| Figure 1. Distribution of duration of participants' follow-ups .....  | 125 |
| Figure 2. Kaplan-Meier curves for resolution of troublesome post-operative pain<br>amongst patients with tibial fracture..... | 126 |

## LIST OF TABLES

### Chapter 2

|   |    |
|---|----|
| Table I. Characteristics of the Eligible Randomized Controlled Trials and Patients<br>in These Studies .....      | 36 |
| Table II. GRADE Evidence Profile of Studies of Antibiotic Prophylaxis Among<br>Patients with Open Fractures ..... | 39 |

### Chapter 3

|  |    |
|--|----|
| Table I. Distribution of publications on prophylactic antibiotics to patients with<br>open fractures of extremities in terms of year of publication .....      | 85 |
| Table II. Distribution of publications on prophylactic antibiotics to patients with<br>open fractures of extremities in terms of location of publication ..... | 86 |
| Table III. Regimen in practice of prophylactic antibiotics systematically given to<br>patients with open fractures of extremities .....                        | 87 |
| Table IV. Duration of antibiotics in practice of prophylactic antibiotics<br>systematically given to patients with open fractures of extremities .....         | 89 |
| Table V. Regimen in recommendations of prophylactic antibiotics systematically<br>given to patients with open fractures of extremities .....                   | 90 |
| Table VI. Duration of antibiotics in recommendations of prophylactic antibiotics<br>systematically given to patients with open fractures of extremities .....  | 92 |

## **Chapter 4**

|   |     |
|---|-----|
| Table I. Baseline characteristics of study participants .....   | 122 |
| Table II. Distribution of duration of participants' follow-ups among patients with persistent post-surgical pain .....        | 123 |
| Table III. Predictors of resolution of post-surgical pain in study participants (Cox survival model, adjusted analysis) ..... | 124 |

## LIST OF APPENDIXES

### Chapter 2

|   |    |
|---|----|
| Appendix 1. MEDLINE title and abstract search strategy for effects of antibiotic prophylaxis in patients with open fracture ..... | 40 |
|---|----|

### Chapter 3

|   |    |
|---|----|
| Appendix 1. MEDLINE title and abstract search strategy for effects of antibiotic prophylaxis in patients with open fracture ..... | 93 |
|---|----|

|  |    |
|--|----|
| Appendix 2. Regimen in practice of prophylactic antibiotics systematically given to patients with open fractures of lower extremities by injury severity ..... | 96 |
|--|----|

|   |    |
|---|----|
| Appendix 3. Level of recommendations about prophylactic systemic antibiotic therapy for patients with open fractures of extremities ..... | 97 |
|---|----|

|   |    |
|---|----|
| Appendix 4. Regimen in recommendations of prophylactic antibiotics systematically given to patients with open fractures of lower extremities by injury severity ..... | 98 |
|---|----|

### Chapter 4

|                                       |     |
|---------------------------------------|-----|
| Appendix 1: TRUST Investigators ..... | 127 |
|---------------------------------------|-----|

|  |     |
|--|-----|
| Appendix 2 Correlation of factors considered in Cox survival model ( $r$ ) ..... | 132 |
|--|-----|

|  |     |
|--|-----|
| Appendix 3. Assessment of multicollinearity of variables ..... | 133 |
|--|-----|

|  |     |
|--|-----|
| Appendix 4. Assessment of proportional hazard assumption for variables in Cox survival model ..... | 134 |
|--|-----|

## LIST OF ABBREVIATIONS

BMI – Body Mass Index

CENTRAL – Cochrane Central Register of Controlled Trials

CI – Confidence Interval

CIHI – Canadian Institute for Health Information

CIHR – Canadian Institutes of Health Research

CINAHL – Index to Nursing and Allied Health

EMBASE – Excerpta Medica Database

FLOW – Fluid lavage of open wounds

GRADE – Grading of Recommendations Assessment, Development, and Evaluation

HR – Hazard Ratio

MRSA – Methicillin-resistant *Staphylococcus aureus*

PMMA – Polymethyl Methacrylate

PPSP – Persistent Post-surgical Pain

RCT – Randomized Controlled Trial

RR – Risk Ratio; Relative Risk

SD – Standard Deviation

TRUST – Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures

MEDLINE – Medical Literature Analysis and Retrieval System Online

VIF – Variance Inflation Factor

WHO – the World Health Organization

## **DECLARATION OF ACADEMIC ACHIEVEMENT**

This is a “sandwich” thesis that consists of five chapters, one of which has been published in a peer-reviewed medical journal (Chapters 2), and two of which has been submitted to a peer-reviewed medical journal but not yet accepted (Chapter 3 and Chapter 4). I am the first author and principle contributor of each chapter in this thesis. My supervisors, Drs. Gordon Guyatt, Mohit Bhandari, Jason Busse and Lehana Thabane, and I myself played the primary role in the conception and design of the study. My independent contributions included drafting each chapter’s study protocol; performing the literature search, designing data abstraction forms, screening titles, abstractions and full texts, collaborating calibration of co-authors for the systematic reviews; cleaning data of TRUST; conducting analyses; designing figures and tables; drafting and critically revising the manuscripts; providing final approval of the versions submitted; and taking responsibility for all aspects of each chapter. I completed all aspects of this thesis between October 2014 and December 2017.

## CHAPTER 1

### Introduction

The principal objective of this thesis was to address prognosis and management of patients who had orthopedic injuries, in particular long bone fractures, addressing the role of antibiotic prophylaxis and predictors of persistent post-surgical pain.

Musculoskeletal injuries are a major cause of disability worldwide, particularly in individuals under 60 years of age <sup>[1-4]</sup>. Estimates show that by 2020, disability from traffic accidents will rank in the top 3 of all causes of disability <sup>[5]</sup>.

Extremity injuries are the most common type of musculoskeletal injuries and represent approximately 65% of all injury admissions to hospitals <sup>[6]</sup>. The Canadian Institute for Health Information reports 257,439 musculoskeletal injury-related hospitalizations in Canada in 2015-2016 <sup>[7]</sup>. Globally, trauma-related care costs are over 100 billion dollars per year <sup>[1,3]</sup>.

Open fractures – fractures associated with soft tissue compromise that result in a communication of the fracture ends with the external environment – are considered to be contaminated wounds <sup>[2,4,8]</sup>. The rate of fracture site infections varies, from 3% in less severe fractures to up to 50% in more severe open fractures <sup>[2,9]</sup>. Infection is an important cause of wound healing problems, and the subsequent development of nonunion and continued osseous instability. The infection, and wound healing complications associated with infection have a significant impact on the patients' quality of life and cost of health care <sup>[2-5,9]</sup>.



Given the certainty of contamination and the very high incidence of infection, prophylactic use of antibiotics after open fracture has become routine <sup>[2-5]</sup>. Some authorities recommend giving intravenous antibiotics, most frequently suggested regimens being first or second generation cephalosporins, as early as possible to the patients with open fractures as prophylaxis for infection <sup>[4,8,10]</sup>. However, debate regarding the duration of use, the choice of antibiotics and the dosage continue. In practice, the individual treating surgeon or emergency room doctor typically chooses the type of antibiotic, dose, route of delivery and duration depending on department protocols or their individual preferences <sup>[11]</sup>.

Therefore we undertook systematic reviews of the available evidence to investigate the impact of antibiotic prophylaxis in patients with open fractures. When our team discussed the research protocol, we realized that we had to take two steps to address the topic “A Systematic Review of Antibiotic Prophylaxis in the Management of Open Fractures”.

Step One was to answer question of the evidence regarding the effectiveness of antibiotic prophylaxis. We therefore conducted a systematic review and meta-analyses of randomized controlled trials (RCTs) to address there specific questions: A) the impact of antibiotic prophylaxis versus no prophylaxis on rate of infection; B) the impact of longer versus shorter duration of antibiotic prophylaxis on rate of infection; and C) the impact of alternative antibiotics on rate of infection. We searched CINAHL, EMBASE, MEDLINE, CENTRAL, and the Cochrane database of systematic reviews from 1965 to December 2013. The quantitative synthesis included two meta-analyses: 4 RCTs compared antibiotic

versus no antibiotic, and 3 RCTs compared longer versus shorter course. The narrative summary included 10 other RCTs with interventions too diverse to pool their results. I include this systematic review, which was published in the JBJS Reviews in 2015, as Chapter 2 of the current thesis. Prior to my submission of the current thesis, we updated the search in above mentioned literature databases on January 7, 2018. We did not find any newly published RCTs between December 2013 and January 2018 to be eligible to our research question.

We undertook Step Two to answer questions of what regimens surgeons are currently using and what regimens experts are currently recommending as prophylaxis. We undertook a systematic survey of reports of surgeons' practice in the use of prophylactic antibiotics, and a complementary systematic survey of the available expert recommendations. We fully considered suggestions and expert opinion of our team and decided to include all articles, textbooks, guidelines and institutional protocols that were published in recent 10 years. We summarized antibiotic regimens, dose, time to antibiotic administration and duration for practice and recommendations. I include this study, which was submitted to the JBJS Reviews in December 2017, as Chapter 3 of the current thesis.

The background and inclusion criteria for Chapters 2 and 3 are similar. The search strategies for the published articles in Chapter 3 are the same as those in Chapter 2. However, the two studies deal with fundamentally different questions, and thus fundamentally different sources of evidence. Chapter 2 includes only RCTs; Chapter 3 includes RCTs and observational studies, as well as textbooks, guidelines and protocols. In Chapter 2, we searched for all eligible studies from

the relevant databases from inception to the date of the search. In Chapter 3, we searched for all eligible publications in recent ten years from January 2007 to June 2017.

Chapter 4 aims to address the association between baseline characteristics and persistent post-surgical pain (PPSP) among patients with a tibial shaft fracture. PPSP is common amongst patients who undergo surgery following lower extremity fractures. A prior prospective cohort study reported that 33.3% had moderate or severe pain intensity among patients with tibia fractures at 7 years after injury<sup>[12]</sup>. Greater duration and severity of post-surgical pain is associated with less mobility, restrictions in activities of daily living, and reduced quality of life<sup>[13]</sup>. Predictors of PPSP after fracture repair have received limited study. We used data collected as part of the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST) and used a multivariable Cox proportional hazards regression model for analysis.

In Chapter 5, I summarized the key findings, addressed limitations, and discussed directions of future studies.

## References

1. Paniker J, Graham S M, Harrison J W. Global trauma: the great divide. *SICOT-J*, 2015, 1.
2. Petrisor B, Sun X, Bhandari M, Guyatt G, Jeray KJ, Sprague S, Tanner S, Schemitsch E, Sancheti P, Anglen J, Tornetta P, Bosse M, Liew S, Walter S; FLOW Investigators. Fluid lavage of open wounds (FLOW): a multicenter, blinded, factorial pilot trial comparing alternative irrigating solutions and pressures in patients with open fractures. *J Trauma*. 2011 Sep;71(3):596-606.
3. Bhandari M, Adili A. Evidence-based orthopedics. Chichester: Wiley-Blackwell; 2011.
4. Bulstrode CJK. Oxford textbook of trauma and orthopaedics. Oxford: Oxford University Press; 2011.
5. Dormans JP, Fisher R, Pill S. Orthopaedics in the developing world: present and future concerns. *J Am Acad Orthop Surg* 2001;9:289-296.
6. Canadian Institute for Health Information (CIHI). National Trauma Registry: Hospital Injury Admissions. Canadian Institute for Health Information: Ottawa; 2003.
7. Injury and Trauma Emergency Department and Hospitalization Statistics, 2015–2016. Canadian Institute for Health Information: Ottawa; 2017.
8. Cross WW 3rd, Swiontkowski MF. Treatment principles in the management of open fractures. *Indian J Orthop*. 2008 Oct-Dec;42(4):377-86.
9. Arti HR. Comparison of early versus delayed debridement in open fractures. *Pak J Medical Sci*. 2012;28(5):856-9.

10. Ali AM. Outcomes of open bicondylar tibial plateau fractures treated with Ilizarov external fixator with or without minimal internal fixation. *Eur J Orthop Surg Traumatol.* 2013 Apr;23(3):349-55.
11. Obremskey W, Molina C, Collinge C, Nana A, Tornetta P 3rd, Sagi C, et al. Current Practice in the Management of Open Fractures Among Orthopaedic Trauma Surgeons. Part A: Initial Management. A Survey of Orthopaedic Trauma Surgeons. *J Orthop Trauma.* 2014 Aug;28(8):e198-202.
12. Castillo RC, MacKenzie EJ, Wegener ST, et al. Prevalence of chronic pain seven years following limb threatening lower extremity trauma. *Pain.* 2006;124(3):321-329.
13. Busse JW, Bhandari M, Einhorn TA, et al. Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial. *The BMJ.* 2016;355:i5351.

## CHAPTER 2

### **Effects of Antibiotic Prophylaxis in Patients with Open Fracture of the Extremities: A Systematic Review of Randomized Controlled Trials**

At the time of writing this thesis, this chapter has been published in a peer-reviewed scientific journal, as follows:

Yaping Chang, Sean Alexander Kennedy, Mohit Bhandari, Luciane Cruz Lopes, Cristiane de Cássia Bergamaschi, Maria Carolina de Oliveira e Silva, Neera Bhatnagar, S Mohsen Mousavi, Saqib Khurshid, Brad Petrisor, Melody Ren, Sukhmani K Sodhi, Reza Donald Mirza, Gordon H Guyatt. Effects of antibiotic prophylaxis in patients with open fracture of the extremities: a systematic review of randomized controlled trials. *JBJS Rev.* 2015 Jun 9;3(6).  
pii: 01874474-201503060-00002. doi: 10.2106/JBJS.RVW.N.00088.

Wolters Kluwer Health, Lippincott Williams & Wilkins ©

**Effects of antibiotic prophylaxis in patients with open fracture of the extremities: a systematic review of randomized controlled trials**

Yaping Chang, MSc<sup>1</sup>, Sean Alexander Kennedy<sup>2</sup>, Mohit Bhandari, PhD, MD<sup>3</sup>,  
Luciane Cruz Lopes, PhD<sup>4</sup>, Cristiane de Cássia Bergamaschi, PhD<sup>4</sup>, Maria  
Carolina de Oliveira e Silva, MSc<sup>4</sup>, Neera Bhatnagar, MLIS<sup>5</sup>, S. Mohsen Mousavi,  
MD<sup>6</sup>, Saqib Khurshid, MBBS<sup>2</sup>, Brad Petrisor, MD<sup>3</sup>, Melody Ren, BSc<sup>2</sup>, Sukhmani  
K Sodhi<sup>7</sup>, Reza Donald Mirza, BSc<sup>2</sup>, Gordon H Guyatt, MD<sup>1</sup>

**Affiliations and Correspondence**

1. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
2. Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
3. Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
4. Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, Sao Paulo, Brazil
5. Health Science Library, McMaster University, Hamilton, Ontario, Canada
6. asim, Swiss Academy of Insurance Medicine, Basel, Switzerland
7. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

## ABSTRACT

**Background:** The purpose of the present study was to perform a systematic review and meta-analysis of the use of alternative antibiotic regimens—including (A) antibiotic prophylaxis versus no prophylaxis, (B) longer versus shorter duration of antibiotic prophylaxis, and (C) alternative drugs—for patients with open fracture of the extremities.

**Methods:** Data sources included CINAHL, EMBASE, MEDLINE, the Cochrane Central Registry of Controlled Trials (CENTRAL), and the Cochrane database of systematic reviews from 1965 to December 2013. All randomized controlled trials comparing the effectiveness of antibiotic prophylaxis in patients with open fracture of the extremities were eligible.

**Results:** We identified 329 potentially eligible articles, of which seventeen proved to be eligible. In four randomized controlled trials involving 472 patients, we found a significantly lower infection rate in patients receiving antibiotic prophylaxis compared with those not receiving antibiotic prophylaxis (risk ratio = 0.37 [95% confidence interval, 0.21 to 0.66]; absolute risk reduction=9.6% [95% confidence interval, 5.2% to 12.1%]). In three studies involving 1104 patients, we found no difference in the infection rate when a longer duration of antibiotics (three to five days) was compared with a shorter duration (one day) (risk ratio = 0.97; 95% confidence interval, 0.69 to 1.37). Confidence in the estimates for both questions was low to moderate. Individual comparisons of alternative drugs yielded estimates warranting only low to very low confidence.



**Conclusions:** Results of randomized controlled trials performed to date provide evidence that antibiotic prophylaxis reduces subsequent infection and that courses as short as one day are as effective as courses of three to five days, although the evidence warrants only low to moderate confidence. Given current practice, a large, multicenter, low risk of bias, randomized controlled trial enrolling representative populations and addressing the duration of antibiotics may be the next optimum step in investigation.

**Key words:**

open fracture; antibiotic; prophylaxis; infection; systematic review

## **Introduction**

Open fractures—fractures involving the communication of bone through the skin and with the external environment[1]—are considered to be contaminated wounds. A key issue in treatment is the prevention of infection, which can occur in association with as many as 50% of open fractures. Strategies to minimize infection include copious irrigation, debridement, optimum fracture repair, and administration of antibiotics[2-4].

Despite the implementation of these strategies, bacterial infection remains an important cause of nonunion and osseous instability after open fracture[2]. According to the results of culture of tissues at open fracture sites prior to orthopaedic operations, gram-positive bacteria are most common in association with Gustilo-Anderson type-I fractures[5,6]. The more severe the fracture type (i.e., Gustilo-Anderson type II or III), the more likely that gram-negative or mixed bacteria are present[7].

Given the certainty of contamination and the very high incidence of infection, prophylactic use of antibiotics after open fracture has become routine[8,9]. Depending on the severity of the fracture and the preferences of the treating surgeon, the antibiotic may be given orally, parenterally, or locally. Surgeons frequently use multiple antibiotics to decrease the risk of resistance and to increase efficacy[10]. Some authorities have recommended that patients with open fractures of the extremities should receive intravenous antibiotics as prophylaxis against infection as early as possible, preferably within three hours after the injury[9,11-13]. Commonly recommended regimens include first or

second-generation cephalosporins or, if the patient has an allergy to such agents, clindamycin[11-14].

However, debate continues with regard to the duration of use, the route of administration, and the choice of antibiotics. Therefore, we undertook a systematic review and meta-analysis of the available evidence from randomized controlled trials to assess (A) the impact of antibiotic prophylaxis versus no prophylaxis on the rate of infection, (B) the impact of longer versus shorter duration of antibiotic prophylaxis on the rate of infection, and (C) the impact of alternative antibiotics on the rate of infection.

## **Materials and Methods**

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines[15] for reporting systemic reviews (Fig. 1).

### **Eligibility Criteria**

We included randomized clinical trials in which (1) the patients had presented with one or more open fractures involving the arms and legs, (2) an antibiotic prophylactic regimen was compared with any other regimen or with no antibiotic prophylaxis, and (3) the incidence of postoperative infection was reported as one of the clinical outcomes. We excluded studies addressing the use of antibiotics in patients with known infections; studies of patients with fractures involving the fingers or toes; and studies restricted to patients with gunshot wounds, injuries from bomb explosions, or HIV/AIDS (human immunodeficiency virus/acquired immune deficiency syndrome).

### **Data Sources and Search Strategy**

We searched CINAHL, EMBASE, MEDLINE, the Cochrane Central Registry of Controlled Trials (CENTRAL), and the Cochrane database of systematic reviews from 1965 to December 2013. We restricted the search to human participants.

Keywords included antibiotics, antimicrobial, antibiotic prophylaxis, open fracture, compound fracture, Gustilo- Anderson type, fracture fixation, nonunion, infection, and the names of specific antibiotics (see Appendix 1). An expert librarian (N.B.) developed the search strategy for our systematic review. One can

retrieve the same search results in our study by entering in the MEDLINE search engine all of the commands listed in the Appendix 1 and by using the translated approach with the same keywords and logic from the Appendix 1 in other literature databases listed above[16].

### **Study Selection and Data Abstraction**

Reviewers, working in pairs, independently screened titles and available abstracts of identified citations and adjudicated the eligibility of the full text of titles and abstracts that were judged to be potentially eligible.

Using a data abstraction form created with Microsoft Excel, teams of reviewers, working in pairs, extracted the following data independently from each eligible study: funding and country of study; duration of follow-up; population characteristics, including sex distribution and age; sites and Gustilo-Anderson types of open fractures[5,6] in terms of both numbers and proportions; intervention data, including antibiotic prophylaxis intervention details (antibiotic drug, dose, route of administration, start time, duration) and fluid irrigation type; and outcome data, including the number and proportion of infections in each study group and the risk ratio (RR) and its 95% confidence interval (CI).

### **Risk of Bias and Confidence in Effect Assessment**

Using a modified version of the Cochrane risk of bias tool[17,18], teams of reviewers, working in pairs, independently assessed seven domains: (1) adequacy of sequence generation; (2) allocation concealment; (3) blinding of participants,

health-care professionals, data collectors, and data analysts; (4) blinding of outcome assessors; (5) incomplete outcome data; (6) selective outcome reporting; and (7) other sources of bias. Reviewers chose from response options of “definitely yes,” “probably yes,” “probably no,” and “definitely no” for each of the domains, with “definitely yes” and “probably yes” ultimately assigned a low risk of bias and “definitely no” and “probably no” assigned a high risk of bias[17]. We used the “risk of bias summary” figure function of Review Manager (RevMan [Computer program]. Version 5.2.Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2012) to present the risk of bias result of individual studies from the seven domains of the modified Cochrane risk of bias instrument[17,19]. The RevMan software generates a red dot with a minus mark when we enter “high risk of bias” for a domain in a particular study and a green dot with a plus mark when we enter “low risk of bias.”[19] The resulting figure provides a vivid and transparent accounting of the risk of bias for every included study (Fig. 2)[19].

Reviewers resolved disagreements regarding eligibility, data abstraction, or risk of bias through discussion[18].

The GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used to rate confidence in estimates of effect (quality of evidence) as high, moderate, low or very low[18,20]. We used detailed GRADE guidance to assess overall risk of bias[18,21], imprecision[18,22], inconsistency[18,23], indirectness[18,24] and publication bias[18,25] and summarized results in an evidence profile[18,26]. In terms of the risk of bias

across studies, there are no serious limitations when most information comes from studies at low risk of bias and we therefore do not rate down for risk of bias.

There are serious limitations when most information comes from studies at moderate or high risk of bias and under these circumstances we rate down one level in the extent of risk of bias[21]. Imprecision relates to the 95% CI around the effect difference between the two groups being compared, with consideration of effect size and sample size[22]. Quality of a body of evidence may vary from high (four plus ⊕ ⊕ ⊕ ⊕), moderate (three plus ⊕ ⊕ ⊕ ○), low (two plus ⊕ ⊕ ○) to very low (one plus ⊕ ○ ○ ○), depending on the overall rating of the studies included in the metaanalysis[27]. We included as footnotes detailed explanations of our judgments in the GRADE evidence profile[26].

### **Data Synthesis and Statistical Analysis**

We assessed chance-corrected agreement in full text eligibility judgments and risk of bias assessments using the Kappa statistic[28]. We calculated pooled RRs and associated 95% CIs for infection using random effects models applying the Mantel-Haenszel (M-H) method[29]. We calculated the risk difference and 95% confidence intervals on the basis of the values of the baseline risk and the risk ratio[18,19]. Specifically, we use the median infection rate of the control groups as the baseline risks. In the case of four studies, the median was the average of the rates in the middle two studies. The heterogeneity among the studies was assessed with the  $I^2$  statistic[19]. Analyses were performed using RevMan version 5.2.

## **Results**

### **Study Identification**

Our search identified 13,499 abstracts from the electronic database search, of which 1,155 were excluded as duplicates and an additional 11,972 excluded on the basis of review of the title and abstract (Fig. 1). We were unable to access the full text of forty-three articles that had been deemed potentially eligible on the basis of a review of the title and abstract. Of the 329 articles for which the full text was reviewed, 276 were not randomized controlled trials and thirty-six did not assess open fractures involving the extremities, leaving seventeen eligible randomized controlled trials (Fig. 1) [30-46].

The agreement regarding full text eligibility selection was excellent (kappa 0.72), and the agreement in risk of bias assessments near perfect (kappa values from 0.85 to 1.0).

These studies allowed us to compare (A) antibiotic prophylaxis versus no prophylaxis, (B) longer versus shorter duration of antibiotic prophylaxis, and (C) miscellaneous antibiotic regimens (Table I).

#### **A) Antibiotic Prophylaxis versus No Prophylaxis**

Four RCTs enrolling 472 patients addressed fracture site infection with and without antibiotic prophylaxis[30-33]. Interventions included penicillins and first-generation cephalosporin administered intravenously. In two studies the patients in the control groups were given no antibiotic prophylaxis and the patients in the intervention groups received antibiotics parenterally for 5



days[30,32]. In two studies the patients in the control group received placebo[31,33], the patients in the intervention group received intravenous antibiotics for 2 days[31] or intravenous antibiotics for 4 days followed by 6 days oral antibiotics[33]. We found that in all 4 trials, randomization sequence generation and blinding of outcome assessment suffered from high risk of bias[17,30-33]. 3 out of 4 trials had high risk of bias on allocation concealment[17,30,32,33]. Risk of bias was also high because of lack of blinding of participants and health care providers in 2 out of 4 trials[17,30,32] (Fig. 2).

Results suggested a large, consistent reduction in infection risk with antibiotic use (RR = 0.37 [95% CI, 0.21 to 0.66],  $I^2 = 0\%$ ) (Fig. 3), resulting in a risk difference of 9.6% fewer (95% CI, 5.2% to 12.1% fewer) infections in the antibiotic prophylaxis groups than the comparator groups. We rated the confidence in the estimates as low to moderate because of risk of bias and imprecision (Table II) [21-27]. We rated down imprecision not because of the width of the confidence interval but rather because of the small number of events, resulting in a failure to meet optimum information size criteria[22].

### **B) Longer versus Shorter Duration of Antibiotic Prophylaxis**

Three randomized controlled trials enrolling 1104 patients were included in the meta-analysis comparing the rates of infection after longer-duration (three to five days) and shorter-duration (one day) prophylactic antibiotic use[34-36].

Interventions included first or second-generation cephalosporin given continuously for three to five days[34-36]. Controls included single-dose

cephalosporin[34], double-dose cephalosporin[34], and one day[35] of second-generation cephalosporin or single-dose fluoroquinolone[36]. In all three studies, we judged allocation concealment and the lack of blinding of outcome assessment as having a high risk of bias[17,34-36]. Randomization sequence generation (two of three trials)[17,34,35] and selective reporting (one of three trials)[17,35] were also judged as having a high risk of bias. The risk was low for attrition, reporting, and other bias[17,34-36] (Fig. 2).

Result showed very similar rates of infection between groups receiving three to five days and one day of antibiotics (RR 0.97, 95% CI 0.69-1.37),  $I^2 = 0\%$  (Fig. 4). We rated the quality of evidence as low to moderate because of the risk of bias and imprecision (Table II)[21-27].

### **C) Individual comparisons of Antibiotic Regimens**

Ten RCTs with a sample size varied from 46 to 301 patients compared infection rates for different regimens[37-46].

The risk of bias in individual studies was generally high, mainly because of inadequate sequence allocation, lack of allocation concealment, and lack of blinding (Fig. 2). The risk of bias was high in all studies[17,37-44] except for those of Johnson et al.[17,45] and Moehring et al.[17,46], which had a moderate risk of bias. Studies compared a variety of different regimens; confidence intervals in most studies were very wide[37-46] (Table I).

Two of the ten studies demonstrated significant differences between antibiotic treatments[38,39]. Vasenius et al. reported that patients in the clindamycin group

had a lower infection rate than patients in the cloxacillin group (RR = 0.46 [95% CI, 0.24 to 0.91]) [38]. Waikakul et al. showed that patients in the ofloxacin group had a higher infection rate than patients in the dicloxacillin group (RR = 0.19 [95% CI, 0.04 to 0.77]) [39]. We rated confidence in the estimates in all studies as low or very low because of the risk of bias and imprecision [21-25,27,37-46].

## Discussion

Results from four randomized controlled trials<sup>30-33</sup> enrolling a total of 472 patients suggested large reductions in the relative risk (RR = 0.37 [95% CI, 0.21 to 0.66]) and absolute risk (9.6% [95% CI, 5% to 12%]) of infection with antibiotic prophylaxis versus no prophylaxis, although the results warrant only low to moderate confidence due to limitations of risk of bias (Fig. 2) and small total sample size and number of events (Fig. 3, Table II). A meta-analysis of three studies<sup>[34-36]</sup> enrolling 1104 patients suggested no difference in the infection rate when a longer duration of antibiotics (three to five days) was compared with a shorter duration (one day) (RR = 0.97 [95% CI, 0.69 to 1.37]), although confidence again was low to moderate because of the risk of bias (Fig. 2) and wide confidence intervals (Fig. 4, Table II). Individual comparisons<sup>[37-46]</sup> all were associated with low or very low confidence in the estimates of effect because of the risk of bias (Fig. 2) and imprecision.

The strengths of the present study include explicit eligibility criteria, a comprehensive search for relevant randomized controlled trials in all languages, duplicate assessments of eligibility and risk of bias with a high level of agreement, and application of GRADE criteria for confidence in estimates of effect. The weaknesses of the present study are related to limitations in the evidence, including the small number of eligible studies, the relatively small sample size, and the high risk of bias in most studies. These limitations led to our relatively low ratings of confidence in the estimates. Among the studies<sup>[34-36]</sup> pooled in Figure 4, the unit of analysis differs, with two of the studies<sup>[35,36]</sup> comparing

infection rates of longer versus shorter durations of antibiotic prophylaxis on the basis of the number of patients and with the other study using the number of fractures[34]. We contacted the first author of the latter study to obtain the number of infection events using patients as the unit of analysis. However, the original data for that study were not retrievable. We did not exclude that study in the pooled result because, with the small number of events, the difference of using either fractures or patients as the unit would not have altered our result.

Our finding regarding the infection-preventing effect of using antibiotic prophylaxis for patients with open fractures is consistent with the findings of previous systematic reviews[14,47-49]. Gosselin et al., in an analysis of eight studies involving 1106 participants, found that antibiotics protected patients from early infection when compared with no antibiotics or placebo (RR = 0.43 [95% CI, 0.29 to 0.65]) [14]. Our study included fewer randomized controlled trials than did the study by Gosselin et al. because we excluded studies involving fractures of the fingers and gunshot wounds. We excluded studies of finger fractures because the prognosis following such fractures differs from that following extremity fractures. For finger fractures, the anatomy of the hand is such that, if an infection occurs, the infection may track down the tendon sheath[50]. For gunshot wounds, optimum management may vary depending on whether the gun was a high-velocity weapon, a low-velocity weapon, or a shotgun, each of which carries its own prognosis[51].

Other systematic reviews have led to the same conclusion that antibiotic prophylaxis has protective effects but have not provided the pooled risk ratios for

the included studies[47-49]. To our knowledge, no previous systematic review has compared the effects of different durations of antibiotic prophylaxis or different antibiotic regimens. Also, to our knowledge, no previous review has used synthetic approaches such as GRADE to assess the quality of evidence[27,52].

The low confidence in the effect of prophylaxis, despite the apparently large effect, suggests that the conduct of additional large studies with designs ensuring low risk of bias would be desirable. The long-established consensus in the community in favor of antibiotics would likely make such a trial unfeasible in the current environment. Our results suggest, however, that a single day's exposure to antibiotics is similar in its effects to more prolonged administration. An initial trial comparing shorter and longer regimens might well be feasible, and, if it showed no difference, the climate of opinion regarding the possibility of a trial of antibiotics versus no antibiotics could possibly change.

Aside from the issues of whether antibiotics should be administered at all and the duration of their use, other issues, including the optimum choice of antibiotic, the route of administration, and the optimum start time, remain unresolved. It is also possible that different regimens and durations may be preferable for different patients according to the site and severity of the fractures. Previous *in vitro* and *in vivo* experimental studies in both animals and humans showed negative effects of topical antibiotics (in the form of impregnated beads or cements in clinical practice) on bone cell function and fracture repair. High concentrations of most antibiotics can inhibit bone-healing by affecting chondrocytes and osteoblasts and increasing mineralization of bone. The optimum dose of topical antibiotics to

prevent infection without negative effects on bone repair is unknown[53].

Resolution of these issues will require randomized trials of superior design to those undertaken to date. Such studies should address the limitations of previous studies, including the failure to document adverse reactions to antibiotics and the nature of the infections that occur (e.g., superficial or deep). In addition, they should be large, multicenter studies that are sufficiently powered to provide definitive results. Finally, they should implement strategies to reduce the risk of bias (including concealed allocation and blinding of patients, clinicians, and those involved in outcome assessment) as well as strategies to minimize loss to follow-up.

### **Source of Funding**

No external funds were received in support of this study.

### **Conflict of Interest**

No conflict declared.

### **Acknowledgement**

The authors thank the following colleagues for their contribution to this research:

Mohamad Alshurafa, Lisa Cronin, Nicole Simunovic, Yanping Zhao, Bill Ristevski, Arnav Agarwal, Michal Seweryn, Kamran Naseem, Thomas Agoritsas, Arnaud Merglen, Ingmarie Skoglund, Aurelia Desplain, Andy Radoslav, Hejia Song, Mark Loeb, Paul Elias Alexander, Nigar Sekercioglu, LiWang, Qi Zhou, Toshiaki A. Furukawa, Souzan Mirza, Regina Kunz, and Victor Wang.

## References

1. Sirkin M, Sanders R, DiPasquale T, Herscovici D Jr. A staged protocol for soft tissue management in the treatment of complex pilon fractures. *J Orthop Trauma*. 2004;18(8 Suppl):S32-38.
2. Petrisor B, Sun X, Bhandari M, Guyatt G, Jeray KJ, Sprague S, Tanner S, Schemitsch E, Sancheti P, Anglen J, Tornetta P, Bosse M, Liew S, Walter S; FLOW Investigators. Fluid lavage of open wounds (FLOW): a multicenter, blinded, factorial pilot trial comparing alternative irrigating solutions and pressures in patients with open fractures. *J Trauma*. 2011 Sep;71(3):596-606.
3. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. *J Trauma*. 2003;55:949-954.
4. Bhandari M, Tornetta P III, Sprague S, et al. Predictors of reoperation following operative management of fractures of the tibial shaft. *J Orthop Trauma*. 2003;17:353-361.
5. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: Retrospective and prospective analyses. *J Bone Joint Surg Am*. 1976;58:453–458.
6. Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: A new classification of type III open fractures. *J Trauma*. 1984;24:742-746.
7. Zhang M, Chen YZ, Huang YQ, et al. Selection of antibiotics in open fracture [Chinese]. *Chin J Trauma Surg*. 2002;4(4):199-203.



8. Jaeger M, Maier D, Kern WV, et al. Antibiotics in trauma and orthopedic surgery-a primer of evidence-based recommendations. *Injury*. 2006;37(2 Suppl):S74-80.
9. Prokuski L, Clyburn TA, Evans RP, et al. Prophylactic antibiotics in orthopaedic surgery. *Instr Course Lect*. 2011;60:545-555.
10. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. *Expert Rev Anti Infect Ther*. 2013Dec;11(12):1333-53. Epub2013Nov 6.
11. Ali AM, Noyes D, Cogswell LK. Management of open fractures of the lower limb. *Br J Hosp Med*. 2013;74(10):577-580.
12. Hehemann D, Hardy MA. Keys to optimal management of open fractures. *Podiatry Management*. 2012;31(8):85-92.
13. Lane JC, Mabvuure NT, Hindocha S, et al. Current concepts of prophylactic antibiotics in trauma: a review. *Open Orthop J*. 2012;6:511-517.
14. Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. *Cochrane Database of Systematic Reviews*. 2009;4:CD003764.
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009;62:e1-34.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies

- that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009 Oct;62(10):e1-34. Epub 2009 Jul 23.
17. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. *Clinical Epidemiology: How to do clinical practice research*. Philadelphia: Lippincott, Williams & Wilkins. 2006.
  18. Spencer FA, Lopes LC, Kennedy SA, Guyatt GH. Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. *BMJ Open*. 2014;4:e004282.
  19. Higgins J PT, Green S. *Cochrane handbook for systematic reviews of interventions (version 5.1.0)*. 2011. The Cochrane Collaboration. <http://handbook.cochrane.org/>. Accessed 2014 Dec 10.
  20. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924–926.
  21. Guyatt GH, Oxman AD, Vist GE, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). *J Clin Epidemiol*. 2011;64:407-415.
  22. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 6. Rating the quality of evidence—imprecision. *J Clin Epidemiol*. 2011;64:1283-1293.
  23. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. *J Clin Epidemiol*. 2011;64:1294-1302.
  24. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence—indirectness. *J Clin Epidemiol*. 2011;64:1303-1310.

25. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. *J Clin Epidemiol.* 2011;64:1277-1282.
26. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. *J Clin Epidemiol.* 2013;66:158-172.
27. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;64:401–406.
28. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med.* 2005 May;37(5):360-3.
29. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst.* 1959; 22:719-748.
30. Rojczyk M, Malottke, R. Effect of antibiotic prophylaxis in treatment of open fractures [German]. *Hefte zur Unfallheilkunde.* 1979;138:355-357.
31. Bergman, Bo R. Antibiotic prophylaxis in open and closed fractures: a controlled clinical trial. *Acta Orthopaedica Scandinavica.* 1982;53(1):57-62.
32. Rojczyk M. Bacteriological and antimicrobial aspects in open fractures [German]. *Orthopade.* 1983;12:23-27.
33. Braun R, Enzler MA, Rittmann WW. A double-blind clinical trial of prophylactic cloxacillin in open fractures. *J Orthop Trauma.* 1987;1(1):12-17.
34. Dellinger EP, Miller SD, Wertz MJ. Risk of infection after open fracture of the arm or leg. *Archives of Surgery.* 1988;123(11):1320-1327.
35. Dellinger EP, Caplan ES, Weaver LD. Duration of preventive antibiotic administration for open extremity fractures. *Archives of Surgery.*

- 1988;123(3):333-339.
36. Carsenti-Etesse H, Doyon F, Desplaces N, et al. Epidemiology of bacterial infection during management of open leg fractures. *Eur J Clin Microbiol.* 1999;18(5):315-323.
37. Benson DR, Riggins RS, Lawrence RM. Treatment of open fractures: A prospective study. *J Trauma.* 1983;23(1):25-30.
38. Vasenius J, Tulikoura I, Vainionpaa S, et al. Clindamycin versus cloxacillin in the treatment of 240 open fractures. A randomized prospective study. *Annales Chirurgiae et Gynaecologiae.* 1998;87(3):224-228.
39. WaikakulS, Penkitti P, Nati S, et al. Oral antimicrobials in compound fracture of the hand: comparison of dicloxacillin and ofloxacin. *J Med Assoc Thai.* 1996;79(9):585-588.
40. Alpar EK. Cephadrine and flucloxacillin in the prophylaxis of infection in patients with open fractures. *J Clin Pharm Ther.* 1988;13(2):117-120.
41. Janmohammadi N, Hasanjani Roshan MR. Comparison the Efficacy of Cefazolin plus Gentamicin with Cefazolin plus Ciprofloxacin in Management of Type -IIIA Open Fractures. *Iran Red Crescent Med J.* 2011;13(4):239-242.
42. Saveli CC, Morgan SJ, Belknap RW, et al. Prophylactic antibiotics in open fractures: a pilot randomized clinical safety study. *J Orthop Trauma.* 2013;27(10):552-557.
43. Sorger JI, Kirk PG, Ruhnke CJ, et al. Once daily, high dose versus divided, low dose gentamicin for open fractures. *Clin Orthop Relat R.* 1999;366:197-204.

44. Patzakis MJ, Bains RS, Lee J, et al. Prospective, randomized, double-blind study comparing single-agent antibiotic therapy, ciprofloxacin, to combination antibiotic therapy in open fracture wounds. *J Orthop Trauma*. 2000;14(8):529-533.
45. Johnson KD, Bone LB, Scheinberg R. Severe open tibial fractures: a study protocol. *J Orthop Trauma*. 1988;2(3):175-180.
46. Moehring HD, Gravel C, Chapman MW, et al. Comparison of antibiotic beads and intravenous antibiotics in open fractures. *Clin Orthop Relat R*. 2000;372:254-261.
47. Stengel D, Bauwens K, Sehouli J, et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. *The Lancet Infectious Diseases*. 2001;1(3):175-188.
48. Hauser CJ, Adams Jr CA, Eachempati SR. Prophylactic antibiotic use in open fractures: An evidence-based guideline. *Surgical Infections*. 2006;7(4):379-405.
49. Weed HG. Antimicrobial prophylaxis in the surgical patient. *Med Clin North Am*. 2003;87(1):59-75.
50. Goldie, Boyd S. *Orthopaedic Diagnosis and Management: A Guide to the Care of Orthopaedic Patients*. Oxford: Oxford Scientific, 1991.
51. Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. *J Trauma*. 2011 Aug;71 (2)(Suppl

2):S210-34.

52. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* 2011 Apr;64(4):383-94. Epub 2010 Dec 31.
53. Kallala R, Graham SM, Nikkhah D, et al. In vitro and in vivo effects of antibiotics on bone cell metabolism and fracture healing. *Expert Opin Drug Saf.* 2012;11(1):15-32.




Fig. 1

Eligibility assessment flow diagram according to PRISMA guidelines

(doi:10.1371/journal.pmed1000097). RCT = randomized controlled trial.




Fig. 2  
Risk of bias in the individual studies included. The seventeen studies are listed on the left side of each row. The seven domains for risk of bias assessment of an individual study are shown at the top of each column. A red dot indicates a high risk of bias. A green dot indicates a low risk of bias.






Fig. 3

Forest plot showing fracture site infection with antibiotic prophylaxis versus no antibiotic prophylaxis. Blue squares indicate the risk ratio (RR); values of <1.0 indicate that antibiotic prophylaxis was associated with decreased hazard (that is, fewer infections). Horizontal lines indicate the 95% confidence intervals (CIs). The width of the CI indicates the precision of the estimate: the greater the width, the less precise the estimate. CIs that do not include 1 indicate a significant difference. The central vertical line indicates no effect of the intervention (RR = 1). The center and tips of the diamond indicate the combined point estimate (risk ratio) and CI for the meta-analysis. df = degrees of freedom.




Fig. 4

Forest plot showing fracture site infection with three to five days versus one day of antibiotic prophylaxis. Because the infection rate based on the numbers of patients was not available after we contacted the first author of the study labeled 05\_Dellinger\_risk 1988, the unit for that study is given as the number of fractures instead of patients. Blue squares indicate the risk ratio (RR); values of <1.0 indicate that antibiotic prophylaxis was associated with decreased hazard (that is, fewer infections). Values of >1.0 indicate that antibiotic prophylaxis was associated with increased hazard (that is, more infections). Horizontal lines indicate the 95% confidence intervals (CIs). The width of the CI indicates the precision of the estimate; the greater the width, the less precise the estimate. CIs that include 1 indicate that there was no significant difference. The central vertical line indicates no effect of the intervention (RR = 1). The center and tips of the diamond indicate the combined point estimate (risk ratio) and CI for the meta-analysis. df = degrees of freedom.

| TABLE I Characteristics of the Eligible Randomized Controlled Trials and Patients in These Studies* |   |   |   |  |   |  |   |                     |
|---|---|---|---|--|---|--|---|---------------------|
| Study Number  | Author (Year)                                   | Patient Characteristics   | Fracture Site (no./%)   | Gustilo-Anderson Type                                    | Intervention†   | Comparator‡  | Infection Rate (no./%)  | Chi-Square Test§    |
| (A) Randomized controlled trials comparing antibiotic prophylaxis to no prophylaxis                 |   |   |   |  |   |  |   |                     |
| 1   | Rojczyk and Malottke (1979) <sup>30</sup>       | 96 patients. Sex distribution and age NR                                | Upper extremity, 48 (50%). Lower extremity, 48 (50%)                      | Type I, 28 (29%). Type II, 43 (45%). Type III, 25 (26%)  | Adocillin (a) IM 3 × 5 g for 5 days. Start time NR  | No antibiotics   | Intervention group, 2 of 49 (4%); 1 deep, 1 superficial). Control group, 6 of 47 (13%); 4 deep, 2 superficial)                  | 0.32 (0.07 to 1.51) |
| 2   | Bergman (1982) <sup>31</sup>                    | 90 patients. Female, 31 (34%). Mean age, 51 yr                          | Upper extremity, 29 (32%). Lower extremity, 61 (68%)                      | Type I, 55 (61%). Type II and III, 35 (39%)              | Dicloxacillin (b) IV 4 × 2 g for 2 days, or benzylpenicillin (a) IV 4 × 3 million IU for 2 days. Start time within 6 hours after injury and before surgery.     | Placebo: saline solution   | Intervention group, 4 of 60 (7%); 4 superficial). Control group, 6 of 30 (20%); 2 deep, 4 superficial)                          | 0.33 (0.10 to 1.09) |
| 3   | Rojczyk (1983) <sup>32</sup>                    | 199 patients. Female, 49 (25%). Mean age, 30 yr                         | Upper extremity, 35 (18%). Lower extremity, 164 (82%)                     | Type I, 62 (31%). Type II, 78 (39%). Type III, 59 (30%)  | Adocillin (a) IM 4 × 1 g for 5 days; for more severely injured patients, used cefazolin (c) instead. Start time NR  | No antibiotics   | Intervention group, 8 of 111 (7%); 3 deep, 5 superficial). Control group, 12 of 88 (14%); 5 deep, 7 superficial)                | 0.53 (0.23 to 1.24) |
| 4   | Braun et al. (1987) <sup>33</sup>               | 87 patients with 91 fractures. Female, 34 (39%). Mean age, 42 yr        | Upper extremity, 20 fractures (22%). Lower extremity, 71 fractures (78%)  | NR   | Cloxacillin (b) IV 4 × 1 g for 4 days; thereafter, 4 × 1.5 g cloxacillin (b) orally given for 6 days. Start time within 6 hours after injury and before surgery | Placebo  | Intervention group, 2 of 43 (5%). Control group, 12 of 44 (27%)   | 0.17 (0.04 to 0.72) |
| (B) Randomized controlled trials comparing 3-5 days versus 1 day of antibiotic prophylaxis          |   |   |   |  |   |  |   |                     |
| 5   | Dellinger et al. _risk (1988) <sup>34</sup>     | 240 patients with 263 fractures. Sex distribution NR. Median age, 33 yr | Upper extremity, 71 fractures (27%). Lower extremity, 192 fractures (73%) | Type I, 60 (25%). Type II, 112 (47%). Type III, 68 (28%) | Cefazolin (c) or cefamandole (d) IV 4 × 1 g for 3 to 5 days. Start time within 6 hours after injury and before surgery  | 2 subgroups: Single dose of cefonicid (d) IV 2 g. Two doses of cefamandole (d) IV. Start time within 6 hours after injury and before surgery | Longer-duration group, 25 (15%) of 172 fractures. Shorter-duration group, 17 (19%) of 91 fractures                              | 0.78 (0.44 to 1.36) |
| 6   | Dellinger et al. _duration (1988) <sup>35</sup> | 248 patients with 264 fractures. Female, 43 (17%). Mean age, 30 yr      | NR  | Type I, 70 (28%). Type II, 72 (29%). Type III, 106 (43%) | Cefazolin (c) or cefamandole (d) IV 4 × 1 g for 3 to 5 days. Start time within 6 hours after injury and before surgery  | Cefonicid (d) IV 2 g for 1 day. Start time within 6 hours after injury and before surgery  | Longer-duration group, 21 of 169 (12%); 16 deep, 5 superficial). Shorter-duration group, 10 of 79 (13%); 5 deep, 5 superficial) | 0.98 (0.49 to 1.98) |
| 7   | Carsenti-Etesse et al. (1999) <sup>36</sup>     | 616 patients. Sex distribution and age NR                               | Leg (lower extremity), 616 (100%)   | NR   | Cefazolin (c) IV 4 × 1 g for 2 days followed by oxacillin (b) orally given 3 × 1 g for 3 days. Start time NR  | Single dose of pefloxacin (f) IV 800 mg. Start time NR   | Longer-duration group, 24 of 300 (8%). Shorter-duration group, 21 of 316 (7%)   | 1.20 (0.68 to 2.12) |

continued

| TABLE I (continued)                                  |  |  |   |   |  |   |   |                     |
|--|--|--|---|---|--|---|---|---------------------|
| Study Number   | Author (Year)  | Patient Characteristics  | Fracture Site (no. /%)  | Gustilo-Anderson Type                                     | Intervention†  | Comparator†   | Infection Rate (no. /%)   | Chi-Square Test‡    |
| (C) Miscellaneous comparisons of antibiotic regimens |  |  |   |   |  |   |   |                     |
| 8  | Benson et al. (1983) <sup>37</sup>                     | 78 patients with 82 fractures. Female, 9 (12%). Mean age, 30 yr    | Upper extremity, 31 (40%). Lower extremity, 44 (56%). Both extremities, 3 (4%)    | NR  | Clindamycin IV for 5 days. Start time within 6 hours after injury and before surgery   | Cefazolin (c) IV for 5 days. Start time within 6 hours after injury and before surgery  | Clindamycin group, 2 of 34 (6%). Cefazolin group, 3 of 42 (7%). 2 patients received only oral cephalexin (c), no infection occurred | 0.82 (0.15 to 4.65) |
| 9  | Vasenius et al. (1998) <sup>38</sup>                   | 227 patients with 240 fractures. Female, 80 (35%). Mean age, 38 yr | Upper extremity, 91 fractures (38%). Lower extremity, 149 fractures (62%)         | Type I, 60 (26%). Type II, 109 (48%). Type III, 58 (26%)  | Clindamycin IV 4 × 300 to 600 mg by patient weight for 3 days. Start time within 6 hours after injury and before surgery   | Cloxacillin (a) IV 4 × 2 g for 3 days. Start time within 6 hours after injury and before surgery  | Clindamycin group, 11 of 118 (9%); 6 deep, 5 superficial). Cloxacillin group, 22 of 109 (20%); 7 deep, 15 superficial)              | 0.46 (0.24 to 0.91) |
| 10   | Waikakul et al. (1996) <sup>39</sup>                   | 56 patients. Female, 16 (29%). Mean age, 23 yr                     | Compound fracture of hand (upper extremity), 56 (100%)                            | Type II, 20 (36%). Type III, 36 (64%)                     | Ofloxacin (f) orally given 2 × 300 mg for 5 days. Start time NR  | Dicloxacillin (b) orally 4 × 1 g for 5 days. Start time NR  | Ofloxacin group, 2 of 29 (7%); 2 superficial). Dicloxacillin group, 10 of 27 (37%); 3 deep, 7 superficial)                          | 0.19 (0.04 to 0.77) |
| 11   | Alpar (1988) <sup>40</sup>                             | 60 patients. Female, 15 (25%). Mean age, 30.5 yr                   | Upper extremity, 11 (18%). Lower extremity, 49 (82%)                              | Type I, 12 (20%). Type II, 20 (33%). Type III, 28 (47%)   | Cephadrine (c) IM 4 × 1 g until patients could tolerate oral administration, at which point given 2 × 500 mg. The whole duration was a maximum of 10 days. Start time within 6 hours after injury and before surgery | Flucloxacillin (b) IM 4 × 250 mg until patients could tolerate oral administration given the same drug and dose. The whole duration was a maximum of 10 days. Start time within 6 hours after injury and before surgery | Cephadrine group, 0 of 30. Flucloxacillin group, 2 of 30 (7%)   | 0.20 (0.01 to 4.00) |
| 12   | Janmohammadi and Hasanjani Roshan (2011) <sup>41</sup> | 301 patients. Female, 86 (29%). Mean age, 37 yr                    | Upper extremity, 69 (23%). Lower extremity, 199 (66%). Both extremities, 33 (11%) | Type IIIA, 301 (100%)                                     | Cefazolin (c) IV 3 × 1 g plus ciprofloxacin (f) orally given 2 × 500 mg for 3 days. Start time NR  | Cefazolin (c) IV 3 × 1 g plus gentamicin (g) 5 mg/kg/d in 3 divided doses for 3 days. Start time NR   | Intervention group, 10 of 153 (7%). Control group, 8 of 148 (5%)  | 1.21 (0.49 to 2.98) |
| 13   | Saveli et al. (2013) <sup>42</sup>                     | 101 patients. Female, 36 (28%). Mean age, 41 yr                    | NR  | Type I, 43 (43%). Type II, 24 (24%). Type III, 34 (34%)   | Cefazolin (c) IV 3 × 1 g (weight <80 kg) or 3 × 2 g (weight ≥80 kg) plus vancomycin IV based on patient glomerular filtration rate, start from presentation to hospital until 24 hours after fracture fixation       | Cefazolin (c) IV 3 × 1 g (weight <80 kg) or 3 × 2 g (weight ≥80 kg) start from presentation to ER until 24 hours after fracture fixation  | Intervention group, 9 of 48 (19%); 6 deep, 3 superficial). Control group, 8 of 53 (15%); 5 deep, 3 superficial)                     | 1.24 (0.52 to 2.96) |
| 14   | Sorger et al. (1999) <sup>43</sup>                     | 71 patients with 75 fractures. Female, 25 (35%). Mean age, 36 yr   | NR  | Type II, 55 fractures (73%). Type III, 20 fractures (27%) | Once daily, high dose gentamicin (g) IV 6 mg/kg plus cefazolin (c) 3 × 1 g begun in ER and continued for 48 hours after each operation until wound closure   | Divided, low-dose gentamicin (g) IV 5 mg/kg/d divided in 2 daily doses plus cefazolin (c) 3 × 1 g begun in ER and continued for 48 hours after each operation until wound closure                                       | Intervention group, 2 of 30 (7%). Control group, 6 of 41 (15%)  | 0.46 (0.10 to 2.10) |

continued

| TABLE I (continued) |                                      |  |   |   |   |  |  |   |
|---------------------|--------------------------------------|--|---|---|---|--|--|---|
| Study Number        | Author (Year)                        | Patient Characteristics  | Fracture Site (no./%)   | Gustilo-Anderson Type   | Intervention†   | Comparator‡  | Infection Rate (no./%)   | Chi-Square Test‡  |
| 15                  | Patzakis et al. (2000) <sup>44</sup> | 163 patients with 171 fractures. Female, 29 (18%), Median age, 30 yr | Upper extremity, 60 fractures (35%). Lower extremity, 111 fractures (65%) | Type I, 65 fractures (38%). Type II, 54 fractures (32%). Type III, 52 fractures (30%) | Ciprofloxacin (f) IV 2 × 400 mg and orally given 2 × 500 mg after surgical irrigation and debridement. The whole duration was from 3 days (1 surgical procedure) to a maximum of 8 days (more than 1 surgical procedure). Start time within 6 hours after injury and before surgery | Cefamandole (d) IV 4 × 2 g, gentamicin (g) IV 3 × 80 mg and placebo in oral phase after surgical irrigation and debridement. The whole duration was from 3 days (1 surgical procedure) to a maximum of 8 days (more than 1 surgical procedure). Start time within 6 hours of injury and before surgery | Ciprofloxacin group, 11 (14%) of 78 fractures. Cefamandole/gentamicin group, 6 (6%) of 93 fractures.   | 2.19 (0.85 to 5.64)   |
| 16                  | Johnson et al. (1988) <sup>45</sup>  | 46 patients. Female, 5 (11%), Mean age, 29 yr                        | Tibia (lower extremity), 46 (100%)  | Type II, 19 (41%). Type III, 27 (59%)   | Cefotaxime (e) IV 3 × 1 g for 2 days. Start time within 6 hours after injury and before surgery   | Cefazolin (c) IV 3 × 1 g for 2 days. Start time within 6 hours after injury and before surgery   | Cefotaxime group, 4 of 21 (19%). Cefazolin group, 6 of 25 (24%)  | 0.79 (0.26 to 2.44)   |
| 16                  | Johnson et al. (1988) <sup>45</sup>  | 46 patients. Female, 5 (11%), Mean age, 29 yr                        | Tibia (lower extremity), 46 (100%)  | Type II, 19 (41%). Type III, 27 (59%)   | Cefotaxime (e) IV 3 × 1 g for 2 days. Start time within 6 hours after injury and before surgery   | Cefazolin (c) IV 3 × 1 g for 2 days. Start time within 6 hours after injury and before surgery   | Cefotaxime group, 4 of 21 (19%). Cefazolin group, 6 of 25 (24%)  | 0.79 (0.26 to 2.44)   |
| 17                  | Moehring et al. (2000) <sup>46</sup> | 67 patients with 75 fractures. Female, 17 (25%), Mean age, 34 yr     | Upper extremity, 5 fractures (7%). Lower extremity, 70 fractures (93%)    | NR  | Cefazolin (c) IV certain mg/kg weight as recommended (source NR) at admission to ER. Beads group: tobramycin (g) impregnated beads implanted at surgical site, no further antibiotics were given. Beads + antibiotic group: beads implanted and regimen same as with control group  | Cefazolin (c) IV certain mg/kg weight as recommended (source NR) at admission to ER. Cefazolin (c) IV 3 × 1 g and where indicated, gentamicin (g) IV 2 × 2.5 mg/kg until wound was closed  | Beads group, 2 of 24 fractures in 22 patients (8% by fractures, 9% by patients). Beads + antibiotic group, 2 of 13 fractures in 12 patients (15% by fractures, 17% by patients). Control group, 2 of 38 fractures in 33 patients (5% by fractures, 6% by patients) | 1.50 (0.23 to 9.87) for comparison of beads group and control group based on number of patients. 2.75 (0.43 to 17.41) for comparison of beads + antibiotic group and control group based on number of patients. |

\*NR = not reported, IM = intramuscular, IV = intravenous, and ER = emergency room. †The classification of antibiotics is indicated by a lower case letter in parentheses as follows: (a) penicillin class or extended spectrum penicillin, (b) penicillinase-resistant penicillin, (c) first-generation cephalosporin, (d) second-generation cephalosporin, (e) third-generation cephalosporin, (f) fluoroquinolone, (g) aminoglycoside. ‡Unless otherwise specified, the data are given as the risk ratio and 95% confidence interval. The online tool MedCalc ([www.medcalc.org](http://www.medcalc.org)) was used to calculate these values for all of the studies.

| TABLE II GRADE Evidence Profile of Studies of Antibiotic Prophylaxis Among Patients with Open Fractures                            |                      |                        |                        |                       |                  |                     |                                  |   |  |
|--|----------------------|------------------------|------------------------|-----------------------|------------------|---------------------|----------------------------------|---|--|
| No. of Participants (No. of Studies)   | Quality Assessment   |                        |                        |                       |                  | Summary of Findings |                                  |   |  |
|  | Risk of Bias         | Inconsistency          | Indirectness           | Imprecision           | Publication Bias | Relative Effect*    | Infection Rate in Control Group† | Risk Difference   | Confidence in Estimates of Effect                        |
| (1) Fracture-site infection with antibiotic prophylaxis versus none<br>472 patients (4 randomized controlled trials)               | Serious limitations# | No serious limitations | No serious limitations | Serious limitations§  | Not detected     | 0.37 (0.21 to 0.66) | 15.3%                            | 9.6% fewer infections in intervention group (95% CI, 5.2% fewer to 12.1% fewer) | ⊕⊕○○ low to moderate due to risk of bias and imprecision |
| (2) Fracture-site infection with 3-5 days versus 1 day of antibiotic prophylaxis<br>1104 patients (3 randomized controlled trials) | Serious limitations# | No serious limitations | No serious limitations | Serious limitations** | Not detected     | 0.97 (0.69 to 1.37) | 12.7%                            | Difference not significant  | ⊕⊕○○ LOW to moderate due to risk of bias and imprecision |

\*The values are given as the risk ratio and the 95% CI. †The median of the event rate of the included studies was used for calculation of risk difference. #Serious risk of bias due to poor performance in randomization sequence generation and the lack of blinding of outcome assessment in all four trials, poor performance in allocation concealment in three of four trials, and lack of blinding of participants and personnel in two of four trials. §Serious limitations due to small sample size and number of events. #Serious risk of bias due to allocation concealment and the lack of blinding of outcome assessment in all three trials, poor performance in randomization sequence generation in two of three trials, and selective reporting in one of three trials. \*\*Serious limitations due to wide confidence intervals in the pooled estimates.

Appendix 1. MEDLINE title and abstract search strategy for effects of antibiotic prophylaxis in patients with open fracture

1. antibiotics.mp. or exp Anti-Bacterial Agents/
2. antibiotic prophylaxis.mp. or exp Antibiotic Prophylaxis/
3. (anti-microb\* or anti bact\* or antibact\*).mp.
4. (antibiotic\* or antimicrob\*).mp.
5. cephalothin.mp.
6. antibioprohylaxis.mp.
7. cloxacillin.mp.
8. exp AMOXICILLIN/ or AMOXICILLIN.mp.
9. exp Ampicillin/ or AMPICILLIN.mp.
10. CLAVULANIC ACID.mp.
11. AMOXICLAV.mp.
12. AUGMENTIN.mp.
13. TICARCILLIN.mp.
14. exp Cephalosporins/ or CEPHALOSPORIN\*.mp.
15. (KEFLEX or CEFAMANDOLE or KEFADOL or CEFAZOLIN\* or KEFZOL or CEFIXIME or SUPRAX).mp.
16. (CEFOTAXIME or CLAFORAN or CEFOXITIN or MEFOXIN or CEFPIROME or CEFROM or CEFPODOXIME).mp.
17. (ORELOX or CEFPROZIL or CEFZIL or CEFRADINE or VELOSEL or CEFTAZIDIM or ORTUM or KEFADIM).mp.

18. (CEFTRIAXONE or ROCEPHIN or CEFUROXIME or ZINACEF or ZINNAT or CEFONICID or AZTREONAM).mp.
19. (AZACTAM or IMIPENEM or ILASTATIN or PRIMAXIN or MEROPENEM).mp.
20. (TETRACYCLINE\* or DETECLO or DEMECLEOCYCLIN or LEDERMYCIN or DOXYCYCLINE or VIBRAMYCIN).mp.
21. (MINOCYCLINE or MINOCINE or OXYTETRACYCLINE or TERRAMYCIN or MACROLIDE\*).mp.
22. (ERYTHROMYCIN or ERYMAX or ERYTHROCIN or ERYTHROPED or AZITHROMYCIN or ZITHROMAX).mp.
23. (CLARITHROMYCIN or KLARICID or TELITHROMYCIN or KETEK or TRIMOXAZOLE or SEPTRIN).mp.
24. (TRIMETHOPRIM or MONOTRIM or TRIMOPAN or METRONIDAZOLE or FLAGYL or METROLYL).mp.
25. (PHENOXYMETHYLPENICILLIN or SULFAMETHOXAZOLE or OXACILLIN or CEPHALOTHIN or SULBACTAM).mp.
26. (OFLOXACIN or CLINDAMYCIN or GENTAMYCIN or VANCOMYCIN).mp.
27. (CEFACLOR or DISTACLOR or CEFADROXIL or BAXAN or CEFALEXIN or CEPOREX).mp.
28. (TIMENTIN or FLUCLOXACILLIN or FLUAMPICIL or MAGNAPEN or PIPERACILLIN or TAZOCIN).mp.
29. (streptomycin or cefalotin or dicloxacillin).mp.



30. or/1-29
31. exp fractures, open/
32. (orthopedic adj2 surg\*).mp.
33. (open adj9 fracture\*).mp.
34. ((open adj2 reduction) and fracture\*).mp.
35. (Gustilo or Gustillo).mp.
36. anderson type\*.mp.
37. (compound adj9 fracture\*).mp.
38. ununited fractures.mp. or exp Fractures, Ununited/
39. fracture fixation.mp. or exp Fracture Fixation/
40. fracture\*.mp. or exp Fractures, Bone/
41. (infect\$ adj3 (bone\$ or fracture\$)).mp.
42. ((nonunion or non union) adj9 fracture\*).tw.
43. or/31-42
44. 30 and 43
45. animals/ not humans/
46. 44 not 45

## **CHAPTER 3**

### **Antibiotic Prophylaxis in the Management of Open Fractures: A Systematic Survey of Current Practice and Recommendations**

Submitted to the JBJS Reviews December 8, 2017

## **Antibiotic prophylaxis in the management of open fractures: a systematic survey of current practice and recommendations**

Yaping Chang, MSc<sup>1</sup>, Mohit Bhandari, PhD, MD<sup>1,2</sup>, Kan Lun Zhu<sup>3</sup>, Reza Donald Mirza, MD<sup>3</sup>, Melody Ren, MD<sup>4</sup>, Sean Alexander Kennedy, MD<sup>5</sup>, Ahmed Negm, MD<sup>2</sup>, Neera Bhatnagar, MLIS<sup>6</sup>, Faysal N Najji, BHSc, MD<sup>7</sup>, Lazar Milovanovic, MD<sup>8</sup>, Yutong Fei, PhD, MD<sup>9</sup>, Arnav Agarwal, BHSc<sup>4</sup>, Rakhshan Kamran<sup>1</sup>, Sung Min Cho, BHSc<sup>4</sup>, Stefan Schandelmaier, MD<sup>1,10</sup>, Li Wang, PhD<sup>11,12</sup>, Lin Jin, MD<sup>1</sup>, Shiyun Hu, PhD, MD<sup>13</sup>, Yanping Zhao, PhD<sup>14</sup>, Luciane Cruz Lopes, PhD<sup>15</sup>, Mei Wang, MSc, MD<sup>1</sup>, Brad Petrisor, MD<sup>2</sup>, Bill Ristevski, MD<sup>2</sup>, Reed A.C. Siemieniuk, MD<sup>1</sup>, Gordon H Guyatt, MD<sup>1,3</sup>

### **Affiliations and Correspondence**

1. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
2. Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
3. Department of Medicine, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
4. Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8, Canada
5. Department of Diagnostic Radiology, University of Toronto, Toronto, Ontario, M5T 1W7, Canada

6. Health Science Library, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
7. Division of Vascular Surgery, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
8. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 2Y9, Canada
9. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
10. Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel and University of Basel, Switzerland
11. Department of Anesthesia, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
12. Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, L8S 4K1, Canada
13. Cardiovascular and Cerebrovascular Disease Prevention and Control Research Center of Zhejiang Province, Zhejiang Hospital, Hangzhou, Zhejiang, 310013, China
14. School of Public Health, The University of Hong Kong, Hong Kong, China
15. Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, Sao Paulo, Brazil

## ABSTRACT

**Background:** Evidence regarding antibiotic prophylaxis is limited, and no systematic summary of clinicians' practice, or of expert recommendations, is available. We therefore conducted a systematic survey addressing current practice and recommendations.

**Methods:** We included publications from January 2007 to June 2017 that addressed antibiotic prophylaxis for patients with open fractures of the extremities. We searched EMBASE, MEDLINE, CINAHL, CENTRAL and the Cochrane database of systematic reviews for clinical studies and surveys of surgeons; WorldCat for textbooks; and websites for guidelines and institutional protocols.

**Results:** We identified 223 eligible publications that reported 100 clinical practice patterns and 276 recommendations regarding systemic antibiotic administration, and 3 recommendations regarding local antibiotic administration alone. In practice, most (55.6%) used regimens with both gram-positive and gram-negative coverage, and continued the administration for 2 to 3 days (39.2%). The large majority recommendations (97.1%) had language consistent with a recommendation for prophylactic systemic antibiotics. Most recommendations (73.5%) suggested gram-positive coverage for less severe injuries and administration duration of 3 days or less (half suggested 1 day). For more severe injuries, most recommendations suggested broad antimicrobial coverage (88.6%) continued for 2 to 3 days (60.7%). Most publications reported practice or recommended intravenous administration of antibiotics immediately or within four hours after

injury.

**Conclusions:** Current practice and recommendations strongly support early systemic antibiotics prophylaxis for patients with open fractures of extremities. Differences in antibiotic regimens, doses and durations of administration remain in both practice and recommendations. Consensus regarding optimal practice will likely require well-designed randomized controlled trials.

**KEY WORDS:**

open fracture; antibiotic regimen; prophylaxis; practice; recommendation

## Introduction

Open fractures are fractures associated with soft tissue compromise that result in a communication of the fracture ends with the outside environment. This may be the result of an “inside-out” type injury where the bone has protruded through the skin or by significant disruption of the soft tissue envelope resulting in skin and soft tissue compromise as can be seen in high energy or other crush type injuries.<sup>[1-3]</sup> The Gustilo classification has been the most widely used system for classification of infection risk associated with fracture severity. The system takes into consideration of the energy of the fracture, soft tissue damage, and the degree of contamination. The Gustilo system was modified in 1984 to allow for consideration of more severe injuries (i.e., Type 3 injuries)<sup>[4]</sup>.

In open fractures, there is communication of the fracture site with the outside environment<sup>[5]</sup>. This communication can result in infection that may not only contribute to wound healing problems, but also play a significant role in the subsequent development of nonunion and continued bony instability<sup>[1,2,6,7]</sup>. Preventing infection is therefore of utmost importance in open fracture management.

Investigations addressing which bacteria are commonly found in open fracture wounds prior to irrigation and debridement have most frequently identified gram-positive bacteria, such as *Streptococcus spp.* and *Staphylococcus spp.* in Gustilo type 1 and 2 fractures. With increasing severity of open fracture, and with soil-contaminated wounds, gram-negative or mixed bacteria are likely to be present. Clinicians should consider using broader coverage in open fractures

contaminated by fresh water (aeromonas and pseudomonas) and salt water (vibrio).<sup>[2,8]</sup> The association between Gustilo classification and the organisms that colonize wounds may have implications for optimal choice of antibiotics, which is the issue of concern in this article.

Surgeons can use a number of strategies to minimize the development of infection, including timely wound irrigation and debridement, fracture stabilization and the early administration of systemic antibiotics<sup>[7,9,10]</sup>. Given the certainty of contamination and the high incidence of infection<sup>[5]</sup>, prophylactic use of antibiotics in open fracture care delivered as early as possible after injury has become routine<sup>[11,12]</sup>. The individual treating surgeon or emergency room doctor typically choose the type of antibiotic, route of delivery and duration. The antibiotic administration may differ depending on department protocols and individual treating surgeons' preferences. Clinicians often use multiple antibiotics together when there is substantial risk that a single agent would not provide antimicrobial coverage against all infecting organisms<sup>[13-17]</sup>.

Given these considerations, a variety of antibiotic regimens are reasonable; the optimal regimen is probably context dependent. Systematic reviews of randomized controlled trials (RCTs) are available and have established that there is moderate quality evidence that antibiotics versus no antibiotics do appreciably reduce wound infections<sup>[18,19]</sup>. The evidence comes from relatively old studies, and no RCTs have effectively addressed issues such as the optimal choice of antibiotics, whether that choice differs with fracture type, or the optimal duration of antibiotic administration.



Under these circumstances, guidelines become important, and clinicians need to understand the nature and range of advice that guidelines provide. No systematic survey of the antibiotics prophylaxis currently in use or recommended exists to inform practice or future research. We therefore undertook a systematic survey with the goal of summarizing current practice and expert guidance in the use of antibiotics prophylaxis for open fractures. The current article is thus not intended as a systematic review of evidence bearing on use of antibiotics. Rather, it is intended as a systematic survey of reports of surgeons' practice in the use of prophylactic antibiotics, and a complementary systematic survey of the available expert recommendations. The scope includes all published articles that describe practice, and all published articles, textbooks, guidelines and institutional protocols that offer recommendations regarding antibiotic prophylaxis.

## **Materials and Methods**

We registered our study protocol with PROSPERO (Prospective Register of Ongoing Systematic Reviews; identifier: CRD42016053285) and reported results according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) recommendations (Fig. 1) <sup>[20]</sup>.

### **Eligibility Criteria**

We included publications over the last decade that include a section addressing either or both of the two questions: (1) what regimens (drug, dose, route of administration, start time and duration) are clinicians using as prophylaxis and (2) what regimens are experts recommending.

We searched and retrieved the evidence from the following publications: (1) multi-center or single-center RCTs, cohort studies, case-control studies and single arm studies (including case series) that indicate use of antibiotic prophylaxis among patients with open fracture, published from January 1, 2007 to June 30, 2017, and with 80% or more patients enrolled after December 31, 2006; (2) review articles of the management of open fractures that provide guidance regarding appropriate prophylactic antibiotic regimens; (3) surveys of surgeons with information regarding use of antibiotic prophylaxis in open fracture management; (4) orthopedic textbooks with sections on the management of open fractures; (5) clinical practice guidelines addressing the management of open fractures that provide guidance regarding appropriate prophylactic antibiotic regimens; and (6) institutional protocols provided on websites of trauma centers,

published from January 1, 2007 to June 30, 2017.

We excluded publications addressing the use of antibiotics in patients with known infections or HIV/AIDS (human immunodeficiency virus/acquired immune deficiency syndrome) and publications restricted to pediatric injuries.

### **Data Sources and Search Strategy**

We identified relevant publications using a systematic search of EMBASE, MEDLINE, CINAHL, the Cochrane Central Registry of Controlled Trials (CENTRAL) and Cochrane database of systematic reviews. Keywords included antibiotics, antimicrobial, antibiotic prophylaxis, open fracture, compound fracture, Gustilo-Anderson type, fracture fixation, nonunion, infection, and the names of specific antibiotics (Appendix 1). A librarian (N.B.) developed the search strategy. One can retrieve the same search results in our study by entering in the MEDLINE search engine all of the commands listed in the Appendix 1 and by using the modified approach with the same keywords and logic from the Appendix 1 in other literature databases listed above <sup>[21]</sup>. We also checked the citations and references of the included articles for any additional eligible studies.

We conducted a search for textbooks using WorldCat (the world's largest online catalogue for textbooks, [www.worldcat.org](http://www.worldcat.org)). Keywords included orthopedic surgery, orthop(a)edic operation, open fracture, antibiotic prophylaxis and infection prevention, and published from 2007 to 2017. We restricted the search to non-fiction publications. We borrowed the eligible textbooks from Health Sciences Library of McMaster University, The University of Hong Kong,

and other universities across Canada via RACER (Rapid Access to Collections by Electronic Requesting) system. In addition, we checked the references of relevant sections in these textbooks for any eligible publications. We used the latest version of a textbook when more than one version was available.

We consulted the Canadian surgeons (M.B., B.P., B.R. and A.N.) and their international orthopedic colleagues about sources of clinical practice guidelines and internet published protocols addressing the management of open fractures. We conducted open-ended Google search with keywords: trauma, injury, open fracture, antibiotic, and (guideline or protocol). We searched websites of the US National Guideline Clearing House ([www.guideline.gov](http://www.guideline.gov)), American Academy of Orthopaedic Surgeons ([www.aaos.org](http://www.aaos.org)), Orthopaedic Trauma Association ([www.ota.org](http://www.ota.org)), the Scottish Intercollegiate Guidelines Network (SIGN) ([www.sign.ac.uk](http://www.sign.ac.uk)), the National Institute for Health and Care Excellence (NICE) ([www.nice.org.uk](http://www.nice.org.uk)), the British Orthopaedic Association ([www.boa.ac.uk](http://www.boa.ac.uk)), the East Practice Management Guidelines Work Group ([www.east.org](http://www.east.org)), the Medscape ([www.medscape.com](http://www.medscape.com)), the SurgWiki ([www.surgwiki.com](http://www.surgwiki.com)), the Cambridge Orthopaedics ([www.cambridgeorthopaedics.com](http://www.cambridgeorthopaedics.com)) and the OrthoBullets ([www.orthobullets.com](http://www.orthobullets.com)) ([www.orthobullets.com/trauma/1004/open-fractures-management](http://www.orthobullets.com/trauma/1004/open-fractures-management)) for relevant clinical practice guidelines, published from 2007 to 2017. We used the latest version of a guideline if one had more than one version from the same source.

### **Study Selection and Data Abstraction**

Before starting eligibility review, reviewers conducted calibration exercises to ensure consistency. Teams of reviewers (KLZ, RDM, MR, SAK, AN, FN, LM, YF, AA, SMC, RK, SS, LJ, SH, YZ, LCL and BR), working in pairs, independently and in duplicate, screened titles (chapter titles for textbooks) and available abstracts and retrieved the full text of potentially eligible publications. For clinical practice guidelines and institutional protocols, reviewers directly screened full texts. Reviewers resolved disagreement by discussion or, if disagreement remained, through discussion with an arbitrator (G.G. or M.B.). We assessed chance-corrected agreement in full text eligibility judgments using the kappa statistic <sup>[22]</sup>.

We created data abstraction forms with Microsoft Excel. Before starting data abstraction, reviewers conducted calibration exercises to ensure consistency. Reviewers, working in pairs, extracted data independently from each eligible data source. One reviewer extracted data; the other double-checked the results. YC checked all the abstracted data. Abstracted data included the strength of recommendations regarding whether antibiotics should be systematically given to patients with open fractures of extremities, injury severity, prophylactic antibiotic regimen, dose, route of administration, start time, duration and type of evidence.

### **Data Summarization**

We categorized all the included information as a description of practice or a recommendation. Based on the advice of orthopedic surgeons (B.P., M.B., B.R. and A.N.) we combined prognostically similar injury severity groups from the

primary articles, textbook chapters and guidelines. Internal medicine physicians (G.G. and R.A.S.) categorized the prophylactic antibiotic regimens, and resolved disagreements through discussion.

We categorized recommendations regarding whether antibiotics should be given to patients with open fractures as follows: must (i.e., strong in favour), probably should, possibly should, uncertain, probably should not, certainly should not, and no opinion by injury severity groups.

We summarized used or recommended antibiotic regimens. In many instances, authors of both practice and recommendation made statements regarding prophylactic antibiotics, but did not specify the name of drugs or whether they were referring to gram-positive, gram-negative coverage, or both. When we summarized and reported the proportion of antibiotic regimens used or recommended, we did not include in the denominator the reports of practice and recommendations in which authors specified neither drug names nor categories of drugs.

We used Microsoft Excel to record the data and make calculations for sorting and summarization.

## **Results**

### **Study Identification**

Our search identified 17,707 titles and abstracts from the electronic database search, of which 279 were excluded as duplicates and an additional 16,514 were excluded on the bases of review of title and abstract (Fig. 1). We identified 11,691 textbooks from search in the WorldCat website, of which 642 were excluded as duplicates and an additional 10,563 were excluded on the bases of review of title, contents and index (Fig. 1). We were unable to access the full text of four articles and 47 textbooks that had been deemed potentially eligible on basis of a title, abstract, contents or index review.

Of the 910 articles, 439 textbooks and 11 online guidelines that underwent full text review, 754 articles, 377 textbooks and 6 online guidelines did not address prophylactic antibiotics for patients with open fracture of extremities or described evidence after the year of 2006, leaving a total of 223 eligible publications (156 articles, 62 textbook chapters and 5 online guidelines) (Fig. 1).

There was a high-level of agreement for full-text eligibility selection of articles in electronic databases (kappa, 0.80); the agreement regarding full-text eligibility selection of textbooks, clinical practice guidelines and institutional protocols was perfect (kappa, 1.0).

### **Overall Characteristics of Clinical Practice and Recommendations**

Among the 223 included publications, 67 reported actual practice and 147 provided recommendations; 9 reported both practice and recommendations (Table

I, Table II). Three of the 147 recommendations addressed local antibiotic administration alone<sup>[23-25]</sup>.

168 out of the 223 (75.3%) publications were from 2011 or later (Table I). Of the 223 publications, 128 (57.4%) were exclusively or jointly from North America (Table II). We present the absolute numbers in Table III and V.

We reported the number of publications containing information of dose and presented the dose of antibiotics in a descriptive way because the dose in included publications was too diverse to be effectively categorized.

## **Current practice**

### ***Type of publications***

Of 76 publications that recorded practice of systemic antibiotic prophylaxis in the treatment of open fractures, 64 (84.2%) were primary clinical studies of single or multiple arms including RCTs, cohort studies, case-control studies, case series and case reports<sup>[7,26-88]</sup>, 3 (3.9%) were surveys completed by surgeons<sup>[89-91]</sup> and 9 (11.8%) contained both primary data of patients and narrative reviews and hence addressed both practice and recommendations<sup>[14-17,92-96]</sup>.

### ***Systemic antibiotic regimen***

The 76 studies included 100 reports of clinical practices by injury severity. Approximately a third reported using only gram-positive coverage (with or without coverage of MRSA or anaerobic coverage), and another 10% only gram-negative coverage (with or without anaerobic coverage) (Table III). The



remainder, just over a half, used regimens covering both gram-positive and gram-negative organisms (Table III).

Thirty-eight publications specified practice in lower extremity injuries (femur [35,43,56,59,60,83,92], tibia [17,28,30,31,35,38-40,44,48,49,51,52,55-57,59,61,62,71,76,78,79,83,84,88,94], ankle [85] and calcaneus [33,34,45]) of varying severity of which 24 specified the antibiotics administered. Two thirds used regimens with broad bacterial coverage and all but one of the others limited coverage to gram-positive organisms [61] (Table V, Appendix 2).

### *Dose*

Nineteen of 100 reports of practice included information regarding dose. Two studies reported either weight-based dosing [95] or empirical administration [83]. The remainder reported use of regimens ranges such as 1-2 g first generation cephalosporin like cefazolin (600-900 mg clindamycin if allergic to cephalosporin) every 6-8 hours or 80-100 mg gentamicin given intravenously (IV) for injuries of various severities [26,40,51,55,56,58,61,62,65,70].

### *Route of administration*

Fifty-six of 100 reports of practice specified that antibiotics were administered IV or IV followed by orally. The remainder did not report route of administration.

Sixteen of 100 reports mentioned that antibiotics were applied locally including, antibiotic-infused equine collagen sponges [37]; nanocrystalline silver dressing [50]; antibiotic-impregnated polymethyl methacrylate (PMMA) beads

[28,31,42,83]; titanium alloy nail with alloy containing antibiotics [39]; impregnated en bloc cement spacer when there was dead space in bones and b-tricalcium phosphate granules coated with bonypid (BonyPid™) which releases doxycycline at constant rate [93]. The antibiotics impregnated in local carriers were gentamicin, or vancomycin plus tobramycin if cultures were negative culture or not obtained [28,31,37,54,87]; imipenem or amikacin if *Acetivobacter spp.* were isolated [29]. In two studies, the antibiotic regimen was changed to target culture and sensitivity results [29,83].

### ***Time to antibiotic administration***

#### *Start time in relation to injury*

Of the 100 reports of practice that addressed patients with open fracture of extremities, 38 reported the start time of antibiotic administration in relation to injury. Of these, approximately half gave the regimen immediately, early or as soon as possible after injury, in the emergency room, or administered on arrival in the emergency department. The remainders administered antibiotics either within one hour, within 2 to 4 hours, or within 10 to 12 hours after the injury. One additional study reported administration within 48 hours (i.e., within 2 days for low velocity ballistic fractures) [89].

#### *Start time in relation to surgery*

Seventeen of 100 reports of practice specified start time in relation to surgery. Of these, 17, over half indicated that antibiotics were given pre-operatively

[33,44,56,59,60,78,88], 1 hour<sup>[16]</sup> or 30 minutes<sup>[58]</sup> before skin incision. The remainder reported giving antibiotics peri-operatively<sup>[27,57]</sup>, post-operatively<sup>[52,71,94]</sup>, or after the operation<sup>[29]</sup>.

### ***Duration***

Fifty-one of 100 reports of practice specified duration of antibiotic administration. One study that investigated 66 surgeons' attitudes toward prophylactic antibiotics reported that most respondents chose single dose<sup>[16]</sup>. For less severe injuries, Gustilo type 1 and 2 open fractures, approximately a quarter of reports specified antibiotic use for one day<sup>[14,63,64]</sup>, almost half for 2 to 3 days<sup>[7,54,66,67,96]</sup>, and the remainder for 4 to 7 days<sup>[86,91]</sup> (Table IV). For more severe injuries, Gustilo type 3, of those that reported duration half gave antibiotics for 2 to 3 days, a quarter for 4 to 7 days, and a quarter gave antibiotics for more than 7 days (Table IV). Practice proved similar over time and across continents.

### **Current recommendations**

#### ***Type of publications***

Of 153 publications (9 of them reported both practice and recommendations) that provided recommendations for systemic antibiotic prophylaxis in the management of open fractures, 61 (39.9%) were textbook chapters<sup>[97-157]</sup>, 15 (9.8%) were clinical practice guidelines<sup>[158-172]</sup>, 70 (45.8%) were review articles<sup>[2,3,6,18,92,94,96,174-236]</sup>, 3 (2.0%) were case series that provided recommendations<sup>[17,93,95]</sup>, and 4 (2.6%) were surveys of surgeons<sup>[14-16,173]</sup>. Of these 4 surveys, 2

were part A and part B of one study conducted in the USA <sup>[14,15]</sup>. That study reported that approximately 85% of the 379 respondents suggested initiating antibiotics within 1 hour after identification of an open fracture. Approximately a quarter of the respondents suggested administering antibiotics for at least 72 hours inpatients with a type 3A fracture, another 30% suggested using aminoglycosides in Gustilo type 1 fractures and three quarters suggested aminoglycosides in type 3B fractures <sup>[14]</sup>.

One study was conducted in Nigeria <sup>[16]</sup>. The authors found that most respondents suggested using the third- and second-generation cephalosporins such as ceftriaxone (46.0%) and cefuroxime (25.0%); 28 of 66 (42.4%) respondents suggested using a single dose of antibiotics within one hour prior to skin incision <sup>[16]</sup>.

### ***Level of recommendations***

The 153 eligible publications provided 276 recommendations addressing systemic antibiotic administration by category of injury severity. Of the 276 recommendations, approximately 90% had language consistent with a strong recommendation for prophylactic systemic antibiotics to prevent wound infection irrespective of level of injury severity. For open fractures of the upper and lower extremities, the proportion making a strong recommendation for antibiotics over no antibiotics was approximately 95%. All recommendations for Gustilo type 3, wounds that had come in contact with soil or water, severely contaminated wounds, and high-velocity gun shot wounds or gun shot wounds where velocity

was not specified at all had wording consistent with a strong recommendation in favour of antibiotic prophylaxis (Appendix 3).

### ***Recommended systemic antibiotic regimen***

The recommendations for specific antibiotic regimens included 276 recommendations for varying injury severities. For Gustilo type 1 and 2 open fractures, approximately three quarters recommended gram-positive coverage (with or without anaerobic coverage); the remainder recommended regimens that we classified as “broad coverage”, including both gram-positive and gram-negative coverage with antibiotics such as carbapenems (e.g., ertapenem, meropenem), piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftazidime, ceftriaxone and cefotaxime). For more severe open fractures, most recommendations favoured broad antimicrobial coverage. For open fractures that had come into contact with soil or a marine environment, and/or for severely contaminated wounds, three quarters recommended broad coverage (Table V).

Twenty-eight publications specifically addressed lower extremity injuries (femur<sup>[199]</sup>, knee<sup>[200]</sup>, tibia<sup>[94,184,188,193,196,201,205,223]</sup>, foot and ankle<sup>[194,204]</sup> and phalanx<sup>[206]</sup>) and lower in general<sup>[3,101,103,107,116,139,140,149,158,164,169,190,208]</sup> and made 34 recommendations for various injury severities. Approximately 40% each suggested a broad regimen or limiting coverage to gram-positive organisms (Table V, Appendix 4).

Twenty-two publications addressed gun or combat injury, of which 6

addressed low-velocity gunshot injury<sup>[136,216,221,226,227,230]</sup>, 14 addressed high-velocity gunshot injury<sup>[127,136,143,147,168,174,209,210,211,224,226,230]</sup>, and 2 gun velocity not specified<sup>[105,133]</sup>. Recommendations were more or less evenly split between gram-positive coverage only and broad coverage (Table V).

### ***Dose***

Sixty-six of 276 (23.9%) recommendations offered suggestions regarding antibiotic dosing. Some gave general suggestion regarding dose, such as “adjusted to weight and renal clearance”<sup>[95,105,122]</sup>. Others provided drug-specific dose recommendations, e.g., IV administration of 1-2 grams of cefazolin every 6-8 hours for Gustilo type 1 and 2 fractures or 600-900 mg clindamycin every 8 hours via IV or 450 mg clindamycin every 4 hours if patients were allergic to cephalosporin or penicillin<sup>[104,170]</sup>, add aminoglycoside 3-5 mg/kg/day for Gustilo type 3 fractures and further add penicillin 2 million units every 4 hours in farm contamination<sup>[109,147]</sup>.

### ***Route of administration***

Approximately half of the recommendations did not specify route of administration. Of those that did, almost all recommended IV administration. Approximately a quarter recommended local antibiotics in addition to systemic antibiotics.

Recommendations for local use included delivery of antimicrobials through antibiotic impregnated PMMA beads or bead pouches, PMMA chains, PMMA

strings or PMMA spacers, cement impregnated or mixed with heat-stable powdered antibiotics of methacrylate, tobramycin, and/or vancomycin<sup>[97-105,181-186]</sup>. A typical recommended ratio of antibiotics to cement was 3.6g tobramycin to 40g PMMA<sup>[236]</sup>. Additional suggestions included BonyPid™, b-tricalcium phosphate granules coated with bonypid which releases doxycycline at constant rate<sup>[94]</sup>.

### ***Time to antibiotic administration***

#### *Time to antibiotic administration in relation to injury*

Approximately half of the 276 recommendations made suggestions regarding the optimal time to antibiotic initiation after injury or presentation to hospital. Of these, over half recommended antibiotics to be administered as soon as/as early as possible after injury or upon arrival to hospital. Of the remainder, most recommended giving antibiotics within three hours of injury.

#### *Time to antibiotic initiation in relation to surgery*

Fewer than 10% of the recommendations addressed timing of antibiotic administration in relation to surgery. Of these, two thirds recommended antibiotics be administered one or two hours prior to surgery (before skin incision); a quarter during surgery/peri-operatively<sup>[118,172]</sup>; and about 10% suggested antibiotic administration post-operatively<sup>[94,230]</sup>.

### ***Duration***

Approximately half of the recommendations specified or addressed duration of antibiotic administration. For less severe injuries, Gustilo type 1 and 2 open fractures, half suggested antibiotics for one day or less and the remainder for 2 to 3 days. For Gustilo type 3, approximately 60% suggested 2 to 3 days (some recommendations suggested 72 hours total or 24 hours after wound closure, whichever comes first<sup>[117,125,135,169,177]</sup>); of the remainder, almost all suggested 4 to 7 days (Table VI).

Recommendations did not differ appreciably by year of publication and or geographic location.



## **Discussion**

We provide a comprehensive overview of actual practice and recommendations for primary antimicrobial prophylaxis in patients with open extremity fractures published over the past 10 years. Recommendations are typically published in textbook chapters, clinical practice guidelines, and review articles.

Information about clinical practice patterns came largely from single arm cohorts and case series, with just a few RCTs and comparative observational studies. Clinicians almost always used broad-spectrum antibiotics rather than antibiotics with only reliable gram-positive coverage, regardless of injury severity (Table III).

The most important difference between recommendations and practice was that, when authors made recommendations for Gustilo 1 or 2 open fractures as a group, they recommended restricting antibiotic use to agents with exclusively gram-positive coverage (Table V). Authors who made recommendations for specific antibiotics to cover gram-positive organisms varied greatly in their suggestions including first and second generation cephalosporins (e.g. example, cefazolin, cephalexin, cefamandole, cefuroxime, cephalixin, or cephradine), as well as anti-staphylococcal penicillins (e.g.s., cloxacillin, flucloxacillin, or dicloxacillin), a macrolide (e.g.erythromycin), ampicillin, amoxicillin, and penicillin.

A minority of authors (around one-fifth) suggested, in contrast, broad antimicrobial coverage with activity against both gram-positive and gram-negative organisms with agents such as carbapenems (e.g., ertapenem,

meropenem), piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftazidime, ceftriaxone and cefotaxime), beta-lactams with a beta-lactamase inhibitor (e.g., amoxicillin plus clavulanic acid, piperacillin plus tazobactam, or ampicillin plus clavulanic acid), or any combination of antibiotics that included reliable gram-positive and gram-negative coverage for both less and more severe injuries (and were thus more in keeping with practice). All recommendations with available information suggested a duration of 3 days or less (Table V, Table VI).

When authors grouped Gustilo 2 and 3 fractures together, almost all suggested using broad coverage with reliable activity against both gram-positive and gram-negative organisms. This was also true, for wounds with soil or marine contamination (Table V).

Strengths of the present study include explicit eligibility criteria, a comprehensive search for relevant primary clinical studies, review articles including many traditional and grey literature sources, clinical practice guidelines in all languages and duplicate assessment of eligibility with a high level of agreement. This study represents the first systematic survey addressing both what studies report in terms of use of antibiotics in prophylaxis in open fractures, and what experts recommend.

The limitations of our study are primarily related to deficiencies in reporting in the eligible articles. Most included studies in our systematic survey were narrative reviews that made practice recommendations. Recommendations did not provide consistent, comprehensive and detailed description in standard formats

that included drug, dose, route of administration, start time and duration. Details were even more likely to be absent in the reports of experience in clinical practice, observational studies, and RCTs. This is understandable given that antibiotic use was not the focus of these articles.

Our previous systematic review of RCTs addressing the use of antibiotic prophylaxis compared to no prophylaxis suggested that antibiotics reduce the risk of infection, supporting both practice and recommendations. The RCTs that compared prophylaxis to no prophylaxis used antibiotics with gram-positive coverage but no reliable gram-negative coverage (first generation cephalosporins and penicillins). Trials comparing longer and shorter regimens (one day versus three to five days) have failed to demonstrate any benefit with longer durations, based on low to moderate quality evidence. Only single studies have compared different antibiotic regimens and sample sizes have been too small for such studies to be informative. The differences in recommendations regarding which antibiotic to use are therefore understandable – the evidence provides little justification for one regimen or another <sup>[18]</sup>.

Several key questions remain unresolved regarding primary prophylaxis with antibiotics in patients with open fractures. Whether there is any benefit, and if so in what situations, of broad versus targeted antimicrobial coverage, or of coverage for specific pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA) or pseudomonas remains uncertain. This is also the case for whether administration can wait until after obtaining reliable cultures, or the results of such cultures, and for the optimal duration, of prophylaxis. The use of broad

spectrum antibiotics and antibiotics for longer durations comes with notable harms to the patient (adverse effects) and to society (antimicrobial resistance in the community – an increasing concern globally).

Resolution of these issues – in particular the degree of coverage required - will require well-designed RCTs. Such studies should address the limitations of previous studies by ensuring concealed randomization, blinding, complete follow-up, documentation of adverse reactions to antibiotics, and describing the nature of the infections that occur (e.g., superficial or deep). Providing definitive guidance will also require that the trials be large, multicenter studies sufficiently powered to provide definitive results that are broadly applicable. In the interim, clinicians can attend to the guidance offered, being aware that there is disagreement and the current best available evidence does not clearly support any particular approach.

## **FUNDING**

No external funding supported this study.

## **CONFLICT OF INTEREST**

No conflict declared.

## REFERENCES

1. Sirkin M, Sanders R, DiPasquale T, Herscovici D Jr. A staged protocol for soft tissue management in the treatment of complex pilon fractures. *J Orthop Trauma*. 2004 Sep;18 Suppl 8:S32-8.
2. Cross WW 3rd, Swiontkowski MF. Treatment principles in the management of open fractures. *Indian J Orthop*. 2008 Oct-Dec;42(4):377-86.
3. Ali MA, Noyes D, L KC. Management of open fractures of the lower limb. *Br J Hosp Med*. 2013 Oct 1;74(10):577-80.
4. Gustilo RB, Mendoza RM, Williams DN: Problems in the management of type III (severe) open fractures: A new classification of type III open fractures. *J Trauma*. 1984;24:742-746.
5. Zalavras CG, Patzakis MJ, Holton PD, Sherman R. Management of open fractures. *Infect Dis Clin North Am* 2005;19:915-29.
6. Carver DC, Kuehn SB, Weinlein JC. Role of Systemic and Local Antibiotics in the Treatment of Open Fractures. *Orthop Clin N Am*. 2017 Apr;48:137-53.
7. The FLOW Investigators. Fluid lavage of open wounds (FLOW): a multicenter, blinded, factorial pilot trial comparing alternative irrigating solutions and pressures in patients with open fractures. *J Trauma*. 2011;71(3):596-606.
8. Zhang M, Chen YZ, Huang YQ, et al. Selection of antibiotics in open fracture. *Chin J Trauma Surg*. 2002;4(4):199-203.
9. Khatod M, Botte MJ, Hoyt DB, et al. Outcomes in open tibia fractures: relationship between delay in treatment and infection. *J Trauma*. 2003;55:949-954.
10. Bhandari M, Tornetta P III, Sprague S, et al. Predictors of reoperation following operative management of fractures of the tibial shaft. *J Orthop Trauma*. 2003;17:353-361.
11. Prokuski L, Clyburn TA, Evans RP, et al. Prophylactic antibiotics in orthopaedic surgery. *Instr Course Lect*. 2011;60:545-555.
12. Braun R, Enzler MA, Rittmann WW. A double-blind clinical trial of prophylactic cloxacillin in open fractures. *J Orthop Trauma*. 1987;1(1):12-17.
13. World Health Organization. Staphylococcal infection. 2010-02-08.
14. Obremskey W, Molina C, Collinge C, Nana A, Tornetta P 3rd, Sagi C, et al. Current Practice in the Management of Open Fractures Among Orthopaedic Trauma Surgeons. Part A: Initial Management. A Survey of Orthopaedic Trauma Surgeons. *J Orthop Trauma*. 2014 Aug;28(8):e198-202.
15. Obremskey W, Molina C, Collinge C, Tornetta P, 3rd, Sagi C, Schmidt A, et al. Current Practice in the Management of Open Fractures Among Orthopaedic Trauma Surgeons. Part B: Management of Segmental Long Bone Defects. A Survey of Orthopaedic Trauma Association Members. *J Orthop Trauma*. 2014 Aug;28(8):e203-7.
16. Madubueze CC, Umaru H, Alada A. Attitudes of Nigerian orthopaedic surgeons to the use of prophylactic antibiotics. *Int Orthop*. 2015

- Nov;39(11):2161-5.
17. Yarrow J, Rahman S, Marsden N, Pallister I, Hemington-Gorse S. Management of open lower limb injuries in South West England and Wales. *Annals R Coll Surg Engl.* 2015 Jan;97(1):35-9.
  18. Chang Y, Kennedy SA, Bhandari M, Lopes LC, Bergamaschi C, Carolina de Oliveira M, et al. Effects of antibiotic prophylaxis in patients with open fracture of the extremities: A systematic review of randomized controlled trials. *JBJS Reviews.* 2015 Jun 09;3(6):e2.
  19. Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. *Cochrane Database Syst Rev.* 2004;4(1):CD003764.
  20. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine.* 2009 Jul 21;6(7):e1000097.
  21. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. *Clinical epidemiology: how to do clinical practice research.* 3rd ed. Philadelphia: Lippincott, Williams & Wilkins; 2006.
  22. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. *Fam Med.* 2005 May;37(5):360-3.
  23. Prasarn ML, Zych G, Ostermann PA. Wound management for severe open fractures: use of antibiotic bead pouches and vacuum-assisted closure. *Am J Orthop.* 2009 Nov 1;38(11):559-63.
  24. Hake ME, Young H, Hak DJ, Stahel PF, Hammerberg EM, Mauffrey C. Local antibiotic therapy strategies in orthopaedic trauma: Practical tips and tricks and review of the literature. *Injury.* 2015 Aug;46(8):1447-56.
  25. Seligson D, Berling S. Antibiotic-laden PMMA bead chains for the prevention of infection in compound fractures: current state of the art. *Eur J Orthop Surg Traumatol.* 2015 Aug;25(6):969-74.
  26. Azam Q, Sherwani M, Abbas M, Gupta R, Asif N, Sabir A. Internal fixation in compound type III fractures presenting after golden period. *Indian J Orthop.* 2007 Jul-Sep;41(3):204-8.
  27. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. *Clin Infect Dis.* 2007 Aug 15;45(4):409-15.
  28. Faschingbauer M, Meiners J, Schulz AP, Rudolf KD, Kienast B. Operative Treatment and Soft Tissue Management of Open Distal Tibial Fractures - Pitfalls and Results. *Eur J Trauma Emerg Surg.* 2009 Dec;35(6):527-31.
  29. Helgeson MD, Potter BK, Tucker CJ, Frisch HM, Shawen SB. Antibiotic-impregnated calcium sulfate use in combat-related open fractures. *Orthopedics.* 2009 May;32(5):323.
  30. Boraiah S, Kemp TJ, Erwtaman A, Lucas PA, Asprinio DE. Outcome following open reduction and internal fixation of open pilon fractures. *J Bone Joint Surg Am.* 2010 Feb;92(2):346-52.
  31. Hutson JJ, Jr., Dayicioglu D, Oeltjen JC, Panthaki ZJ, Armstrong MB. The treatment of gustilo grade IIIB tibia fractures with application of antibiotic spacer, flap, and sequential distraction osteogenesis. *Ann Plast Surg.* 2010 May;64(5):541-52.

32. Lenarz CJ, Watson JT, Moed BR, Israel H, Mullen JD, MacDonald JB. Timing of wound closure in open fractures based on cultures obtained after debridement. *JBSJ*. 2010 Aug 18;92(10):1921-6.
33. Mehta S, Mirza AJ, Dunbar RP, Barei DP, Benirschke SK. A staged treatment plan for the management of Type II and Type IIIA open calcaneus fractures. *J Orthop Trauma*. 2010 Mar;24(3):142-7.
34. Yu GR, Zhao HM, Zhou JQ, Yuan F, Li HF, Yang YF, et al. Treatment of open calcaneal fractures. *Zhongguo Gu Shang*. 2010 Nov 1;23(11):804-8. Chinese.
35. Zhang CQ, Zheng HY, Wang B, Huang H, He F, Zhao XL. Treatment of Gustilo grade III leg fractures by external fixation associated with limited internal fixation. *Chin J Traumatol*. 2010 Apr;13(2):96-100.
36. Capo JT, Hall M, Nourbakhsh A, Tan V, Henry P. Initial management of open hand fractures in an emergency department. *Am J Orthop*. 2011 Dec;40(12):e243-8.
37. Chaudhary S, Sen RK, Saini UC, Soni A, Gahlot N, Singh D. Use of gentamicin-loaded collagen sponge in internal fixation of open fractures. *Chin J Traumatol*. 2011 Aug;14(4):209-14.
38. Enninghorst N, McDougall D, Hunt JJ, Balogh ZJ. Open tibia fractures: timely debridement leaves injury severity as the only determinant of poor outcome. *J Trauma*. 2011 Feb;70(2):352-6.
39. Fuchs T, Stange R, Schmidmaier G, Raschke MJ. The use of gentamicin-coated nails in the tibia: preliminary results of a prospective study. *Arch Orthop Trauma Surg*. 2011 Oct;131(10):1419-25.
40. Glass GE, Barrett SP, Sanderson F, Pearse MF, Nanchahal J. The microbiological basis for a revised antibiotic regimen in high-energy tibial fractures: preventing deep infections by nosocomial organisms. *J Plast Reconstr Aesthet Surg*. 2011 Mar;64(3):375-80.
41. Kurylo JC, Axelrad TW, Tornetta P3rd, Jawa A. Open fractures of the distal radius: the effects of delayed debridement and immediate internal fixation on infection rates and the need for secondary procedures. *J Hand Surg*. 2011 Jul;36(7):1131-4.
42. Schlitzkus LL, Goettler CE, Waibel BH, Sagraves SG, Hasty CC, Edwards M, Rotondo MF. Open fractures: it doesn't come out in the wash. *Surg Infect*. 2011 Oct 24;12(5):359-63.
43. Singh D, Garg R, Bassi JL, Tripathi SK. Open grade III fractures of femoral shaft: Outcome after early reamed intramedullary nailing. *Orthopaedics and Traumatology: Surgery and Research*. 2011 Sept;97(5):506-11.
44. Vallier HA, Cureton BA, Patterson BM. Randomized, prospective comparison of plate versus intramedullary nail fixation for distal tibia shaft fractures. *J Orthop Trauma*. 2011 Dec;25(12):736-41.
45. Wiersema B, Brokaw D, Weber T, Psaradellis T, Panero C, Weber C, et al. Complications associated with open calcaneus fractures. *Foot Ankle Int*. 2011 Nov 1;32(11):1052-7.
46. Arti HR. Comparison of early versus delayed debridement in open fractures. *Pak J Medical Sci*. 2012;28(5):856-9.
47. Barton CA, McMillian WD, Crookes BA, Osler T, Bartlett CS 3rd.

- Compliance with the Eastern Association for the Surgery of Trauma guidelines for prophylactic antibiotics after open extremity fracture. *Int J Crit Illn Inj Sci.* 2012 May;2(2):57-62.
48. Chua W, Murphy D, Siow W, Kagda F, Thambiah J. Epidemiological analysis of outcomes in 323 open tibial diaphyseal fractures: A nine-year experience. *Singapore Med J.* 2012 Jun;53(6):385-9.
  49. Foster PAL, Barton SB, Jones SCE, Morrison RJM, Britten S. The treatment of complex tibial shaft fractures by the Ilizarov method. *JBJS (Br).* 2012 Nov 27;94 B(12):1678-83.
  50. Keen JS, Desai PP, Smith CS, Suk M. Efficacy of hydrosurgical debridement and nanocrystalline silver dressings for infection prevention in type II and III open injuries. *Int Wound J.* 2012 Feb;9(1):7-13.
  51. Agrawal A, Devisingh Chauhan V, Maheshwari RK, Kumar Juyal A. Primary nailing in the open fractures of the Tibia-Is it worth?. *J Clin Diagn Res.* 2013 Jun;7(6):1125-30.
  52. Ali AM. Outcomes of open bicondylar tibial plateau fractures treated with Ilizarov external fixator with or without minimal internal fixation. *Eur J Orthop Surg Traumatol.* 2013 Apr;23(3):349-55.
  53. Dunkel N, Pittet D, Tovmirzaeva L, Suva D, Bernard L, Lew D, et al. Short duration of antibiotic prophylaxis in open fractures does not enhance risk of subsequent infection. *Bone Joint J.* 2013 May 30;95-B(6):831-7.
  54. Haider MG. Ways to prevent infection after open fracture of the lower limb. *Clujul Med.* 2013;86(3):240.
  55. Jafree SBH, Hamid A, Saeed R, Ali N. Comparison of two techniques of interlocking intramedullary nailing in fractures of Tibia. *Pak J Med Health Sci.* 2013 Jan-Mar;7(1):231-5.
  56. Krieb DL, Blokhuis TJ, Van Wessem KJP, Bemelman M, Lansink KWW, Leenen LPH. Intramedullary nailing without interlocking screws for femoral and tibial shaft fractures. *Arch Orthop Trauma Surg.* 2013 Aug;133(8):1109-13.
  57. Rasool G, Ahmed MU, Iqbal M, Khwaja Z. Vacuum assisted wound closure and normal saline dressing in treatment of Gustilo type II, type IIIa and IIIb open fracture of tibia. *Rawal Medical Journal.* 2013 Oct-Dec;38(4):382-4.
  58. Shahabuddin, Shahab F, Sikka RS. Incidence, etiological profile, and treatment of surgical site infections in patients with gunshot injuries and bomb blast injuries in Pakistan. *Infect Dis Clin Pract.* 2013 Sept;21(5):302-4.
  59. Young S, Lie SA, Hallan G, Zirkle LG, Engesaeter LB, Havelin LI. Risk factors for infection after 46,113 intramedullary nail operations in low- and middle-income countries. *World J Surg.* 2013 Feb;37(2):349-55.
  60. Young S, Banza LN, Hallan G, Beniyasi F, Manda KG, Munthali BS, et al. Complications after intramedullary nailing of femoral fractures in a low-income country. *Acta Orthop.* 2013 Oct 31;84(5):460-7.
  61. Yusof NM, Khalid KA, Zulkifly AH, Zakaria Z, Amin MA, Awang MS, et al. Factors associated with the outcome of open tibial fractures. *Malays J Med Sci.* 2013 Oct;20(5):47-53.
  62. Ahearn N, Oppy A, Halliday R, Rowett-Harris J, Morris SA, Chesser TJ, et al.



- The outcome following fixation of bicondylar tibial plateau fractures. *Bone Joint J.* 2014 Jul 1;96(7):956-62.
63. Dixon J. Delayed Wound Closure Increases Deep-infection Rate Associated with Lower-grade Open Fractures. *J Emerg Med.* 2014 Jun;46(6): 876-877.
  64. Hull PD, Johnson SC, Stephen DJ, Kreder HJ, Jenkinson RJ. Delayed debridement of severe open fractures is associated with a higher rate of deep infection. *Bone Joint J.* 2014 Mar 3;96-B(3):379-84.
  65. Gonzalez A, Suva D, Dunkel N, Nicodeme JD, Lomessy A, Lauper N, et al. Are there clinical variables determining antibiotic prophylaxis-susceptible versus resistant infection in open fractures?. *International Orthopaedics.* 2014 Nov;38(11):2323-7.
  66. Jenkinson RJ, Kiss A, Johnson S, Stephen DJG, Kreder HJ. Delayed Wound Closure Increases Deep-infection Rate Associated with Lower-grade Open Fractures: A Propensity-Matched Cohort. *JBJS (Am).* 2014 Mar 5;96-A(5):380-6.
  67. Malhotra AK, Goldberg S, Graham J, Malhotra NR, Willis MC, Mounasamy V, et al. Open extremity fractures: Impact of delay in operative debridement and irrigation. *J Trauma Acute Care Surg.* 2014 May;76(5):1201-7.
  68. Leonidou A, Kiraly Z, Gality H, Apperley S, Vanstone S, Woods DA. The effect of the timing of antibiotics and surgical treatment on infection rates in open long-bone fractures: a 6-year prospective study after a change in policy. *Strategies in Trauma and Limb Reconstruction.* 2014 Nov;9(3):167-171.
  69. Mortier A. Prophylactic antibiotics in major trauma patients. *Anaesthesia.* 2014 Oct 1;69:69.
  70. Ng T, Unadkat J, Bilonick RA, Wollstein R. The importance of early operative treatment in open fractures of the fingers. *Ann Plast Surg.* 2014 Apr;72(4):408-10.
  71. Usman Ul Haq M, Hussain FN, Iqbal M. Outcome of immediate primary skin closure in type-II and type-IIIA open tibial fractures. *Rawal Medical Journal.* 2014;39(3):285-8.
  72. Weber D, Dulai SK, Bergman J, Buckley R, Beaupre LA. Time to Initial Operative Treatment Following Open Fracture Does Not Impact Development of Deep Infection: A Prospective Cohort Study of 736 subjects. *J Orthop Trauma.* 2014 Nov;28(11):613-9.
  73. Zumsteg JW, Molina CS, Lee DH, Pappas ND. Factors influencing infection rates after open fractures of the radius and/or ulna. *J Hand Surg Am.* 2014 May;39(5):956-61.
  74. Bhandari M, Jeray KJ, Petrisor BA, Devereaux PJ, Heels-Ansdell D, Schemitsch EH, et al. A Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. *New England J of Med.* 2015 Dec 31;373(27):2629-41.
  75. Bolt A, Wei R, Pinder R, Hodson J, Waldram M, Chester D. Open hand fractures: 2 years of experience at a hand centre. *Eur J of Plast Surg.* 2015 Aug;38(4):309-14.
  76. Lack WD, Karunakar MA, Angerame MR, Seymour RB, Sims S, Kellam JF, et al. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes

- infection. *J Orthop Trauma*. 2015 Jan;29(1):1-6. Erratum in: *J Orthop Trauma*. 2015 Jun;29(6):e213.
77. Mathews JA, Ward J, Chapman TW, Khan UM, Kelly MB. Single-stage orthoplastic reconstruction of Gustilo-Anderson Grade III open tibial fractures greatly reduces infection rates. *Injury*. 2015 Nov;46(11):2263-6.
  78. Metsemakers WJ, Reul M, Nijs S. The use of gentamicin-coated nails in complex open tibia fracture and revision cases: A retrospective analysis of a single centre case series and review of the literature. *Injury*. 2015 Dec;46(12):2433-7.
  79. Mir FR, Mehta R. Management protocol for open fractures of Tibia. *JK-Practitioner*. 2015 Jul-Dec;20(3-4):18-25.
  80. Otchwemah R, Grams V, Tjardes T, Shafizadeh S, Bathis H, Maegele M, et al. Bacterial contamination of open fractures - pathogens, antibiotic resistances and therapeutic regimes in four hospitals of the trauma network Cologne, Germany. *Injury*. 2015 Oct;46 Suppl 4:S104-8.
  81. Srour M, Inaba K, Okoye O, Chan C, Skiada D, Schnuriger B, et al. Prospective evaluation of treatment of open fractures: effect of time to irrigation and debridement. *JAMA Surg*. 2015 Apr;150(4):332-6.
  82. Yusuf E, Steinrucken J, Buchegger T, Trampuz A, Borens O. A descriptive study on the surgery and the microbiology of Gustilo type III fractures in an university hospital in Switzerland. *Acta Orthop Belg*. 2015;81(2):327-33.
  83. Mahajan K, Verma V, Singh GK, Kumar S, Avasthi S. A randomized controlled study to compare conventional and evidence based treatment protocols in fresh compound fractures. *J Clin Diagn Res*. 2016 Sept;10(9):RC01-RC5.
  84. Ondari JN, Masika MM, Ombachi RB, Ating'a JE. Unblinded randomized control trial on prophylactic antibiotic use in gustilo II open tibia fractures at Kenyatta National Hospital, Kenya. *Injury*. 2016 Oct;47(10):2288-93.
  85. Ovaska MT, Madanat R, Makinen TJ. Predictors of Postoperative Wound Necrosis Following Primary Wound Closure of Open Ankle Fractures. *Foot Ankle Int*. 2016 Apr 1;37(4):401-6.
  86. Pannell WC, Banks K, Hahn J, Inaba K, Marecek GS. Antibiotic related acute kidney injury in patients treated for open fractures. *Injury*. 2016 Mar;47(3):653-57.
  87. Redfern J, Wasilko SM, Groth ME, McMillian WD, Bartlett CS 3rd. Surgical Site Infections in Patients With Type 3 Open Fractures: Comparing Antibiotic Prophylaxis With Cefazolin Plus Gentamicin Versus Piperacillin/Tazobactam. *J Orthop Trauma*. 2016 Aug;30(8):415-19.
  88. Shorin HR, Daghi MG, Mirkazemi M, Assadian M, Ashraf H, Izanloo A. Antibiotic prophylaxis in bacterial infection of type IIIA open fracture of tibial shaft with or without fibula fracture. *Razavi Int J Med*. 2016;4(2):e37811.
  89. Marecek GS, Earhart JS, Gardner MJ, Davis J, Merk BR. Surgeon preferences regarding antibiotic prophylaxis for ballistic fractures. *Arch Orthop Trauma Surg*. 2016 Jun;136(6):751-54.
  90. Gumbel D, Matthes G, Napp M, Lange J, Hinz P, Spitzmuller R, et al. Current management of open fractures: results from an online survey. *Arch Orthop*

- Trauma Surg. 2016 Dec;136(12):1663-72.
91. Reith G, Wyen H, Wafaisade A, Paffrath T, Flohe S, Bouillon B, et al. Current standard of care for initial management of open fractures in emergency departments : A nationwide survey in German trauma centers. *Unfallchirurg*. 2016 Aug;119(8):642-47. German.
  92. Bhadra AK, Roberts CS. Indications for antibiotic cement nails. *J Orthop Trauma*. 2009 May-Jun;23 Suppl 5:S26-30.
  93. Emanuel N, Estrada Jr RO, Pasion MU, Ramos RC, Segal D, Gustilo RB, et al. BonyPid: Osteoconductive and antimicrobial outcome in patients with Gustilo III open fractures: Six months follow up results. *Eur Cell Mater*. 2013;26 Suppl 3:51.
  94. Raschke MJ, Rosslenbroich SB, Fuchs TF. Gentamicin-coated tibia nails: Can we afford NOT to use them. *Tech Orthop*. 2014 Jun;29(2):62-8.
  95. Collinge CA, McWilliam-Ross K, Kelly KC, Dombroski D. Substantial improvement in prophylactic antibiotic administration for open fracture patients: results of a performance improvement program. *J Orthop Trauma*. 2014 Nov;28(11):620-25.
  96. Rodriguez L, Jung HS, Goulet JA, Cicalo A, Machado-Aranda DA, Napolitano LM. Evidence-based protocol for prophylactic antibiotics in open fractures: Improved antibiotic stewardship with no increase in infection rates. *J Trauma Acute Care Surg*. 2014 Sept;77(3):400-8.
  97. Sanders RW. *Trauma: Core knowledge in orthopaedics*. 1st ed. Philadelphia: Mosby/Elsevier; 2008.
  98. Schemitsch EH, McKee MD. *Cirurgia do trauma ortopédico*. Rio de Janeiro: Elsevier; 2012. Portuguese.
  99. Solomin LN. *The basic principles of external skeletal fixation using Ilizarov and other devices*. Milan: Springer; 2012.
  100. Sumant S. Antibiotic loaded acrylic bone cement in orthopaedic trauma. *Osteomyelitis*. InTech; 2012.
  101. Toy EC, Rosenbaum AJ, Roberts T, Dines JS. *Case files: orthopaedic surgery*. New York: McGraw-Hill Education, Medical; 2013.
  102. Skinner H, McMahan PJ. *Diagnosis and treatment in orthopedics*. 5th ed. New York: McGraw-Hill Professional Publishing; 2013.
  103. Oestern H, Trentz O, Uranues S. *Bone and joint injuries: trauma surgery III*. Heidelberg: Springer; 2014.
  104. Castoldi F, Blonna D, Assom M. *Simple and complex fractures of the humerus a guide to assessment and treatment*. Milano: Springer Milan; 2015.
  105. Azar FM, Beaty JH, Canale ST. *Campbell's operative orthopaedics*. 13th ed. Philadelphia, PA : Elsevier, 2017.
  106. Bisanzo M, Filbin MR, Bhatia K. *Emergency management of the trauma patient: cases, algorithms, evidence*. Philadelphia: Lippincott Williams & Wilkins; 2007.
  107. DiGiovanni CW, Greisberg J. *Foot and ankle: core knowledge in orthopaedics*. Philadelphia: Elsevier Mosby; 2007.
  108. Granick MS., Gamelli RL. *Surgical wound healing and management*. New York: Informa Healthcare; 2007.

109. Lerner A, Reis D, Soudry M. Severe injuries to the limbs staged treatment. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg; 2007.
110. Anwar R, Tuson K, Khan SA. Classification and diagnosis in orthopaedic trauma. Leiden: Cambridge University Press; 2008.
111. Asensio JA, Trunkey DD. Current therapy of trauma and surgical critical care. Philadelphia: Mosby/Elsevier; 2008.
112. Haddad F, Oussedik S, Patel R. Orthopaedic trauma: a systematic approach. London: Quay Books; 2008.
113. Ip D. Orthopedic traumatology: a resident's guide. Berlin: Springer; 2006.
114. McRae R, Esser M. Practical fracture treatment. Edinburgh: Elsevier Churchill Livingstone; 2008.
115. Boer PGD, Morgan SJ, van der Werken C. 2009. Handbook: orthopaedic trauma care. Thieme: Davos AOTrauma Publishing; 2009.
116. Dandy DJ, Edwards DJ. Essential orthopaedics and trauma. Edinburgh: Churchill Livingstone; 2009.
117. Nanchahal J. Standards for the management of open fractures of the lower limb. London: Royal Society of Medicine Press Ltd; 2009.
118. Wood PR, Mahoney PF, Cooper JP. Trauma and orthopedic surgery in clinical practice. London: Springer; 2009.
119. Wright JG. Evidence-based orthopaedics: the best answers to clinical questions. Philadelphia, Saunders/Elsevier; 2009.
120. Bowden G. Oxford handbook of orthopaedics and trauma. Oxford: Oxford University Press; 2010.
121. Duckworth T, Blundell CM, Duckworth T. Lecture notes: orthopaedics and fractures. 4th ed. Chichester, West Sussex: Wiley-Blackwell; 2010.
122. Schemitsch EH, McKee MD. Orthopaedic trauma surgery. Philadelphia: Saunders/Elsevier; 2010.
123. Solomon L, Warwick D, Nayagam S, Apley AG. Apley's system of orthopaedics and fractures. London: Hodder Arnold; 2010.
124. Bhandari M, Adili A. Evidence-based orthopedics. Chichester: Wiley-Blackwell; 2011.
125. Boffard K. Manual of definitive surgical trauma care. Oxford: Hodder Arnold; 2011.
126. Bulstrode CJK. Oxford textbook of trauma and orthopaedics. Oxford: Oxford University Press; 2011.
127. Lerner A, Soudry M. Armed conflict injuries to the extremities a treatment manual. Berlin: Springer; 2011.
128. Pape H, Sanders R, Borrelli J. The poly-traumatized patient with fractures: a multi-disciplinary approach. Berlin: Springer; 2011.
129. Simon RR, Scott CS, Sharieff GQ. Emergency orthopedics. 6th ed. New York: McGraw-Hill Medical, 2011.
130. Shah K, Egan D, Quaas J. Essential emergency trauma. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
131. Wiesel SW, Delahay JN. Essentials of orthopaedic surgery. New York: Springer; 2011.

132. Browner BD, Fuller R. Musculoskeletal emergencies. Philadelphia: Elsevier Saunders; 2013.
133. Dhillon MS, Dhatt SS, Boer PGD. First aid and emergency management in orthopedic injuries. London: Jaypee Brothers Medical Pub; 2012.
134. McDonagh DO, Micheli LJ. FIMS sports medicine manual: event planning and emergency care. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
135. Seligson D, Mauffrey C, Roberts C. External fixation in orthopedic traumatology. London: Springer; 2012.
136. Swiontkowski MF, Stovitz SD. Manual of orthopaedics. Philadelphia: Lippincott Williams & Wilkins; 2006.
137. Bond MC, Perron AD, Abraham MK. Orthopedic emergencies. Cambridge University Press; 2013.
138. O’Keefe RJ, Chu CR, Jacobs JJ, Einhorn TA. Orthopaedic basic science: foundations of clinical practice. Rosemont: American Academy of Orthopaedic Surgeons; 2013.
139. Rodriguez-Merchan EC. Traumatic injuries of the knee. Milan: Springer; 2013.
140. Saxena A. Special procedures in foot and ankle surgery. London: Springer; 2013.
141. Sethi MK., Jahangir AA, Obremskey WT, Bhandari M. Orthopedic traumatology: an evidence-based approach. New York: Springer; 2013.
142. Bentley G. European surgical orthopaedics and traumatology: the EFORT textbook. Heidelberg: Springer Reference, 2014.
143. Bone LB, Mamczak CN. Front line extremity and orthopaedic surgery: a practical guide. Heidelberg: Springer; 2014.
144. Cannada LK, American Academy of Orthopaedic Surgeons. Orthopaedic Knowledge Update 11. Rosemont: American Academy of Orthopaedic Surgeons; 2014.
145. Gosselin RA, Spiegel DA, Foltz M. Global orthopedics caring for musculoskeletal conditions and injuries in austere settings. New York, NY: Springer; 2014.
146. MacKenzie CR, Cornell CN, Memtsoudis SG. Perioperative care of the orthopedic patient. New York: Springer; 2014.
147. Sculco TP, Lim MR, Pearle AD, Ranawat AS. Hospital for special surgery orthopaedic manual. Philadelphia: Lippincott Williams & Wilkins; 2014.
148. Smith WR, Stahel PF. Management of musculoskeletal injuries in the trauma patient. New York: Springer; 2014.
149. Sölveborn S. Emergency orthopedics: a manual on acute conditions of the locomotor system. Heidelberg: Springer; 2014.
150. Klingensmith ME. Washington manual of surgery. Philadelphia: Wolters Kluwer; 2015.
151. Calandruccio JH, Gear BJ, Mauck BM, Sawyer JR, Toy PC, Weinlein JC. Common complications in orthopedics. Philadelphia: Elsevier; 2016.
152. Korkusuz F. Musculoskeletal research and basic science. Cham: Springer;

- 2016.
153. Miller MD, Thompson SR. Miller's review of orthopaedics. 7th ed. Philadelphia, PA : Elsevier, 2016.
  154. Robinson JDD. Orthopaedic trauma in the austere environment: a practical guide to care in the humanitarian setting. Cham: Springer Nature; 2016.
  155. Stannard J, Schmidt A. Surgical treatment of orthopaedic trauma. 2nd ed. New York : Thieme, 2016.
  156. Pape HC, Peitzman AB, Rotondo MF, Giannoudis PV. Damage control management in the polytrauma patient. 2nd ed. New York: Springer; 2017.
  157. Wheelless CR III. Wheelless' Textbook of Orthopaedics [Internet]. 2017 [cited 2017 Jun 15]. Available from: [http://www.wheelsonline.com/ortho/open\\_fractures](http://www.wheelsonline.com/ortho/open_fractures)
  158. British Orthopedic Association and British Association of Plastic, Reconstructive and Aesthetic Surgeons. BOAST 4: the management of severe open lower limb fractures [Internet]. 2009 [cited 2017 Jun 15]. Available from: <https://www.boa.ac.uk/wp-content/uploads/2014/12/BOAST-4.pdf>
  159. Medscape, Schaller TM, Rabin SI, Talavera F, Agnew S, Calhoun JH. medscape-Open Fractures [Internet]. 2016 [cited 2017 Jun 15]. Available from: <http://emedicine.medscape.com/article/1269242-overview>
  160. Abbasi D, Taylor B. Orthobullets-Open Fractures Management [Internet]. 2017 [cited 2017 Jun 15]. Available from: <http://www.orthobullets.com/trauma/1004/open-fractures-management>
  161. American Academy of Orthopaedic Surgeons. OrthoInfo-open fracture [Internet]. 2017 [cited 2017 Jun 15]. Available from: <http://orthoinfo.aaos.org/topic.cfm?topic=A00582>
  162. Scottish Intercollegiate Guidelines Network. Antibiotic prophylaxis in surgery: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008.
  163. European Centre for Disease Prevention and Control. Systematic review and evidence-based guidance on perioperative antibiotic prophylaxis. Stockholm: European Centre for Disease Prevention and Control; 2013.
  164. Anderson A, Miller AD, Brandon Bookstaver P. Antimicrobial prophylaxis in open lower extremity fractures. *Open Access Emerg Med.* 2011;3:7-11.
  165. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg Infect.* 2013 Mar 14;14(1):73-156.
  166. Hehemann D, Hardy MA. Keys to optimal management of open fractures. *Podiatry Management.* 2012;31(8):85-92.
  167. Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. *J Trauma.* 2011 Mar;70(3):751-4.
  168. Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, et al. Guidelines for the prevention of infections associated with


- combat-related injuries: 2011 update endorsed by the infectious diseases society of America and the surgical infection society. *J Trauma*. 2011 Aug;71(2 Suppl. 2):S210-S34.
169. Louie KW. Management of open fractures of the lower limb. *BMJ*. 2009 Dec 17;339:b5092.
170. Mauffrey C, Bailey JR, Bowles RJ, Price C, Hasson D, Hak DJ, et al. Acute management of open fractures: proposal of a new multidisciplinary algorithm. *Orthopedics*. 2012 Oct;35(10):877-81.
171. Tejwani NC, Webb LX, Harvey EJ, Wolinsky PR. Soft-tissue management after trauma: initial management and wound coverage. *Instr Course Lect*. 2011;60:15-25.
172. Wacha H, Hoyme U, Isenmann R, Kujath P, Lebert C, Naber K, et al. Perioperative antibiotic prophylaxis. Evidence based guidelines by an expert panel of the Paul Ehrlich Gesellschaft. *Chemotherapie Journal*. 2010;19(3):70-84. German.
173. Lavelle WF, Uhl R, Krieves M, Drvaric DM. Management of open fractures in adult patients: current teaching in ACGME accredited residency programs. *J Surg Orthop Adv*. 2007 Jan 1;16(3):111-7.
174. Abubaker AO. Use of prophylactic antibiotics in preventing infection of traumatic injuries. *Oral Maxillofac Surg Clin North Am*. 2009 May;21(2):259-64.
175. Back DA, Scheuermann-Poley C, Willy C. Recommendations on negative pressure wound therapy with instillation and antimicrobial solutions—when, where and how to use: what does the evidence show? *Int Wound J*. 2013 Dec;10(s1):32-42.
176. Barnard AR, Allison K. The classification and principles of management of wounds in trauma. *Trauma*. 2009 Jul;11(3):163-76.
177. Bennett AR, Smith KD. (ii) Open fractures. *Orthopaedics and Trauma*. 2013 Feb;27(1):9-14.
178. Berberich C, Seidel P. Antibiotics in orthopaedic use - is there a right choice? *Eur Cell and Mater*. 2011;21(Suppl.2):5.
179. Brousil J, Forward D, Moran C. (ii) Resuscitation of the adult trauma victim. *Orthopaedics and Trauma*. 2015 Dec;29(6):350-8.
180. Calhoun JH. Optimal timing of operative debridement: A known unknown: Commentary on an article by Mara L Schenker Md, et al.: “Does Timing to Operative Debridement Affect Infectious Complications in Open Long-Bone Fractures? A Systematic Review”. *JBJS - Series A*. 2012 Jun 20;94(12):e90.
181. Cancienne JM, Burrus MT, Weiss DB, Yarboro SR. Applications of local antibiotics in orthopedic trauma. *Orthopedic Clinics*. 2015 Oct;46(4):495-510.
182. Cat T, Hall L. Trauma: antibiotics in open fractures. *Hospital Pharmacy*. 2007;42(5):413-21.
183. Ciriello V, Maccauro G, Ziranu A, Saccomanno M, Pagano E, Logroscino G. Collatamp sponges in the management of open fractures. *Acta Bio Medica Atenei Parmensis*. 2012 Jun;83(1):62-8.

184. Craig J, Fuchs T, Jenks M, Fleetwood K, Franz D, Iff J, et al. Systematic review and meta-analysis of the additional benefit of local prophylactic antibiotic therapy for infection rates in open tibia fractures treated with intramedullary nailing. *Int Orthop*. 2014 May;38(5):1025-30.
185. Decoster TA, Bozorgnia S. Antibiotic beads. *J Am Acad Orthop Surg*. 2008 Nov;16(11):674-8.
186. Di Mascio L. Classification and management of acute wounds and open fractures. *Surgery (Oxford)*. 2011 Feb;29(2):76-9.
187. Evans AR. The treatment of open fractures. *Oper Tech in Orthop*. 2016;26(1):34-9.
188. Giannoudis PV, Papakostidis C, Kouvidis G, Kanakaris NK. The role of plating in the operative treatment of severe open tibial fractures: a systematic review. *Int Orthop*. 2009 Feb;33(1):19-26.
189. Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. *Cochrane Database Syst Rev*. 2009;4:CD003764.
190. Griffin M, Malahias M, Hindocha S, Khan W. Update on the management of compound lower limb fractures. *Open Orthop J*. 2012;6:518-24.
191. Halawi MJ, Morwood MP. Acute management of open fractures: an evidence-based review. *Orthopedics*. 2015 Nov;38(11):e1025-33.
192. Hannigan GD, Pulos N, Grice EA, Mehta S. Current concepts and ongoing research in the prevention and treatment of open fracture infections. *Adv Wound Care*. 2015 Jan;4(1):59-74.
193. Hull P. The management of open tibial fractures. *Eur J Orthop Surg and Traumatol*. 2008 Aug;18(6):441-7.
194. Hulsker CC, Kleinveld S, Zonnenberg CB, Hogervorst M, van den Bekerom MP. Evidence-based treatment of open ankle fractures. *Arch Orthop Trauma Surg*. 2011 Nov;131(11):1545-53.
195. Jedlicka N, Summers NJ, Murdoch MM. Overview of concepts and treatments in open fractures. *Clin Podiatr Med Surg*. 2012 Apr;29(2):279-90.
196. Jenkins PJ, Keating JF, Simpson AH. Fractures of the tibial shaft. *Surgery (Oxford)*. 2010 Oct;28(10):489-93.
197. Jorge-Mora A, Rodriguez-Martin J, Pretell-Mazzini J. Timing issue in open fractures debridement: a review article. *Eur J Orthop Surg and Traumatol*. 2013 Feb;23(2):125-9.
198. Kim PH, Leopold SS. Gustilo-Anderson classification. *Clin Orthop Relat Res*. 2012 Nov;470(11):3270-4.
199. Kovar FM, Jaindl M, Schuster R, Endler G, Platzer P. Incidence and analysis of open fractures of the midshaft and distal femur. *Wien Klin Wochenschr*. 2013 Jun 25;125(13-14):396-401.
200. Konda SR, Davidovitch RI, Egol KA. Open Knee Joint Injuries: An evidence-based approach to management. *Bull NYU Hosp Jt Dis*. 2014;72(1):61-9.
201. Ktistakis I, Giannoudi M, Giannoudis PV. Infection rates after open tibial fractures: are they decreasing? *Injury*. 2014 Jul;45(7):1025-7.



202. Lane JC, Mabvuure NT, Hindocha S, Khan W. Current concepts of prophylactic antibiotics in trauma: a review. *Open Orthop J.* 2012;6 (Suppl. 3):511-7.
203. Lee N, Di Mascio L. Classification and management of acute wounds and open fractures. *Surgery (Oxford).* 2014 Mar;32(3):134-8.
204. Manway J, Highlander P. Open fractures of the foot and ankle: an evidence-based review. *Foot Ankle Spec.* 2015 Feb 1;8(1):59-64.
205. Melvin JS, Dombroski DG, Torbert JT, Kovach SJ, Esterhai JL, Mehta S. Open tibial shaft fractures: I. Evaluation and initial wound management. *J Am Acad Orthop Surg.* 2010 Jan;18(1):10-9.
206. Metcalfe D, Aquilina AL, Hedley HM. Prophylactic antibiotics in open distal phalanx fractures: systematic review and meta-analysis. *J Hand Surg Eur Vol.* 2016 May 1;41(4):423-30.
207. Moran GJ, Talan DA, Abrahamian FM. Antimicrobial Prophylaxis for Wounds and Procedures in the Emergency Department. *Infect Dis Clin North Am.* 2008 Mar;22(1):117-43.
208. Mundi R, Chaudhry H, Niroopan G, Petrisor B, Bhandari M. Open tibial fractures: updated guidelines for management. *JBJS Reviews.* 2015 Feb 3;3(2):e1.
209. Murray CK, Hsu JR, Solomkin JS, Keeling JJ, Andersen RC, Ficke JR, et al. Prevention and management of infections associated with combat-related extremity injuries. *J Trauma.* 2008 Mar;64(3 Suppl):S239-51.
210. Murray CK, Obremskey WT, Hsu JR, Andersen RC, Calhoun JH, Clasper JC, et al. Prevention of infections associated with combat-related extremity injuries. *J Trauma.* 2011 Aug;71(2 Suppl. 2):S235-S57.
211. Nakamura Y, Daya M. Use of Appropriate Antimicrobials in Wound Management. *Emerg Med Clin North Am.* 2007 Feb;25(1):159-76.
212. Newton EJ. Acute Complications of Extremity Trauma. *Emerg Med Clin North Am.* 2007 Aug;25(3):751-61.
213. Nyary T, Scammell BE. Principles of bone and joint injuries and their healing. *Surgery (Oxford).* 2015 Jan;33(1):7-14.
214. O'Brien CL, Menon M, Jomha NM. Controversies in the management of open fractures. *The Open Orthopaedics Journal.* 2014;8(Suppl. 1: M7):178-184.
215. Ortega GR, Ortega AA. Posttraumatic orthopaedic wound infections: a current review of the literature. *Current Orthopaedic Practice.* 2014 May-Jun;25(3):217-20.
216. Pappasoulis E, Patzakis MJ, Zalavras CG. Antibiotics in the Treatment of Low-velocity Gunshot-induced Fractures: A Systematic Literature Review. *Clin Orthop Relat Res.* 2013 Dec;471(12):3937-44.
217. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. *J Am Acad Orthop Surg.* 2008 May;16(5):283-93.
218. Rhee PC, Dennison DG, Kakar S. Avoiding and treating perioperative complications of distal radius fractures. *Hand Clin.* 2012 May;28(2):185-98.
219. Ricci WM, McAndrew C, Merriman D, Gardner MJ. What's new in orthopaedic trauma. *JBJS-Series A.* 2011 Sept 21;93(18):1746-56.

220. Rozell JC, Connolly KP, Mehta S. Timing of operative debridement in open fractures. *Orthopedic Clinics*. 2017 Jan;48(1):24-34.
221. Sathiyakumar V, Thakore RV, Stinner DJ, Obremskey WT, Ficke JR, Sethi MK. Gunshot-induced fractures of the extremities: a review of antibiotic and debridement practices. *Curr Rev Musculoskelet Med*. 2015 Sept;8(3):276-89.
222. Schenker ML, Yannascoli S, Baldwin KD, Ahn J, Mehta S. Does timing to operative debridement affect infectious complications in open long-bone fractures? A systematic review. *JBJS-Series A*. 2012 Jun 20;94(12):1057-64.
223. Sharr PJ, Buckley RE. Current concepts review: open tibial fractures. *Acta Chir Orthop Traumatol Cech*. 2014;81(2):95-107.
224. Sinha VK, Anand LCS. Extremity and orthopaedic injuries. *Med J Armed Forces India*. 2010 Oct;66(4):342-6.
225. ter Boo GJ, Grijpma DW, Moriarty TF, Richards RG, Eglin D. Antimicrobial delivery systems for local infection prophylaxis in orthopedic and trauma surgery. *Biomaterials*. 2015 Jun;52:113-25.
226. Tosti R, Rehman S. Surgical management principles of gunshot-related fractures. *Orthop Clin N Am*. 2013 Oct;44(4):529-40.
227. Turker T, Capdarest-Arest N. Management of gunshot wounds to the hand: a literature review. *J Hand Surg* . 2013 Aug;38(8):1641-50.
228. Uckay I, Hoffmeyer P, Lew D, Pittet D. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. *J Hosp Infect*. 2013 May;84(1):5-12.
229. Unnikrishnan PN, Bhalai V. (ii) Management of acute fractures of the hand. *Orthopaedics and Trauma*. 2014 Aug;28(4):205-13.
230. Vaidya R, Sethi A, Oliphant BW, Gibson V, Sethi S, Meehan R. Civilian gunshot injuries of the humerus. *Orthopedics*. 2014 Mar;37(3):e307-e12.
231. Wenke JC, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. *Expert Opin Drug Deliv*. 2011;8(12):1555-69.
232. Werner CM, Pierpont Y, Pollak AN. The urgency of surgical débridement in the management of open fractures. *J Am Acad of Orthop Surg*. 2008 Jul;16(7):369-75.
233. Whitehouse MR, McDaid C, Kelly MB, Moran CG, Costa ML. The effect of timing of antibiotic delivery on infection rates related to open limb fractures: a systematic review. *Emerg Med J*, 2016: emermed-2016-205900.
234. Young S. Orthopaedic trauma surgery in low-income countries. *Acta Orthop*. 2014;85(Suppl. 356):1-35.
235. Yun HC, Murray CK, Nelson KJ, Bosse MJ. Infection after orthopaedic trauma: prevention and treatment. *J Orthop Trauma*. 2016 Oct;30(Suppl.3):S21-6.
236. Zalavras CG, Marcus RE, Levin LS, Patzakis MJ. Management of open fractures and subsequent complications. *JBJS-Series A*. 2007 Apr;89(4):884-95.



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).

Table I. Distribution of publications on prophylactic antibiotics to patients with open fractures of extremities in terms of year of publication

| Year  | Total |      | Practice |      | Practice and Recommendation |      | Recommendation |      |
|-------|-------|------|----------|------|-----------------------------|------|----------------|------|
|       | n     | (%)  | n        | (%)  | n                           | (%)  | n              | (%)  |
| 2007  | 11    | 4.9  | 2        | 3.0  |                             |      | 9              | 6.1  |
| 2008  | 14    | 6.3  |          |      |                             |      | 14             | 9.5  |
| 2009  | 15    | 6.7  | 2        | 3.0  | 1                           | 11.1 | 12             | 8.2  |
| 2010  | 15    | 6.7  | 6        | 9.0  |                             |      | 9              | 6.1  |
| 2011  | 30    | 13.5 | 11       | 16.4 |                             |      | 19             | 12.9 |
| 2012  | 23    | 10.3 | 5        | 7.5  |                             |      | 18             | 12.2 |
| 2013  | 30    | 13.5 | 11       | 16.4 | 1                           | 11.1 | 18             | 12.2 |
| 2014  | 37    | 16.6 | 12       | 17.9 | 5                           | 55.6 | 20             | 13.6 |
| 2015  | 23    | 10.3 | 9        | 13.4 | 2                           | 22.2 | 12             | 8.2  |
| 2016  | 19    | 8.5  | 9        | 13.4 |                             |      | 10             | 6.8  |
| 2017  | 6     | 2.7  |          |      |                             |      | 6              | 4.1  |
| Total | 223   | 100  | 67       | 100  | 9                           | 100  | 147            | 100  |

Table II. Distribution of publications on prophylactic antibiotics to patients with open fractures of extremities in terms of location of publication

| Continent           | Total |      | Practice |      | Practice and Recommendation |      | Recommendation |      |
|---------------------|-------|------|----------|------|-----------------------------|------|----------------|------|
|                     | n     | (%)  | n        | (%)  | n                           | (%)  | n              | (%)  |
| North America       | 117   | 52.5 | 25       | 37.3 | 5                           | 55.6 | 87             | 59.2 |
| Europe              | 63    | 28.3 | 17       | 25.4 | 2                           | 22.2 | 44             | 29.9 |
| Asia                | 23    | 10.3 | 17       | 25.4 |                             |      | 6              | 4.1  |
| Africa              | 6     | 2.7  | 4        | 6    | 1                           | 11.1 | 1              | 0.7  |
| Oceania             | 1     | 0.4  | 1        | 1.5  |                             |      |                |      |
| Multiple continents | 13    | 5.8  | 3*       | 4.5  | 1†                          | 11.1 | 9§             | 6.1  |
| Total               | 223   | 100  | 67       | 100  | 9                           | 100  | 147            | 100  |

## Notes:

\* One study was conducted in North America and Europe. One study was conducted in North America and Asia. One study was conducted in North America and Oceania.

† One study was conducted in North America and Asia.

§ Five evidence records were written by authors from North America and Europe. One was written by authors from North America and Oceania. One was written by authors from Europe and Oceania. One was written by authors from Europe and Asia. One was written by authors from North America, Europe and Asia.

Table III. Regimen in practice of prophylactic antibiotics systematically given to patients with open fractures of extremities\*

| Antibiotic regimen in practice¶       | Injury severity not specified or for all levels |      | Gustilo type 1 and 2 |      | Gustilo type 2 and 3 |      | Gustilo type 3 |      | Upper extremity† |      | Lower extremity§ |      | Soil, marine or severely contaminated wounds |     | Gun low-velocity |     | Gun high-velocity |      |
|---------------------------------------|---|------|----------------------|------|----------------------|------|----------------|------|------------------|------|------------------|------|--|-----|------------------|-----|-------------------|------|
|                                       | n   | (%)  | n                    | (%)  | n                    | (%)  | n              | (%)  | n                | (%)  | n                | (%)  | n  | (%) | n                | (%) | n                 | (%)  |
| Gram-positive coverage **             | 2   | 16.7 | 3                    | 17.6 | 1                    | 5.0  | 2              | 40.0 | 7                | 18.4 |                  |      |  |     |                  |     |                   |      |
| Gram-positive + anaerobic coverage †† | 1   | 8.3  | 4                    | 23.5 | 2                    | 10.0 |                |      |                  |      | 1                | 50.0 |  |     |                  |     |                   |      |
| Gram-positive + MRSA coverage §§      |   |      |                      |      |                      |      |                |      |                  |      | 1                | 50.0 |  |     |                  |     | 1                 | 33.3 |
| Gram-negative coverage ¶¶             |   |      | 3                    | 17.6 | 3                    | 15.0 |                |      |                  |      |                  |      |  |     |                  |     |                   |      |
| Gram-negative + anaerobic coverage    |   |      |                      |      |                      |      |                |      |                  |      | 1                | 2.6  |  |     |                  |     |                   |      |
| Broad coverage ***                    | 1   | 8.3  | 7                    | 41.2 | 2                    | 10.0 | 7              | 35.0 | 12               | 31.6 |                  |      |  |     |                  |     | 1                 | 33.3 |
| Broad + anaerobic coverage            |   |      |                      |      |                      |      | 3              | 15.0 | 2                | 5.3  |                  |      |  |     |                  |     |                   |      |
| Broad + MRSA coverage                 | 1   | 8.3  |                      |      |                      |      |                |      |                  |      | 2                | 5.3  |  |     |                  | 1   | 100               |      |
| Broad + MRSA + anaerobic coverage     | 7   | 58.3 |                      |      | 4                    | 20.0 |                |      | 2                | 40.0 | 14               | 36.8 |  |     |                  |     | 1                 | 33.3 |
| Drug name not specified               | 12  | 100  | 17                   | 100  | 2                    | 100  | 20             | 100  | 38               | 100  | 5                | 100  | 2  | 100 | 2                | 100 | 3                 | 100  |
| Total                                 |   |      |                      |      |                      |      |                |      |                  |      |                  |      |  |     |                  |     |                   |      |

MRSA, methicillin-resistant Staphylococcus aureus

Notes:

\* “Practice” was abstracted from multi-center or single-center randomized controlled trials (RCTs), cohort studies, case-control studies, single arm studies (including case series) and surveys of surgeons that indicate use of antibiotic prophylaxis among open fracture patients.

† Upper extremity fractures include open fractures of hand, radius and fingers, for all Gustilo types of injury severity.

§ Lower extremity fractures include open fractures of tibia, femur, ankle and calcaneus, for all Gustilo types of injury severity.

¶ Clindamycin was used in patients with beta-lactam/penicillin allergies.

\*\* Gram-positive coverage includes first and second generation cephalosporins (e.g., cefazolin, cephalexin, cefacidal, cefadroxil and cefuroxime), macrolide, ampicillin or augmentin, amoxicillin or co-amoxiclav, penicillin and any combination of these drugs.

†† Anaerobic coverage includes metronidazole (flagyl), clindamycin, beta-lactam/beta-lactamase inhibitors (e.g., ampicillin/sulbactam, piperacillin/tazobactam), and carbapenems.

§ § MRSA coverage includes vancomycin or teicoplanin.

¶¶ Gram-negative coverage, in this case, refers to aminoglycosides (e.g., gentamicin, tobramycin and amikacin).

\*\*\* “Broad” means broad-spectrum antibiotic coverage, including both Gram-positive and Gram-negative coverage. Such antibiotics include carbapenems (e.g. ertapenem, meropenem), piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftriaxone), and any combination of antibiotics that include both Gram-positive and Gram-negative coverage.

Table IV. Duration of antibiotics in practice of prophylactic antibiotics systematically given to patients with open fractures of extremities

|                                     | Injury severity not specified or for all levels |      | Gustilo type 1 and 2 |      | Gustilo type 2 and 3 |      | Gustilo type 3 |      | Upper extremity† |      | Lower extremity‡ |      | Soil, marine or severely contaminated wounds |      | Gun low-velocity |     | Gun high-velocity |      |
|-------------------------------------|---|------|----------------------|------|----------------------|------|----------------|------|------------------|------|------------------|------|--|------|------------------|-----|-------------------|------|
|                                     | n   | (%)  | n                    | (%)  | n                    | (%)  | n              | (%)  | n                | (%)  | n                | (%)  | n  | (%)  | n                | (%) | n                 | (%)  |
| Duration of antibiotics in practice |   |      |                      |      |                      |      |                |      |                  |      |                  |      |  |      |                  |     |                   |      |
| Up to 1 day                         | 1   | 8.3  | 3                    | 17.6 |                      |      |                |      | 2                | 40.0 | 4                | 10.5 |  |      |                  |     | 1                 | 33.3 |
| 2 to 3 days                         | 1   | 8.3  | 5                    | 29.4 | 1                    | 50.0 | 4              | 20.0 |                  |      | 8                | 21.1 |  |      |                  |     |                   |      |
| 4 to 7 days                         | 1   | 8.3  | 3                    | 17.6 |                      |      | 2              | 10.0 |                  |      | 7                | 18.4 | 1  | 50.0 |                  |     |                   |      |
| More than 7 days                    |   |      |                      |      |                      |      | 2              | 10.0 |                  |      | 5                | 13.2 |  |      |                  |     |                   |      |
| Duration not specified              | 9   | 75.0 | 6                    | 35.3 | 1                    | 50.0 | 12             | 60.0 | 3                | 60.0 | 14               | 36.8 | 1  | 50.0 | 1                | 100 | 2                 | 66.7 |
| Total                               | 12  | 100  | 17                   | 100  | 2                    | 100  | 20             | 100  | 5                | 100  | 38               | 100  | 2  | 100  | 1                | 100 | 3                 | 100  |



Table V. Regimen in recommendations of prophylactic antibiotics systematically given to patients with open fractures of extremities\*

| Recommended drugs¶                   | Injury severity not specified or for all injuries |      | Gustilo type 1 and 2 |      | Gustilo type 2 and 3 |      | Gustilo type 3 |      | Upper extremity† |     | Lower extremity§ |      | Soil, manure or severely contaminated wounds |      | Gun velocity not specified |      | Gun low-velocity |      | Gun high-velocity |      |
|--------------------------------------|---|------|----------------------|------|----------------------|------|----------------|------|------------------|-----|------------------|------|--|------|----------------------------|------|------------------|------|-------------------|------|
|                                      | n   | (%)  | n                    | (%)  | n                    | (%)  | n              | (%)  | n                | (%) | n                | (%)  | n  | (%)  | n                          | (%)  | n                | (%)  | n                 | (%)  |
| Gram-positive coverage**             | 13  | 18.1 | 34                   | 68.0 |                      |      |                |      |                  |     | 9                | 26.5 | 9  | 22.0 | 1                          | 50.0 | 3                | 50.0 | 6                 | 42.9 |
| Gram-positive + anaerobic coverage†† |   |      | 2                    | 4.0  |                      |      |                |      |                  |     |                  |      |  |      |                            |      |                  |      | 1                 | 7.1  |
| Gram-positive + MRSA coverage§§      | 1   | 1.4  |                      |      |                      |      |                |      |                  |     |                  |      | 1  | 2.4  |                            |      |                  |      |                   |      |
| Gram-negative coverage¶¶             | 1   | 1.4  | 2                    | 4.0  |                      |      | 5              | 10.9 |                  |     | 1                | 2.9  |  |      |                            |      |                  |      |                   |      |
| Broad coverage***                    | 14  | 19.4 | 10                   | 20.0 | 6                    | 85.7 | 35             | 76.1 |                  |     | 9                | 26.5 | 26   | 63.4 | 1                          | 50.0 | 1                | 16.7 | 5                 | 35.7 |
| Broad + anaerobic coverage           | 3   | 4.2  | 1                    | 2.0  | 1                    | 14.3 | 3              | 6.5  |                  |     | 1                | 2.9  | 4  | 9.8  |                            |      |                  |      | 1                 | 7.1  |
| Broad + MRSA coverage                |   |      |                      |      |                      |      | 1              | 2.2  |                  |     |                  |      | 1  | 2.4  |                            |      |                  |      |                   |      |
| Broad + MRSA + anaerobic coverage    | 5   | 6.9  |                      |      |                      |      |                |      |                  |     | 3                | 8.8  |  |      |                            |      |                  |      |                   |      |
| Drug name not specified              | 35  | 48.6 | 1                    | 2.0  |                      |      | 2              | 4.3  | 4                | 100 | 11               | 32.4 |  |      |                            |      | 2                | 33.3 | 1                 | 7.1  |
| Total                                | 72  | 100  | 50                   | 100  | 7                    | 100  | 46             | 100  | 4                | 100 | 34               | 100  | 41   | 100  | 2                          | 100  | 6                | 100  | 14                | 100  |

MRSA, methicillin-resistant *Staphylococcus aureus*

Notes:

\* “Recommendation” was abstracted from review articles, surveys of surgeons, guidelines, textbooks and some clinical studies if they made recommendations.

† Upper extremity fractures include open fractures of radius, humerus and ulna, for all Gustilo types of injury severity.

§ Lower extremity fractures include open fractures of tibia, femur, knee, foot and ankle, forefoot, phalanx and calcaneus, for all Gustilo types of injury severity.

¶ Several authors of original sources recommended clindamycin as an alternative to beta-lactams in patients who are allergic to beta-lactams or in patients with suspected Group A Streptococcus infections.

\*\* Gram-positive coverage includes first and second generation cephalosporins (e.g., cefazolin, cephalexin, cefamandole, cefuroxime and cephadrine), cloxacillin or flucloxacillin or dicloxacillin, erythromycin, ampicillin or augmentin, amoxicillin or co-amoxiclav, penicillin, high-dose penicillin, penicillin G (benzylpenicillin) and any combination of these drugs.

†† Anaerobic coverage includes metronidazole, clindamycin, beta-lactam/beta-lactamase inhibitors (e.g., ampicillin/sulbactam, piperacillin/tazobactam), and carbapenems.

§§ MRSA coverage includes vancomycin or teicoplanin.

¶¶ Gram-negative coverage, in this case, refers to aminoglycosides (e.g., gentamicin, tobramycin and amikacin).

\*\*\* “Broad” means broad-spectrum antibiotic coverage, including both Gram-positive and Gram-negative coverage. Such antibiotics include carbapenems (e.g., ertapenem, meropenem), meronem, piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftazidime, ceftriaxone and cefotaxime), and any combination of antibiotics that include both Gram-positive and Gram-negative coverage.

Table VI. Duration of antibiotics in recommendations of prophylactic antibiotics systematically given to patients with open fractures of extremities

|   | Injury severity not specified or for all injuries | Gustilo type 1 and 2 | Gustilo type 2 and 3 | Gustilo type 3 | Upper extremity† | Lower extremity‡ | Soil, marine or severely contaminated wounds | Gun velocity not specified | Gun low-velocity |        | Gun high-velocity |        |
|---|---|----------------------|----------------------|----------------|------------------|------------------|--|----------------------------|------------------|--------|-------------------|--------|
|   |   |                      |                      |                |                  |                  |  |                            | n (%)            | n (%)  | n (%)             | n (%)  |
| Recommended duration of antibiotic administration |   |                      |                      |                |                  |                  |  |                            |                  |        |                   |        |
| Up to 1 day                                       | 14 19.4   | 17 34                | 1 14.3               | 1 25           | 4 11.8           | 1 50             | 1 16.7                                       | 1 50                       | 1 16.7           | 1 16.7 | 1 16.7            | 1 16.7 |
| 2 to 3 days                                       | 5 6.9   | 17 34                | 2 28.6               | 17 37          | 13 38.2          | 1 50             | 6 14.6                                       | 1 50                       | 2 33.3           | 2 33.3 | 2 33.3            | 2 33.3 |
| 4 to 7 days                                       | 3 4.2   |                      |                      | 10 21.7        | 1 2.9            | 4 9.8            |  |                            |                  |        |                   |        |
| More than 7 days                                  |   |                      |                      | 1 2.2          | 3 8.8            |                  |  |                            |                  |        |                   |        |
| Duration not specified                            | 50 69.4   | 16 32                | 4 57.1               | 18 39.1        | 13 38.2          | 31 75.6          | 3 7.5  | 3 7.5                      | 3 50             | 3 50   | 5 35.7            | 5 35.7 |
| Total   | 72 100  | 50 100               | 7 100                | 46 100         | 34 100           | 41 100           | 6 100  | 2 100                      | 6 100            | 6 100  | 14 100            | 14 100 |

Appendix 1. MEDLINE title and abstract search strategy for effects of antibiotic prophylaxis in patients with open fracture

1. antibiotics.mp. or exp Anti-Bacterial Agents/
2. antibiotic prophylaxis.mp. or exp Antibiotic Prophylaxis/
3. (anti-microb\* or anti bact\* or antibact\*).mp.
4. (antibiotic\* or antimicrob\*).mp.
5. cephalothin.mp.
6. antibioprohylaxis.mp.
7. cloxacillin.mp.
8. exp AMOXICILLIN/ or AMOXICILLIN.mp.
9. exp Ampicillin/ or AMPICILLIN.mp.
10. CLAVULANIC ACID.mp.
11. AMOXICLAV.mp.
12. AUGMENTIN.mp.
13. TICARCILLIN.mp.
14. exp Cephalosporins/ or CEPHALOSPORIN\*.mp.
15. (KEFLEX or CEFAMANDOLE or KEFADOL or CEFAZOLIN\* or KEFZOL or CEFIXIME or SUPRAX).mp.
16. (CEFOTAXIME or CLAFORAN or CEFOXITIN or MEFOXIN or CEFPIROME or CEFROM or CEFPODOXIME).mp.
17. (ORELOX or CEFPROZIL or CEFZIL or CEFRADINE or VELOSEL or CEFTAZIDIM or ORTUM or KEFADIM).mp.

18. (CEFTRIAXONE or ROCEPHIN or CEFUROXIME or ZINACEF or ZINNAT or CEFONICID or AZTREONAM).mp.
19. (AZACTAM or IMIPENEM or ILASTATIN or PRIMAXIN or MEROPENEM).mp.
20. (TETRACYCLINE\* or DETECLO or DEMECLEOCYCLIN or LEDERMYCIN or DOXYCYCLINE or VIBRAMYCIN).mp.
21. (MINOCYCLINE or MINOCINE or OXYTETRACYCLINE or TERRAMYCIN or MACROLIDE\*).mp.
22. (ERYTHROMYCIN or ERYMAX or ERYTHROCIN or ERYTHROPEL or AZITHROMYCIN or ZITHROMAX).mp.
23. (CLARITHROMYCIN or KLARICID or TELITHROMYCIN or KETEK or TRIMOXAZOLE or SEPTRIN).mp.
24. (TRIMETHOPRIM or MONOTRIM or TRIMOPAN or METRONIDAZOLE or FLAGYL or METROLYL).mp.
25. (PHENOXYMETHYLPENICILLIN or SULFAMETHOXAZOLE or OXACILLIN or CEPHALOTHIN or SULBACTAM).mp.
26. (OFLOXACIN or CLINDAMYCIN or GENTAMYCIN or VANCOMYCIN).mp.
27. (CEFACLOR or DISTACLOR or CEFADROXIL or BAXAN or CEFALEXIN or CEPOREX).mp.
28. (TIMENTIN or FLUCLOXACILLIN or FLUAMPICIL or MAGNAPEN or PIPERACILLIN or TAZOCIN).mp.
29. (streptomycin or cefalotin or dicloxacillin).mp.

30. or/1-29
31. exp fractures, open/
32. (orthopedic adj2 surg\*).mp.
33. (open adj9 fracture\*).mp.
34. ((open adj2 reduction) and fracture\*).mp.
35. (Gustilo or Gustillo).mp.
36. anderson type\*.mp.
37. (compound adj9 fracture\*).mp.
38. ununited fractures.mp. or exp Fractures, Ununited/
39. fracture fixation.mp. or exp Fracture Fixation/
40. fracture\*.mp. or exp Fractures, Bone/
41. (infect\$ adj3 (bone\$ or fracture\$)).mp.
42. ((nonunion or non union) adj9 fracture\*).tw.
43. or/31-42
44. 30 and 43
45. animals/ not humans/
46. 44 not 45

Appendix 2. Regimen in practice of prophylactic antibiotics systematically given to patients with open fractures of lower extremities by injury severity (published between January 2007 and June 2017)<sup>\*†</sup>

|  | Lower extremity injury severity not specified or for all levels |      | Lower extremity Gustilo type 1 and 2 |      | Lower extremity Gustilo type 2 and 3 |     | Lower extremity Gustilo type 3 |      |
|--|---|------|--------------------------------------|------|--------------------------------------|-----|--------------------------------|------|
|  | n   | (%)  | n                                    | (%)  | n                                    | (%) | n                              | (%)  |
| Antibiotic regimen in practice <sup>§</sup>        |   |      |                                      |      |                                      |     |                                |      |
| Gram-positive coverage <sup>¶</sup>                | 3   | 17.6 | 3                                    | 42.9 |                                      |     | 1                              | 7.7  |
| Gram-negative** + anaerobic coverage <sup>††</sup> |   |      |                                      |      |                                      |     | 1                              | 7.7  |
| Broad coverage <sup>§§</sup>                       | 2   | 11.8 | 4                                    | 57.1 |                                      |     | 6                              | 46.2 |
| Broad + anaerobic coverage                         | 1   | 5.9  |                                      |      |                                      |     | 1                              | 7.7  |
| Broad + MRSA <sup>¶¶</sup> + anaerobic coverage    | 1   | 5.9  |                                      |      |                                      |     | 1                              | 7.7  |
| Drug name not specified                            | 10  | 58.8 |                                      |      | 1                                    | 100 | 3                              | 23.1 |
| Total  | 17  | 100  | 7                                    | 100  | 1                                    | 100 | 13                             | 100  |

MRSA, methicillin-resistant *Staphylococcus aureus*

Notes:

\* “Practice” was abstracted from multi-center or single-center randomized controlled trials (RCTs), cohort studies, case-control studies, single arm studies (including case series) and surveys of surgeons that indicate use of antibiotic prophylaxis among open fracture patients.

† Lower extremity fractures include open fractures of tibia, femur, ankle and calcaneus.

§ Clindamycin was used in patients with beta-lactam/penicillin allergies.

¶ Gram-positive coverage includes first and second generation cephalosporins (e.g., cefazolin, cephalexin, cefacidal, cefadroxil and cefuroxime), macrolide, ampicillin or augmentin, amoxicillin or co-amoxiclav, penicillin and any combination of these drugs.

\*\* Gram-negative coverage, in this case, refers to aminoglycosides (e.g., gentamicin, tobramycin and amikacin).

†† Anaerobic coverage includes metronidazole (flagyl), clindamycin, beta-lactam/beta-lactamase inhibitors (e.g., ampicillin/sulbactam, piperacillin/tazobactam), and carbapenems.

§§ “Broad” means broad-spectrum antibiotic coverage, including both Gram-positive and Gram-negative coverage. Such antibiotics include carbapenems (e.g., ertapenem, meropenem), piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftriaxone), and any combination of antibiotics that include both Gram-positive and Gram-negative coverage.

¶¶ MRSA coverage includes vancomycin or teicoplanin.

Appendix 3. Level of recommendations about prophylactic systemic antibiotic therapy for patients with open fractures of extremities (published between January 2007 and June 2017)

|                      | Total |      | Injury severity not specified or for all injuries |      | Gustilo type 1 and 2 |      | Gustilo type 2 and 3 |     | Gustilo type 3 |      | Upper extremity† |      | Lower extremity‡ |      | Soil, marine or severely contaminated wounds |     | Gun velocity not specified |     | Gun low-velocity |      | Gun high-velocity |     |
|----------------------|-------|------|---|------|----------------------|------|----------------------|-----|----------------|------|------------------|------|------------------|------|--|-----|----------------------------|-----|------------------|------|-------------------|-----|
|                      | n     | (%)  | n   | (%)  | n                    | (%)  | n                    | (%) | n              | (%)  | n                | (%)  | n                | (%)  | n  | (%) | n                          | (%) | n                | (%)  | n                 | (%) |
| Must                 | 252   | 91.3 | 58  | 80.6 | 47                   | 94.0 | 7                    | 100 | 43             | 93.5 | 3                | 75.0 | 33               | 97.1 | 41   | 100 | 2                          | 100 | 4                | 66.7 | 14                | 100 |
| Probably should      | 14    | 5.1  | 7   | 9.7  | 3                    | 6.0  |                      |     | 3              | 6.5  |                  |      |                  |      |  |     |                            |     | 1                | 16.7 |                   |     |
| Possibly should      | 2     | 0.7  | 1   | 1.4  |                      |      |                      |     |                |      | 1                | 25.0 |                  |      |  |     |                            |     |                  |      |                   |     |
| Uncertain            | 1     | 0.4  |   |      |                      |      |                      |     |                |      |                  |      |                  |      |  |     |                            |     |                  |      |                   |     |
| Probably should not  | 3     | 1.1  | 2   | 2.8  |                      |      |                      |     |                |      |                  |      | 1                | 2.9  |  |     |                            |     |                  |      |                   |     |
| Certainly should not | 2*    | 0.7  | 2*  | 2.8  |                      |      |                      |     |                |      |                  |      |                  |      |  |     |                            |     |                  |      |                   |     |
| No opinion           | 2     | 0.7  | 2   | 2.8  |                      |      |                      |     |                |      |                  |      |                  |      |  |     |                            |     |                  |      |                   |     |
| Total                | 276   | 100  | 72  | 100  | 50                   | 100  | 7                    | 100 | 46             | 100  | 4                | 100  | 34               | 100  | 41   | 100 | 2                          | 100 | 6                | 100  | 14                | 100 |

Recommendations level of recommendations about whether antibiotics should to be systematically given to patients with open fractures of extremities, per article/book chapter/guideline

Note:

\* Two review articles with recommendation of certainly should not use antibiotics only refer to fluoroquinolone.



Appendix 4. Regimen in recommendations of prophylactic antibiotics systematically given to patients with open fractures of lower extremities by injury severity (published between January 2007 and June 2017)\*<sup>†</sup>

|   | Lower extremity injury severity not specified or for all levels |      | Lower extremity Gustilo type 1 and 2 |      | Lower extremity Gustilo type 3 |      |
|---|---|------|--------------------------------------|------|--------------------------------|------|
|   | n   | (%)  | n                                    | (%)  | n                              | (%)  |
| Recommended drugs <sup>§</sup>                  |   |      |                                      |      |                                |      |
| Gram-positive coverage <sup>¶</sup>             | 6   | 25.0 | 3                                    | 60.0 |                                |      |
| Gram-negative coverage <sup>**</sup>            |   |      |                                      |      | 1                              | 20.0 |
| Broad coverage <sup>††</sup>                    | 3   | 12.5 | 2                                    | 40.0 | 4                              | 80.0 |
| Broad + anaerobic coverage <sup>§§</sup>        | 1   | 4.2  |                                      |      |                                |      |
| Broad + MRSA <sup>¶¶</sup> + anaerobic coverage | 3   | 12.5 |                                      |      |                                |      |
| Drug name not specified                         | 11  | 45.8 |                                      |      |                                |      |
| Total   | 24  | 100  | 5                                    | 100  | 5                              | 100  |

MRSA, methicillin-resistant *Staphylococcus aureus*

Notes:

\* “Practice” was abstracted from multi-center or single-center randomized controlled trials (RCTs), cohort studies, case-control studies, single arm studies (including case series) and surveys of surgeons that indicate use of antibiotic prophylaxis among open fracture patients.

<sup>†</sup> Lower extremity fractures include open fractures of tibia, femur, knee, foot and ankle, forefoot, phalanx and calcaneus.

<sup>§</sup> Clindamycin was used in patients with beta-lactam/penicillin allergies.

<sup>¶</sup> Gram-positive coverage includes first and second generation cephalosporins (e.g., cefazolin, cephalexin, cefacidal, cefadroxil and cefuroxime), macrolide, ampicillin or augmentin, amoxicillin or co-amoxiclav, penicillin and any combination of these drugs.

<sup>\*\*</sup> Gram-negative coverage, in this case, refers to aminoglycosides (e.g., gentamicin, tobramycin and amikacin).

<sup>††</sup> “Broad” means broad-spectrum antibiotic coverage, including both Gram-positive and Gram-negative coverage. Such antibiotics include carbapenems (e.g., ertapenem, meropenem), piperacillin/tazobactam, third or/and fourth generation cephalosporins (e.g., ceftriaxone), and any combination of antibiotics that include both Gram-positive and Gram-negative coverage.

<sup>§§</sup> Anaerobic coverage includes metronidazole (flagyl), clindamycin, beta-lactam/beta-lactamase inhibitors (e.g., ampicillin/sulbactam, piperacillin/tazobactam), and carbapenems.

<sup>¶¶</sup> MRSA coverage includes vancomycin or teicoplanin.

## **CHAPTER 4**

### **Risk Factors for Persistent Post-surgical Pain after Tibia Fracture: A Longitudinal Study**

Submitted to the Clinical Orthopaedics and Related Research January 22, 2018

## **Risk factors for persistent post-surgical pain after tibia fracture: a longitudinal study**

Yaping Chang, MSc<sup>1</sup>, Jason W. Busse, DC, PhD<sup>1,2,3</sup>, Mohit Bhandari, PhD, MD<sup>1,4</sup>, Wei Qi<sup>5</sup>, Li Wang, PhD<sup>2,3</sup>, Diane Heels-Ansdell, MSc<sup>1</sup>, Qi Zhou, PhD<sup>1</sup>, Lehana Thabane, PhD<sup>1,6</sup>, Mei Wang, MSc<sup>1</sup>, Kan Lun Zhu<sup>7</sup>, Brad Petrisor, MD<sup>4</sup>, Lin Jin, MD<sup>1</sup>, Sean Alexander Kennedy, MD<sup>8</sup>, Sheila Sprague, PhD<sup>1,4</sup>, Paula McKay, BSc<sup>4</sup>, Nicole Simunovic, MSc<sup>4</sup>, Shiyun Hu, PhD, MD<sup>9</sup>, Yuan Zhang, PhD<sup>1</sup>, Ying Zhang, PhD<sup>10</sup>, Gordon H Guyatt, MD, MSc<sup>1</sup> on behalf of the TRUST Investigators\*

### **Affiliations and Correspondence**

1. Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
2. Department of Anesthesia, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
3. Michael G. DeGroote Institute for Pain Research and Care, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
4. Division of Orthopaedic Surgery, Department of Surgery, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
5. Tianjin Centres for Disease Control and Prevention, 6 Huayuedao Road, Tianjin, 300041, China
6. Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada

7. Department of Diagnostic Radiology, University of Toronto, 263 McCaul Street, Toronto, Ontario, M5T 1W7, Canada

8. Cardiovascular and Cerebrovascular Disease Prevention and Control Research Center of Zhejiang Province, Zhejiang Hospital, 12 Lingyin Road, Hangzhou, Zhejiang, 310013, China

9. Centre for Evaluation of Medicines, St. Joseph's Healthcare Hamilton, McMaster University, 25 Main Street West, Hamilton, Ontario, L8P 1H1, Canada

10. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Beijing, 100029, China

\*Please refer to Appendix 1 for a listing of the TRUST Investigators

## ABSTRACT

**Background:** Although persistent post-surgical pain after tibia fracture is common, its predictors have received limited study.

**Objectives:** We used data collected as part of the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST) to address, among patients with a tibial shaft fracture, the association between baseline characteristics and persistent pain up to 12 months post-operatively.

**Methods:** We defined our study outcome, the resolution of troublesome pain, as no more than mild persistent pain (pain score  $\leq 3$  on a 0-10 Numeric Rating Scale) at two consecutive follow-up visits. We used a multivariable Cox proportional hazards regression model for analysis.

**Results:** We included 481 patients with open or closed fractures of the tibia who underwent surgical repair. During the 12-month follow-up period, 313 of 481 (65.1%) participants reported resolution of pain. We found significant independent associations between resolution of pain and male sex (hazard ratio [HR]=1.34 [95% confidence interval (CI), 1.04 to 1.72]), non-smoking (HR=1.74 [95% CI, 1.33 to 2.29]) and alcohol consumption (HR=1.35 [95% CI, 1.06 to 1.73]). Age, obesity, type of fracture (closed versus open), additional injuries, and post-operative weight-bearing status did not predict resolution of pain.

**Conclusions:** In our study, non-medical factors were predictive of persistent post-surgical pain after tibial fracture repair, whereas injury severity was not. Results of the study will alert clinicians of the higher risk of persistent

post-operative pain in female smokers who do not use alcohol, and allow them to use this information as a means to counsel female smokers to discontinue smoking. Further prospective studies are needed to confirm or refute the findings in our study.

**Key words:** persistent pain; post-surgery; tibial shaft fracture; predictor

## **1. Introduction**

Tibia fractures are the most frequent type of long bone fracture <sup>[1-3]</sup>. The National Center for Health Statistics reported 492,000 tibia fractures per year in the United States <sup>[3]</sup>. Tibia fractures often require prolonged rehabilitation or multiple operative procedures to achieve maximal functional recovery.

Persistent post-surgical pain (PPSP), defined in the 11<sup>th</sup> version of the International Classification of Diseases of the World Health Organization (WHO) as pain that lasts for at least three months after a surgical procedure excluding other causes of pain <sup>[4-6]</sup>, is common amongst patients who undergo surgery following lower extremity fractures <sup>[7]</sup>. Greater duration and severity of post-surgical pain is associated with less mobility <sup>[8]</sup>, restrictions in activities of daily living, and reduced quality of life <sup>[2,3,9-11]</sup>.

Although PPSP after fracture repair is common, predictors of persistent pain have received limited study. Therefore, to determine the association between patients' characteristics and PPSP in adults with tibial fracture, we assessed the association between pain status at the time of surgery and PPSP up to 12 months postoperatively.

## **2. Methods**

### *2.1 Study Design and Participants*

The current study used data collected as part of a large, prospective, multi-center randomized controlled trial, the Trial to Re-evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST)<sup>[12,13]</sup>. The TRUST Investigators (Appendix 1) evaluated the impact of low-intensity, pulsed ultrasound applied to tibial shaft fractures treated with intramedullary nailing on functional status, time to radiographic healing of fractures and rates of nonunion. The trial enrolled adults aged 18 years or older, with an open or closed tibial fracture amenable to intramedullary nail fixation seen at 43 participating centers across Canada and the United States between October 2008 and September 2012 (last assessment April 2013, data of last contact in May 2013). The trial found no benefit of the Sonic Accelerated Fracture Healing System (SAFHS®) device applied within 14 days of fracture nailing treatment versus placebo<sup>[12,13]</sup>.

The McMaster University Research Ethics Board and local ethics boards at each participating site approved the TRUST protocol (REB #08-171). All participants provided written informed consent prior to participation. The TRUST pilot study<sup>[12]</sup> and the TRUST definitive trial<sup>[13]</sup> have been published elsewhere.

### *2.2 Measurement of PPSP*

Patients were evaluated prior to surgery and at 6, 12, 18, 26, 32, 38, 44 and 52 weeks after surgical repair of their tibia fractures. At each of these visits, patients rated their level of pain intensity on a 0-10 Numeric Rating Scale, with 0



representing no pain and 10 representing the worst pain possible.

### *2.3 Definition of outcome - Resolution of troublesome pain*

In the current study, we defined PPSP as pain persisting either continuously or intermittently for 3 months or more after surgery<sup>[4-6]</sup>. We defined our study outcome, the resolution of troublesome pain, as a patient report of mild or no pain (pain score  $\leq 3$ )<sup>[14,15]</sup> at two consecutive follow-up visits, and pain score would not increase beyond 3 anymore.

### *2.4 Independent Variables*

We present continuous variables as means and standard deviations and categorical and binary variables as proportions. Orthopedic surgeons and pain researchers (MB, JWB, BP and GG) identified the following possible predictors of post-operative pain: age, sex, body mass index (BMI), smoking status, alcohol use, diabetes, kidney disease or renal insufficiency, vascular disease, rheumatoid arthritis, co-morbidity requiring chronic steroid use, fracture type (open from Gustilo type I-IIIIB or closed from Tscherne grade 0-3), whether there were additional injuries, intramedullary nailing with or without reaming, and post-operative weight-bearing status on the day of surgery (non, partial or full).

Based on the standard BMI cutoff points that the WHO has recommended for classification of obesity ( $\geq 30$  kg/m<sup>2</sup>)<sup>[16]</sup>, we categorized BMI into two groups: 1) non-obese (BMI  $< 30$  kg/m<sup>2</sup>) and 2) obese (BMI  $\geq 30$  kg/m<sup>2</sup>). We also categorized post-operative weight-bearing status into two groups: 1) non weight-bearing and 2)

partial or full weight-bearing.

### *2.5 Statistical Analysis*

Before entering the potential prognostic factors into the multivariable models, we examined all pair-wise correlations by calculating the  $r$  index, considering the threshold of highly correlated to be  $> 0.7$  <sup>[17]</sup>. For binary and categorical variables we looked at Phi or Cramer's V statistics; for continuous variables we looked at Pearson's correlation coefficient; and for continuous and categorical variables we looked at Point-Biserial correlation or the correlation coefficient from the R-square from of the ANOVA analysis <sup>[17]</sup>. For variables with correlations over 0.7, we planned to include only the variables that we considered most likely to be predictive of PPSP. We used variance inflation factor (VIF) to detect the multicollinearity of variables and planned to exclude the variables with VIF over 4.0 <sup>[18]</sup>. We also excluded variables in which there were less than 10 events in each of the groups with or without the presence of the putative predictor <sup>[19]</sup>. To determine the 12-month association between possible predictors and resolution of troublesome pain, we conducted a time-to-event analysis by including all other pre-specified variables in a multivariable Cox proportional hazards regression model <sup>[20]</sup> and tested the model to ensure the proportional hazard assumption was met. We consulted the orthopedic surgeon (BP) for any postulated interactions prior to analysis.

We report the number of participants and proportions at their last follow-ups. We look at the distribution of duration of follow-up in those who had PPSP. We

report all association estimates as hazard ratios (HRs) and 95% confidence intervals (CIs). All calculated P-values are two-tailed, with the criterion for statistical significance set at 0.05. We calculated the pair-wise correlations for variables using SAS version 9.4 (SAS Institute Inc., NC, USA) and performed the remaining analyses using SPSS version 24.0 (IBM Corp., NY, USA).

### 3. Results

Of 501 patients enrolled in the TRUST study, two did not have any records of pain measurement, and 18 had only a baseline record of pain measurement. The remaining 481 patients, all of whom had data available for pain scores at least three months after surgery, were included in the analysis. Table I summarizes the characteristics of these 481 patients. No participants had kidney disease or renal insufficiency, vascular disease or rheumatoid arthritis. There were fewer than 10 events in each of the groups of diabetes, a comorbidity requiring chronic steroid use and type of fixation (Table I). We therefore did not consider any of these potential predictors of troublesome post-operative pain further.

We were able to follow the majority of patients (301/481, 62.6%) for the full 12 months post-surgery. Of the 481 participants, 313 (65.1%) experienced resolution of troublesome pain over 12 months. Resolution of pain was related to duration of follow-up. The greatest reduction in the proportion experiencing important PPSP occurred between 18 and 26 weeks of follow-up. For those followed for 26 weeks or more, there was little difference in the proportion with persistent troublesome pain (Table II, Figure 1). If one considers only those followed for 26 weeks or more, 297/402 patients (73.9%) achieved resolution of PPSP. No two variables were correlated with one another at the threshold value of 0.7 or higher (Appendix 2). No variables had VIF at the threshold value of 4.0 or higher (Appendix 3).

In the multivariable Cox survival regression, we found significant independent associations between resolution of troublesome pain and male sex

(HR=1.34, 95% CI 1.04 to 1.72; p value=0.02), non-smoking (HR=1.74, 95% CI, 1.33 to 2.29; p value < 0.001) and alcohol consumption (HR=1.35, 95% CI, 1.06 to 1.73; p value=0.02). We did not find significant associations between PPSP and age, obesity, type of fracture (closed versus open), additional injuries or post-operative weight-bearing status (Table III, Figure 2). In every case, we found no violation of the proportional hazards assumption (Appendix 4). The surgeon did not have concerns about any postulated interactions.

#### 4. Discussion

We found that 65.1% of patients who underwent repair of closed or open tibial shaft fracture achieved stable resolution of troublesome pain 3 to 12 months after surgery; the remaining 34.9% continued to report PPSP. Few patients achieved resolution prior to 26 weeks; of those followed for 36 weeks or more almost three quarters of patients achieved resolution (Table II). Independent predictors of resolution of troublesome pain were male sex, non-smoking and drinking alcohol (Table III). The association was particularly strong for smoking status: non-smokers were almost twice likely to be free of pain than were smokers (HR=1.74, 95% CI, 1.33 to 2.29). We did not find significant association between age, obesity, additional injuries, post-operative weight-bearing status on the day of surgery and, perhaps most surprisingly, type of fracture (open versus closed) and PPSP.

Strengths of this study include multicenter participation from two countries, which enhanced generalizability, a sample size sufficient to generate satisfactory confidence intervals, a follow-up period of one-year achieved in the majority of patients, a patient-important and conservative outcome definition of resolution of troublesome pain,<sup>[12,13]</sup> and analytic approaches.

However, this study also has limitations. First, the study failed to obtain 100% follow-up for all enrolled patients. We applied a time-to-event analysis (Cox regression) and provided results of complete observed data, which provides some assurances that loss to follow-up was unlikely to bias our results. Second, according to design of the TRUST, we were only able to measure our event,

resolution of pain, at time of patient visits (6, 12, 18, 26, 32, 38, 44 and 52 weeks after surgery), rather than the actual time point of the pain resolution. Finally, data regarding a number of other potential predictors that other investigators have addressed was not available in our cohort. In particular, we did not explore the role of level of education <sup>[21-25]</sup>, pre- or post-injury depression, anxiety and/or distress <sup>[21-23,26-28]</sup>, acute post-surgical pain <sup>[21-23,25]</sup>, pre-surgical physical dysfunction <sup>[21,23,25]</sup>, somatic pre-occupation or impaired coping <sup>[29-32]</sup>, receipt of disability benefits/involvement in litigation <sup>[33]</sup>, or use of opioids <sup>[26,34,35]</sup>, which may be relevant in terms of prognostic implications.

PPSP is common among patients with orthopedic injuries. Rivara and colleagues reported that in 527 patients with lower extremity fractures, 63.9% reported some pain at one year after injury with a mean (SD) severity of pain of 5.6 (4.9) on a 0 (none) to 10 (worst possible pain) point scale <sup>[21]</sup>. Castillo and colleagues reported that 33.3% had moderate or severe pain intensity among patients with tibia fractures at 7 years after injury <sup>[26]</sup>. The proportion of PPSP in our study, approximately 35% for all follow-up and just over 25% for those followed six months or more, was substantially lower than the value reported by Rivara, though not substantially different than Castillo <sup>[21,26]</sup>. Rivara did not separate the results of patients with tibia fractures from the overall results, which included patients with any type of lower extremity fracture <sup>[21]</sup>. Also, Rivara only reported the proportion of any pain <sup>[21]</sup> while Castillo reported proportions of no pain, low, moderate and severe pain separately <sup>[26]</sup>. These may explain the difference.

The association we found of female sex being at a higher risk of PPSP is consistent with the results of prior studies examining trauma patients<sup>[21-23,36]</sup>. A large, prospective observational study by Holbrook and colleagues indicated that women had not only worse pain, but also significantly worse short- and long-term functional and psychological outcomes after major trauma than men<sup>[37]</sup>. The mechanisms of gender differences observed in chronic pain are not yet clear. Hypothetical explanations may include generic<sup>[38]</sup>, socio-psychological<sup>[37,39]</sup>, and enhanced central sensitization in women after orthopedic trauma<sup>[40]</sup>.

Our finding of the association between smoking and persistence of troublesome pain is also consistent with prior studies<sup>[21-23,41]</sup>. For instance, Rivara and colleagues found that pre-injury smokers had higher risk of pain presence and pain severity one year after trauma: mean (SD) scores of pain were 5.8 (4.9) for smokers and 5.2 (4.6) for non-smokers, respectively ( $p < 0.001$ )<sup>[21]</sup>.

With regard to alcohol assumption and PPSP, prior studies have reported inconsistent results<sup>[22,23]</sup>. Castillo and colleagues found high levels of average alcohol consumption at baseline predicted chronic pain 7 years after limb threatening lower extremity trauma<sup>[26]</sup>. In a study by Rivara and colleagues, self-reported hazardous alcohol drinkers had lower pain severity, but did not differ in pain presence compared to the other two groups of nonhazardous drinkers or non-drinkers one year after trauma<sup>[21]</sup>. Thus, our finding of alcohol consumption being associated with a lower risk of PPSP is consistent with the reports by Walker-Bone and Rivara<sup>[21,36]</sup> but not with the report by Castillo<sup>[26]</sup>. The data in our study did not allow us to distinguish between hazardous and nonhazardous



drinkers.

We did not find obesity and severity of injury to be predictors of PPSP. Our results are consistent with a Dutch cohort study of trauma patients in terms of BMI<sup>[24]</sup> and a systematic review of orthopedic trauma patients in terms of injury severity<sup>[22]</sup>. Prior evidence also indicated that older age is associated with persistent pain after trauma surgery<sup>[22,23]</sup>; however, age was not associated with PPSP in our cohort.

Our findings suggest that clinicians should be particularly alert to the possibility of troublesome post-operative pain in female smokers who do not drink alcohol. Clinicians may consider counseling patients to discontinue smoking, inform them that they are at nearly double the risk of incidence of troublesome post-operative pain (in addition to the long-term adverse health consequences of smoking). Our findings regarding associations of post-operative pain with female sex and smoking appear robust: they are consistent with a number of prior reports. Subsequent prospective studies addressing issues of age and alcohol consumption would likely add further valuable evidence. Such studies would ideally have a sufficient sample size, follow-up duration, completeness of follow-up, and collect data on all possible predictors of PPSP.

## **FUNDING**

The TRUST study was an investigator-initiated trial, supported by grants from the Canadian Institutes of Health Research (CIHR) (MCT 67815, Co-PIs: GH Guyatt, M Bhandari), and an industry grant from Smith & Nephew. The CIHR had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Smith & Nephew personnel reviewed initial drafts of the trial protocol and raised many issues about alternative approaches to study design. Issues regarding the protocol were resolved through negotiation between Smith & Nephew and the trial steering committee. Final decisions regarding the protocol and issues that arose during the conduct of the trial were the purview of the trial steering committee. The investigators had full access to all trial data. The current study had no external funding.

## **CONFLICT OF INTEREST**

No conflicts declared.

## REFERENCES

1. Larsen P, Elsoe R, Hansen SH, Graven-Nielsen T, Laessoe U, Rasmussen S. Incidence and epidemiology of tibial shaft fractures. *Injury*. 2015;46(4),746-750.
2. Heckman JD, Sarasohn-Kahn J. The economics of treating fracture healing. *Bull Hosp Jt Dis*. 1997; 56: 63-72.
3. Russell TA: Fractures of the tibial diaphysis. In Levine AM (ed) *Orthopaedic Knowledge Update Trauma*. Rosemont IL, American Academy of Orthopaedic Surgeons, Rosemont, Illinois. pp 171-9, 1996.
4. Treede R D, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. *Pain*. 2015;156(6):1003.
5. Werner MU, Kongsgaard UEI. Defining persistent post-surgical pain: is an update required? *British Journal of Anaesthesia*. 2014;113 (1):1–4.
6. Macrae WA. Chronic post-surgical pain: 10 years on. *British journal of anaesthesia*. 2008;101(1):77-86.
7. Crombie IK, Davies HTO, Macrae WA. Cut and thrust: antecedent surgery and trauma among patients attending a chronic pain clinic. *Pain*. 1998;76(1):167-171.
8. Morrison RS, Magaziner J, McLaughlin MA, Orosz G, Silberzweig SB, Koval KJ, Siu AL. The impact of post-operative pain on outcomes following hip fracture. *Pain*. 2003;103(3),303-311.
9. Turen CH, Burgess AR, Vanco B. Skeletal stabilization of tibial fractures

- associated with acute compartment syndrome. *Clin Orthop*. 1995; 315:163-9.
10. Dave AJ, Selzer F, Losina E, et al. The association of pre-operative body pain diagram scores with pain outcomes following total knee arthroplasty. *Osteoarthritis and cartilage*. 2017; 25(5): 667-675.
  11. Herrick C, Steger- May K, Sinacore DR, et al. Persistent pain in frail older adults after hip fracture repair. *Journal of the American Geriatrics Society*. 2004; 52(12): 2062-2068.
  12. Busse JW, Bhandari M, Einhorn TA, et al. The TRUST Investigators. Trial to re-evaluate ultrasound in the treatment of tibial fractures (TRUST): a multicenter randomized pilot study. *Trials*. 2014; 15: 206.
  13. Busse JW, Bhandari M, Einhorn TA, et al. Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial. *The BMJ*. 2016;355:i5351.
  14. Miró J, de la Vega R, Solé E, Racine M, Jensen MP, Galán S, Engel JM. Defining mild, moderate, and severe pain in young people with physical disabilities. *Disabil Rehabil*. 2017 Jun;39(11):1131-1135.
  15. Alschuler KN, Jensen MP, Ehde DM. Defining mild, moderate, and severe pain in persons with multiple sclerosis. *Pain Med*. 2012 Oct; 13(10): 1358–1365.
  16. World Health Organization, 1995. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Consultation: World Health Organization Technical Report, Series number 854. World Health Organization, Geneva.

17. Dormann CF, Elith J, Bacher S, et al. Collinearity: a review of methods to deal with it and a simulation study evaluating their performance. *Ecography*. 2013;36(1):27-46.
18. Garson G D. Testing statistical assumptions. Asheboro, NC: Statistical Associates Publishing, 2012.
19. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol* 1995;48:1503–10.
20. Harrell Jr FE. Cox proportional hazards regression model. *Regression modeling strategies*. Springer International Publishing, 2015: 475-519.
21. Rivara FP, MacKenzie EJ, Jurkovich GJ, et al. Prevalence of pain in patients 1 year after major trauma. *Archives of Surgery*. 2008;143(3):282-287.
22. Clay FJ, Watson WL, Newstead SV, McClure RJ. A systematic review of early prognostic factors for persistent pain following acute orthopedic trauma. *Pain Res Manage*. 2012;17(1):35-44.
23. Radresa O, Chauny J M, Lavigne G, et al. Current views on acute to chronic pain transition in post-traumatic patients: risk factors and potential for pre-emptive treatments. *Journal of Trauma and Acute Care Surgery*. 2014;76(4):1142-1150.
24. Holtslag HR, van Beeck EF, Lindeman E, et al. Determinants of long-term functional consequences after major trauma. *Journal of Trauma and Acute Care Surgery*. 2007;62(4):919-927.
25. Williamson OD, Epi GD, Gabbe BJ, Physio B, Cameron PA, Edwards ER,

- Richardson MD. Predictors of moderate or severe pain 6 months after orthopaedic injury: a prospective cohort study. *J Orthop Trauma*. 2009;23:139-144.
26. Castillo RC, MacKenzie EJ, Wegener ST, et al. Prevalence of chronic pain seven years following limb threatening lower extremity trauma. *Pain*. 2006;124(3):321-329.
27. Johansen A, Romundstad L, Nielsen C S, et al. Persistent postsurgical pain in a general population: prevalence and predictors in the Tromsø study. *Pain*. 2012;153(7):1390-1396.
28. Bhandari M, Busse JW, Hanson BP, Leece P, Ayeni OR, Schemitsch EH. Psychological Distress and Quality of Life after Orthopedic Trauma: An Observational Study. *Canadian Journal of Surgery*. 2008; 51(1):15-22.
29. Busse JW, Bhandari M, Guyatt GH, et al. Development and validation of an instrument to predict functional recovery in tibial fracture patients: the Somatic Pre-Occupation and Coping (SPOC) questionnaire. *J Orthop Trauma* 2012; 26:370–8.
30. Khan JS, Devereaux PJ, LeManach Y, Busse JW. Patient coping and expectations about recovery predict the development of chronic post-surgical pain after traumatic tibial fracture repair. *Br J Anaesth* 2016; 117:365-70.
31. Reininga IHF, Brouwer S, Dijkstra A, et al. Measuring illness beliefs in patients with lower extremity injuries: reliability and validity of the Dutch version of the Somatic PreOccupation and Coping questionnaire (SPOC-NL). *Injury* 2015; 46:308–14.

32. Busse JW, Heels-Ansdell D, Makosso-Kallyth S, Petrisor B, Jeray K, Tufescu T, Laflamme Y, McKay P, McCabe RE, Le Manach Y, Bhandari M; on behalf of the FLOW Investigators. Patient Coping and Expectations Predict Recovery Following Major Trauma. Accepted for publication in the *British Journal of Anesthesia*.
33. Harris I, Mulford J, Solomon M, van Gelder JM, Young J. Association between compensation status and outcome after surgery: a meta-analysis. *JAMA*. 2005 Apr 6;293(13):1644-52.
34. Nadeau SE. Opioids for chronic noncancer pain to prescribe or not to prescribe—What is the question? *Neurology*. 2015; 85(7): 646-651.
35. Alam A, Juurlink DN. The prescription opioid epidemic: An overview for anesthesiologists. *Can J Anaesth*. 2016; 63(1): 61-68.
36. Walker-Bone K, Harvey NC, Ntani G, et al. Chronic widespread bodily pain is increased among individuals with history of fracture: findings from UK Biobank. *Archives of osteoporosis*. 2016;11(1):1.
37. Holbrook TL, Hoyt DB, Anderson JP. The importance of gender on outcome after major trauma: functional and psychologic outcomes in women versus men. *J Trauma*. 2001;50:270 –273.
38. Dao TTT, LeResche L. Gender differences in pain. *Journal of orofacial pain*. *J Orofacial Pain*. 2000;14(3):169– 184.
39. Teuber N, Thiele A, Eberhardt B. A questionnaire study of the relationship between gender and chronic pain. [German] *Schmerz*. 2006 Aug;20(4):307-13.

40. Jensen MT, Petersen KL. Gender differences in pain and secondary hyperalgesia after heat/capsaicin sensitization in healthy volunteers. *J Pain*. 2006 Mar;7(3):211-7.
41. Shi Y, Weingarten TN, Mantilla CB, Hooten WM, Warner DO. Smoking and Pain Pathophysiology and Clinical Implications. *The Journal of the American Society of Anesthesiologists*. 2010;113(4):977-992.



Table I. Baseline characteristics of study participants

|  | Total                    | Resolution of<br>troublesome<br>pain | PPSP*                    |
|--|--------------------------|--------------------------------------|--------------------------|
|  | N (% in column)          | N (% in row)                         | N (% in row)             |
| Total  | 481 (100)                | 313 (65.1)                           | 168 (34.9)               |
| Age (years)  | 37.9 (14.0) <sup>†</sup> | 38.7 (14.5) <sup>†</sup>             | 36.3 (12.8) <sup>†</sup> |
| Sex  |                          |                                      |                          |
| Male   | 331 (68.8)               | 217 (65.6)                           | 114 (34.4)               |
| Female   | 150 (31.2)               | 96 (64.0)                            | 54 (36.0)                |
| BMI <sup>§</sup>   |                          |                                      |                          |
| <30  | 349 (73.5)               | 222 (63.6)                           | 127 (36.4)               |
| ≥30  | 126 (26.5)               | 85 (67.5)                            | 41 (32.5)                |
| Smoking  |                          |                                      |                          |
| No   | 330 (68.6)               | 236 (71.5)                           | 94 (28.5)                |
| Yes  | 151 (31.4)               | 77 (51.0)                            | 74 (49.0)                |
| Alcohol consumption  |                          |                                      |                          |
| Yes  | 317 (65.9)               | 210 (66.2)                           | 107 (33.8)               |
| No   | 164 (34.1)               | 103 (62.8)                           | 61 (37.2)                |
| Diabetes <sup>¶</sup>                                      |                          |                                      |                          |
| No   | 453 (94.4)               | 294 (64.9)                           | 159 (35.1)               |
| Yes  | 27 (5.6)                 | 18 (66.7)                            | 9 (33.3)                 |
| Comorbidity requiring chronic steroid use <sup>**</sup>    |                          |                                      |                          |
| No   | 471 (98.1)               | 306 (65.0)                           | 165 (35.0)               |
| Yes  | 9 (1.9)                  | 6 (66.7)                             | 3 (33.3)                 |
| Type of fracture   |                          |                                      |                          |
| Closed   | 371 (77.1)               | 252 (67.9)                           | 119 (32.1)               |
| Open   | 110 (22.9)               | 61 (55.5)                            | 49 (44.5)                |
| Additional injuries  |                          |                                      |                          |
| No   | 71 (14.8)                | 47 (66.2)                            | 24 (33.8)                |
| Yes  | 410 (85.2)               | 266 (64.9)                           | 144 (35.1)               |
| Type of fixation <sup>††</sup>                             |                          |                                      |                          |
| Nail with prior reaming                                    | 478 (99.6)               | 311 (65.1)                           | 167 (34.9)               |
| Nail without prior reaming                                 | 2 (0.4)                  | 2 (100)                              | 0 (0)                    |
| Post-operative weight-bearing status on the day of surgery |                          |                                      |                          |
| Full or partial weight-bearing                             | 264 (54.9)               | 174 (65.9)                           | 90 (34.1)                |
| Non-weight bearing   | 217 (45.1)               | 139 (64.1)                           | 78 (35.9)                |

Notes:

\* PPSP: persistent post-surgical pain

† Mean and standard deviation

§ n=475 (349 and 126); BMI: body mass index. BMI&lt;30: overweight, normal weight and underweight; BMI≥30: obese

¶ n=480 (453 and 27)

\*\* n=480 (471 and 9)

†† n=480 (478 and 2)

Table II. Distribution of duration of participants' follow-ups among patients with persistent post-surgical pain ( $\geq 12$  weeks, absolute number of patients)

|                     | Total | Patients with PPSP* |        |
|---------------------|-------|---------------------|--------|
|                     | N     | N                   | (%)    |
| Total               | 452   | 139                 |        |
| 12 weeks            | 24    | 15                  | (62.5) |
| 18 weeks            | 26    | 19                  | (73.1) |
| 26 weeks            | 51    | 17                  | (33.3) |
| 32, 38 and 44 weeks | 50    | 11                  | (22.0) |
| 52 weeks            | 301   | 77                  | (25.6) |

Note:


\* PPSP: persistent post-surgical pain

Table III. Predictors of resolution of post-surgical pain in study participants (Cox survival model, adjusted analysis)

|  | Hazard Ratio (95% Confidence Interval) | P value          |
|--|--|------------------|
| Total  |  |                  |
| Age, per 10 years  | 1.04 (0.96-1.13)                       | 0.36             |
| Sex  |  |                  |
| Male   | <b>1.34 (1.04-1.72)</b>                | <b>0.02</b>      |
| Female   | 1.00                                   |                  |
| BMI*   |  |                  |
| <30  | 1.03 (0.80-1.32)                       | 0.83             |
| ≥30  | 1.00                                   |                  |
| Smoking  |  |                  |
| No   | <b>1.74 (1.33-2.29)</b>                | <b>&lt;0.001</b> |
| Yes  | 1.00                                   |                  |
| Alcohol consumption  |  |                  |
| Yes  | <b>1.35 (1.06-1.73)</b>                | <b>0.02</b>      |
| No   | 1.00                                   |                  |
| Type of fracture   |  |                  |
| Closed   | 1.12 (0.84-1.49)                       | 0.45             |
| Open   | 1.00                                   |                  |
| Additional injuries  |  |                  |
| No   | 0.90 (0.65-1.24)                       | 0.50             |
| Yes  | 1.00                                   |                  |
| Post-operative weight-bearing status on the day of surgery |  |                  |
| Full or partial weight-bearing                             | 1.12 (0.88-1.41)                       | 0.36             |
| Non-weight bearing   | 1.00                                   |                  |

Note:

\* BMI: body mass index



Note:

PPSP: persistent post-surgical pain

Fig. 1 Distribution of duration of participants' follow-ups (≥12 weeks, absolute number of patients)




Fig. 2 Kaplan-Meier curves for resolution of troublesome post-operative pain amongst patients with tibial fracture: a. overall results; b. results by gender; c. results by smoking status; d. results by alcohol consumption status

Appendix 1: TRUST Investigators:

**Steering Committee:** Mohit Bhandari (Chair), Jason W. Busse, Thomas A.

Einhorn, James D. Heckman, Kwok-Sui Leung, Emil H. Schemitsch, Paul

Tornetta III, Stephen D. Walter, Gordon H. Guyatt; **Central Adjudication**

**Committee:** Mohit Bhandari (Chair), Emil H. Schemitsch, David Sanders;

**TRUST Methods Centre Staff: McMaster University, Hamilton, Ontario:**

Sheila Sprague, Paula McKay, Kim Madden, Nicole Simunovic, Diane

Heels-Ansdell, Lisa Buckingham, Helena Viveiros, Qi Zhou, Marilyn Swinton.;

**TRUST Data Safety and Monitoring Board Members:** George A. Tomlinson

(Chair), Mark Munro, Rob GHH Nelissen.

**TRUST Study Investigators:** Greenville Health System – Kyle J. Jeray, J. Scott

Broderick, Stephanie L. Tanner, Becky Snider.

Orthopaedics of Indianapolis – Dean Maar, Renn Crichlow, Greg Reveal, David

Kaehr, Joseph Baele, Kevin Douglas Scheid, David Brokaw, Tim Weber, Brad

Jelen, Matt Edison, Anna Clark

Temple University Hospital – Saqib Rehman, Alyssa A. Schaffer, Asif M. Ilyas, J.

Milo Sowards, Joanne M. Donnelly.

QEII Health Sciences Centre – Chad Coles, Michael Dunbar, David Alexander,

David Amirault, Catherine Coady, Mark Glazebrook, Michael Gross, David

Johnston, Ross Leighton, William Oxner, Gerald Reardon, William Stanish, Glen

Richardson, Michael Biddulph, Kelly Trask, Gwen Dobbin, Shelley MacDonald.

Duke University Medical Center – Steven Olson, Robert Zura, Rachel Reilly,

Maria Manson.

University of California, San Francisco/San Francisco General Hospital –

Theodore Miclau, Saam Morshed, Amir Matityahu, Utku Kandemir, Tigist Belaye,

Jonathan Kwong.

Vancouver General Hospital – Peter O’Brien, Piotr Blachut, Pierre Guy, Henry

Broekhuysse, Kelly A Lefaiivre, Raman Johal, Irene Leung.

Orthopaedic Speciality Associates – Cory A. Collinge, Keith Watson, Derek

Dombroski, Tara Craig.

West Virginia University – David Hubbard, Michelle A Bramer, John France, E.

Barry McDonough, George K. Bal, John P. Lubicky, Brock Lindsey, Robert

Santrock, Scott Daffner, Sheila Rye, Christina Carey, Stacy Skidmore, Nina

Clovis.

Rothman Institute – Javad Parvizi, Matt Austin, John A. Abraham, Charlie Getz,

James Purtill, Steven Raikin, Tiffany Morrison, Bora Og.

Emory University – Thomas Moore, George Wright, Allen McDonald, Maria

Davila, Lauren Rabach, Whitney Barnes.

Cooper University Hospital – Kenneth Graf, Robert Ostrum, David Fuller, Robert

Marburger

University of Missouri Health Care - Gregory J. Della Rocca, Brett D. Crist,

Yvonne M. Murtha, David A. Volgas, James P. Stannard, Toni K. Kliever, Sharon

L. Jarrett, Kelly A. Moore, Kathleen Markley, Angela Ballew, Abigail K. Stidham.

Foothills Medical Centre – Paul Duffy, Robert Korley, Shannon Puloski, Richard

Buckley, Kelly Johnston, Kimberly Carcary, Ross McKercher.

University of Kentucky – Jeffrey Selby, Mauro Giordani, Eric Moghadamian, Daniel D. Primm, Raymond D. Wright Jr, Brandon Bruce, Justin Perry, Amy Trivette, Regina Mosley, Melinda M. Dowden-Kruger, Dorothy Ross.

Insall Scott Kelly Institute – Craig S. Radnay, Timothy Reish, Michael Kang, William Long, Michael Nett, Priya Chadha, Elizabeth H. Jett, Jesie Paniagua.

Florida Orthopaedic Institute – H. Claude Sagi, Anthony Infante, David T. Watson, Daniel Chan, George Haidukewych, Anjan Shah, Barbara Steverson, Veronica Colon.

Eastern Maine Medical Center – David Carmack, Rajendra Tripathi, F. Parke Oldenburg, Denise Michaud, Teresa White.

University of South Alabama – Jorge Alonso, Kelley Prutzman.

University of British Columbia/Royal Columbian Hospital/Fraser Health Authority – Trevor Stone, Kelly Apostle, Dory Boyer, Farhad Moola, Bertrand Perey, Darius Viskontas, H. Michael Lemke, Robert McCormack, Mauri Zomar, Karyn Moon, Raely Moon, Amber Oatt.

Shrock Orthopaedic Research – Kevin Shrock, Matthew Wells, Natalie Shrock  
Denver Health – David Hak, Philip F Stahel, Mark Hammerberg, Cyril Mauffrey, Corey Henderson, Erin Ross, Douglas Gibula, Hannah Gissel.

University of Virginia – David B. Weiss, David Kahler, Jacquelyn Sedlock, Vasantha Reddi, Veronica C. Lester-Ballard, Wendy M. Novicoff.

Pensacola Research Consultants Inc – Eugene Jean Dabezies, Kurt Morrison, Kirby Turnage, Robert Lurate, Gay Crawley, Donna Lawson, Iris McCants, Anna



Brunson, Mary Whitaker, Stefanie White, Michael Ellis.

Sunnybrook Health Sciences Centre – Hans Kreder, Terry S. Axelrod, Joel A.

Finkelstein, Patrick D.G. Henry, Richard Jenkinson, John J. Murnaghan, Diane

Nam, Markku Nousiainen, Sebastian Rodriguez-Elizalde, Veronica M.R. Wadey,

Robin Richards, David Stephen and Albert Yee, Katrine Milner, Monica Kunz,

Melanie MacNevin, Ayushi Dhingra.

London Health Sciences Centre – Abdel-Rahman Lawendy, David Sanders,

Christina Tieszer.

Texas Orthopedic Specialists – O. David Taunton Jr., Jason Ahuero, Amber

Morgan.

University of Kansas Medical Center – Archie Heddings, John Sojka, Michael

Tilley, Sharon Bradshaw.

Orthopaedic Associates of Michigan – Clifford B. Jones, James R. Ringler,

Terrence J. Endres, Debra L. Sietsema, Jane E. Walker, Susan M. Engerman.

Lahey Hospital and Medical Center – Andrew Marcantonio, Michael S. Kain,

John Garfi.

Texas Orthopedics, Sports & Rehabilitation Associates – Christopher M. Danney,

Marc DeHart, Scott Smith, Barbara Bergin, Joel Hurt, Tyler Miller, Todd Curry,

Karl Adcock.

Marshall University – Franklin D. Shuler, Amber Simmons.

Southlake Regional Health Centre – Christopher Lindsay, Cleo Rogakou, Pat

Gamble, Debbie Nemtean.

KSF Orthopaedic Center– John P. Seaberg, Derrick Clay, Cameron Wood, Todd

Curry, Tyler Miller

Clinical Research Niagara, Inc. – David Martin, John Song, Robert Josefchak,

Paul Robert, Avril McKenna-Norton, Marnie-Lynn Sennett, Olwen McKenna.

York Hospital/WellSpan Health – Thomas DiPasquale, Mark Richardson, Paul

Muccino, Adrienne Brandon.

Mission Hospital – H. Michael Frisch, C. Michael LeCroy, Susan Sutherland,

Rachel Alosky, Leslie Elliott, Lynne Hampton, Tracy Nanney, Claudine Cuento,

Stephanie Shepard.

Louisiana State University – Melissa Gorman, Peter Krause, Ronald Rooney,

Jennifer Perilloux.

Inova Fairfax Hospital – Robert A. Hymes, Cary Schwartzbach, A. Stephen

Malekzadeh, Jeff E. Schulman, Daniel Dziadosz, Laura Thurston, Jihui Li.

Texas Sports Medicine Institute – Michael C. Maier, Tyler Miller, Todd Curry.

Anthony G. Sanzone, MD, Inc – Anthony Sanzone, Kaelin Schickedanz.

Orthopaedic Associates of South Broward, P.A – Steven D. Steinlauf, Richard E.

Strain, Daniel Chan, Warren Grossman, Judy Magnum.

University Orthopaedics Center – Bradley A. Barter, Douglas Roeshot, Thomas

Ellis, Edwin Rogusky, Paula Sensiba, Andrew Marcus, Kenneth Cherry, Sue

Jepson, Jennifer Gramley.

Appendix 2 Correlation of factors considered in Cox survival model (*r*)

|                                      | Age   | Sex   | BMI   | Smoking | Alcohol | Type of fracture | Additional injuries |
|--------------------------------------|-------|-------|-------|---------|---------|------------------|---------------------|
| Sex                                  | -0.13 |       |       |         |         |                  |                     |
| BMI*                                 | -0.08 | 0.07  |       |         |         |                  |                     |
| Smoking                              | 0.17  | -0.14 | -0.08 |         |         |                  |                     |
| Alcohol                              | -0.12 | 0.10  | 0.09  | -0.21   |         |                  |                     |
| Type of fracture                     | 0.08  | -0.11 | -0.07 | 0.11    | -0.04   |                  |                     |
| Additional injuries                  | -0.11 | 0.07  | -0.02 | 0.04    | 0.003   | 0.05             |                     |
| Post-operative weight-bearing status | -0.14 | 0.16  | 0.01  | -0.08   | 0.04    | -0.12            | 0.13                |

Note:

\* BMI: body mass index

Appendix 3. Assessment of multicollinearity of variables

| Variables                            | VIF*  |
|--------------------------------------|-------|
| Age                                  | 1.077 |
| Sex                                  | 1.063 |
| BMI <sup>†</sup>                     | 1.023 |
| Smoking                              | 1.096 |
| Alcohol                              | 1.066 |
| Type of fracture                     | 1.041 |
| Additional injuries                  | 1.041 |
| Post-operative weight-bearing status | 1.065 |

Notes:

\* VIF: variance inflation factor




† BMI: body mass index

Appendix 4. Assessment of proportional hazard assumption for variables in Cox survival model

| Variables                            | P value |
|--------------------------------------|---------|
| Age                                  | 0.834   |
| Sex                                  | 0.270   |
| BMI*                                 | 0.223   |
| Smoking                              | 0.393   |
| Alcohol                              | 0.124   |
| Type of fracture                     | 0.530   |
| Additional injuries                  | 0.239   |
| Post-operative weight-bearing status | 0.287   |

Note:

\* BMI: body mass index



## CHAPTER 5

### Conclusion

The current thesis includes three individual studies with a focus on the prognosis and management of patients who have injuries necessitating orthopedic surgeries, in particular, fractures of extremities. We used different methods to collect and analyze the data. I list the key findings from the three studies below:

#### **I. Effects of Antibiotic Prophylaxis in Patients with Open Fracture of the Extremities: A Systematic Review of Randomized Controlled Trials**

- i) There is moderate quality evidence that patients receiving, versus not receiving, antibiotic prophylaxis experience a large and important reduction in infection rate (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.21-0.66, absolute risk reduction 9.6%, 95% CI 5.2% to 12.1%).
- ii) We found no difference in infection rate with longer (3 to 5 days) versus shorter (1 day) duration of antibiotics (RR 0.97, 95% CI 0.69-1.37), but the evidence is only low quality.
- iii) Results of RCTs performed to date provide evidence that antibiotic prophylaxis reduces subsequent infection, and that courses as short as one day are as effective as courses of 3 to 5 days, though evidence warrants only low to moderate confidence.
- iv) Results of RCTs provide very limited guidance regarding the optimal

antibiotics to use in prophylaxis.

## **II. Antibiotic Prophylaxis in the Management of Open Fractures: A**

### **Systematic Survey of Current Practice and Recommendations**

- v) Clinicians and investigators' practices, as well as expert recommendations, over the last decade strongly support early systemic antibiotics prophylaxis for patients with open fractures of extremities. Differences in antibiotic regimens, doses and durations of administration remain in both practice and recommendations.
- vi) In practice, a majority used systemic antibiotics with both gram-positive and gram-negative coverage, and continued the administration for 2 to 3 days.
- vii) Most recommendations suggested gram-positive coverage for less severe injuries i.e., Gustilo type 1 and 2 open fractures, and administration duration of 3 days or less (half suggested 1 day).
- viii) For more severe injuries, i.e., Gustilo type 3 open fractures, most recommendations suggested broad antimicrobial coverage continued for 2 to 3 days.
- ix) The most important difference between recommendations and practice was that, when authors made recommendations for Gustilo 1 or 2 open fractures as a group, they recommended restricting antibiotic use to agents with exclusively gram-positive coverage, while in practice surgeons used broader coverage. When authors grouped Gustilo 2 and 3 fractures together, almost all suggested using broad coverage with

reliable activity against both gram-positive and gram-negative organisms.

### **III. Risk Factors for Persistent Post-surgical Pain after Tibia Fracture: A Longitudinal Study**

- x) 313 of 481 (65.1%) patients with open or closed fractures of the tibia reported resolution of pain after surgery.
- xi) We found significant independent associations between resolution of pain and male sex (hazard ratio [HR]=1.34, 95% CI, 1.04 to 1.72), non-smoking (HR=1.74 [95% CI, 1.33 to 2.29]) and alcohol consumption (HR=1.35 [95% CI, 1.06 to 1.73]).
- xii) Age, obesity, type of fracture (closed versus open), additional injuries, and post-operative weight-bearing status did not predict resolution of pain.

Weaknesses of the current thesis are primarily related to the limitation in evidence. RCTs comparing antibiotic prophylaxis versus no prophylaxis, and RCTs comparing different regimens, routes of administration, dose, and/or duration of antibiotic administration are very limited. The included RCTs have limitations of relatively small sample size and high risk of bias. This led to our low to moderate ratings of confidence in estimates of effectiveness of the intervention. Current recommendations, although they are many in numbers of publications, have a very limited evidence base supporting their advice regarding the choice of optimal regimens, dose and duration of antibiotic administration among patients with open



fractures of extremities depending on different injury severity.

Nevertheless, our survey of practice and recommendations represents a valuable contribution: the work represents the first systematic survey addressing both what studies report in terms of use of antibiotics in prophylaxis in open fractures, and what experts recommend. Many clinicians may, under circumstances of low quality evidence, find experts' views of the optimal approaches helpful.

With regard to Chapter 4, our longitudinal study using results from a randomized trial to explore predictors of post-operative pain, data proved unavailable for some variables that may be relevant in terms of PPSP prognostic implications, not all patients were followed for the full year, and pain ratings were not available for some follow-up visits in patients followed for longer durations.

In relation to our findings, researchers may consider future study directions listed below:

- i) Given limited and low-quality evidence regarding optimal antibiotic prophylaxis for open fractures, a large, multi-center, low risk of bias RCT enrolling representative populations and addressing duration of antibiotics (1 day versus 3 or 5 days as prophylaxis) may be the next optimal step in investigation.
- ii) For Gustilo type 2 open fractures, whether antibiotics with gram-positive has similar effectiveness with antibiotics with broad coverage. Researchers may consider sub-group participants' analysis in a large RCT, or design a

separate RCT to address the question.

- iii) Our findings regarding associations of post-operative pain with female sex and smoking appear robust: they are consistent with a number of prior reports. Subsequent prospective studies addressing issues of age and alcohol consumption would likely add further valuable evidence. Such studies would ideally have a sufficient sample size, follow-up duration, completeness of follow-up, and collect data on all possible predictors of PPSP.